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Abstract 
Abstract 
Background 
Primary prevention of cardiovascular disease (CVD) based on an 
absolute risk approach is more cost-effective than the traditional individual risk 
factor approach based on blood pressure (BP) or lipid thresholds alone. 
Although BP lowering drug treatment is recommended in high-risk individuals 
even for those below traditional BP thresholds (e.g. <140/90 mmHg) in many 
guidelines, withholding BP lowering drug in individuals with mildly elevated BP 
and low-moderate risk is controversial as it is contrary to historical 
recommendations and there are concerns regarding legacy effects.  Similarly, 
lipid-lowering drug treatment (LLT) is widely prescribed in high-risk individuals 
based on evidence from large randomised controlled trials.  However, these 
trials lacked elderly participants who are at high baseline risk due to their age.  
The effects of lipid-lowering drug treatment in the healthy elderly remain 
unclear. 
Aim 
To investigate the effect of BP and LLT on short- and long-term mortality 
outcomes stratified by absolute CVD risk.  
Methods: 
Two post-hoc observational studies of the Australian National Blood 
Pressure study (ANBP), the Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT) and a systematic review and meta-
analysis were conducted to investigate the effects of BP lowering drug 
treatment in individuals stratified by absolute CVD risk on short- and long-term 
outcomes.  ANBP was a community-based randomised placebo-controlled trial 
in ‘mild hypertension’ defined as diastolic BP ranging from 95-109 mmHg and 
systolic BP lower than 200 mmHg conducted in Australia in the 1970s.  ALLHAT 
was a double-blind, randomised active-controlled trial conducted in multiple 
centres in North America that included participants with untreated systolic BP 
lower than 180 or treated systolic BP lower than 160 mmHg.  Based on the BP 
treatment status at baseline, participants were re-stratified to ‘treatment naïve’ 
xxvi 
Abstract 
and ‘previous treatment’ group.  The systematic review and meta-analysis 
included randomised controlled trials with a post-trial phase and which enrolled 
participants who were middle-aged and had mildly elevated BP.  Similarly, to 
investigate the effects of LLT in the elderly, a post-hoc observational study on 
the Second Australian National Blood Pressure study (ANBP2) was conducted 
that re-stratified participants into ‘LLT’ and ‘no LLT’ group based on their 
treatment status at baseline.  All four studies excluded participants with 
previous CVD events.  Treatment effects were estimated by hazard ratio with 
95% confidence interval (CI) using a Cox proportional hazard model.  Subgroup 
analyses by baseline estimated CVD risk score were performed.  
Results 
Generally, the three studies on the effects of BP lowering drug treatment 
did not record any clinical harms as a result of delayed drug treatment in low-
moderate risk individuals or in middle-aged adults with mildly elevated BP.  The 
post-hoc study on the ANBP population (median follow-up 4.4. years) observed 
a substantial beneficial effect of BP lowering drug treatment regarding absolute 
risk reduction in any trial endpoint, all-cause mortality and major CVD events in 
the highest risk tertile group, whereas the low or moderate risk tertile was 
unlikely to benefit.  In the ALLHAT trial with a longer follow-up period (up to 14.1 
years), delayed BP lowering drug treatment was not associated with any 
significantly increased risk of all-cause or CVD mortality at any level of CVD 
risk stratification when drug therapy was closely monitored by a clinician. 
Similarly, in the systematic review and meta-analysis in middle-aged adults with 
mildly elevated BP, we found non-significant effects of delayed BP lowering 
drug treatment in short- and long-term all-cause and CVD mortality regardless 
of the CVD risk stratification.  In the study looking at the effects of LLT in those 
aged 65 years or over stratified by absolute CVD risk, LLT was associated with 
a reduced long-term all-cause mortality suggesting that the mortality benefit of 
LLT for the elderly may take longer to become evident at any level of CVD risk. 
High-risk participants also obtained further benefits for short-term all-cause 
mortality.  
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Abstract 
Conclusions 
In terms of the effects of BP lowering drug treatment, our analysis 
provides further justification that an absolute risk strategy is superior to 
management based on the BP level alone in identifying those who are most 
likely to benefit from drug therapy. The results support using absolute CVD risk 
to determine when to initiate BP lowering drug treatment for primary prevention 
of CVD.  These studies found no long-term adverse risk of all-cause or CVD 
mortality in low-moderate risk individuals or middle-aged adults with mildly 
elevated BP, thus partly addressing clinician concerns of ‘legacy effects’ when 
BP lowering drug therapy is delayed.  In contrast, LLT in the elderly may require 
long-time follow-up (e.g. 10 years) to become evident. 
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Definition of cardiovascular disease (CVD) used in current 
guidelines 
CVD refers to a group of disorders related to the heart and blood vessels. 
The use of the CVD term differs slightly between various organisations. 
Fundamentally, CVD includes ‘hard’ coronary heart disease (myocardial 
infarction and fatal coronary heart disease) and ‘hard’ cerebrovascular disease 
(non-fatal and fatal stroke) 1-5. In addition, CVD in some guidelines 1-3, 5 
incorporate angina, heart failure, peripheral vascular disease or transient 
ischemic attack.  
The burden and trend of CVD  
Global 
Over the past decade, CVD remains the dominant burden of disease 
worldwide.  According to the Global Burden of Disease study 2015 6, 7, 
approximately one-third of all deaths (18 million) worldwide were attributable 
to CVD and was projected to exceed 24 million by 2030 8. Coronary heart 
disease (CHD) and stroke were the two most common causes of CVD 
mortality and accounted for 85% (15.2 million) of CVD deaths (15.2 million) 6. 
Also, the prevalence of CVD increased by 25% from 2005 to 2015, with the 
highest prevalence recorded in sub-Saharan Africa, Eastern Europe, and 
Central Asia 7. CVD is no longer limited to high-income countries. It has 
shifted to low-middle income countries (LMI) and now accounts for 80% of 
global CVD deaths 9, a so-called “epidemiologic transition” 10 (Figure 1.1). 
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Figure 1.1 Global Map, Age-Standardized Death Rate of CVD in 2015  
Figure adapted from Roth et al7. Journal of the American College of Cardiology 
2017;70(1):1-25. 
 
The “epidemiologic transition” is characterised by five main stages (i.e. 
age of pestilence and famine, age of receding pandemics, age of degenerative 
and man-made diseases, age of delayed degenerative diseases and age of 
health regression and social upheaval)   with different geographic areas  10. 
While regions at stage 1 such as Sub-Saharan Africa, rural India and South 
America have mainly suffered from rheumatic heart disease, infection and 
nutritional cardiomyopathies, countries at stage 2 (e.g. China) have 
experienced said diseases and additionally hypertensive heart disease and 
haemorrhagic stroke. Stage 3 and stage 4 are primarily represented by strokes 
and ischemic heart disease. However, the diseases occurred mostly in young 
people in areas at stage 3 (Urban India, former socialist economies, aboriginal 
communities), whereas areas at stage 4 (Western Europe, North America, 
Australia, New Zealand, etc.) observed a delayed degenerative disease in the 
older population. While the progress from stage 1 to stage 4 indicates a positive 
health development, countries in stage 5 (e.g. Russia) have witnessed a social 
catastrophe with the re-emergence of rheumatic heart disease, infection, 
alcoholism, violence; ischaemic and hypertensive disease in the young.  
Low-middle income countries (LMI) 
In recent years, LMI countries have been heavily impacted by 
globalisation, urbanisation and industrialisation more than ever before 11. This 
progress has led to changes in behaviour and lifestyle, called ‘westernisation’. 
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This phenomenon was characterised by the increased consumption of high-
energy, salted and high saturated food and a decrease in physical activity 12, 13.  
In addition, the decrease in premature deaths from infectious and nutrition 
disease has improved life-expectancy in LMI countries thus increasing the 
number of people in middle and old age where CVD is more prevalent, with 
accumulative risk factors from childhood to early adulthood. In the period 1990-
2013, the number of CVD-related deaths increased by 66% (from 7.2 million to 
12 million) in LMI countries 14. Due to the relatively young age structure, CVD 
affected a larger number of working-age adults that contributed to increasing 
the cost of CVD to the relevant communities. As reported in the PURE study 
15(Prospective Urban-Rural Epidemiology) the risk factor burden estimated by 
INTERHEART risk score in LMI countries was lower than the corresponding in 
high-income countries, although the incidence and mortality were higher. Thus, 
not CVD RFs, but other determinants associated with healthcare systems and 
services, treatment strategy, education level dominantly contributed to the CVD 
burden in the developing world. As estimated by the World Health Organisation, 
more than 50% (US$3.76 trillion) of economic loss of non-communicable 
disease would be attributable to CVD in the period 2011-2025 (Figure 1.2) 16.  
Figure 1.2 Non-communicable disease cost by disease and income levels in 
Low-middle income countries.  
Figure adapted from the World Health Organization and World Economic 
Forum. From Burden to “Best Buys”: Reducing the Economic Impact of NCDs 
in Low and Middle-Income Countries. Geneva, Switzerland: WHO; 201116 
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High-income countries 
Since the peak level in the early 1970s, the mortality and incidence of 
CHD and stroke significantly declined by up to 50% in high-income countries 
(e.g. Australia, Canada, France, Japan, the United Kingdom and the United 
State) 17-22.  This achievement mainly resulted from the reduction in CVD risk 
factors and an improved treatment strategy21-26. However, in the last 25 years 
(1990-2015), this improvement has slowed or even plateaued 7. In the UK from 
1996 to 2005, age-standardised incidence and mortality from CHD annually 
decreased by approximately 2% and 4% respectively, but the age-standardised 
prevalence increased by about 1.5% 27. As a global phenomenon, ageing 
contributed to the increased prevalence of CHD and stroke, and the cost of 
medical expenditure throughout a lifetime course increased correspondingly 20, 
27, 28. In the US, direct (medical) and indirect (lost-productivity) cost of CVD was 
US$555 billion in 2015 and was projected to increase to $1.1 trillion by 2035 29.  
CVD is likely to remain a leading cause of death in both developed and 
developing worlds in the next few years 30-33. 
Primary prevention of CVD 
Primary prevention of CVD aims at reducing the development of CVD 
risks to prevent the occurrence of a first CVD event in ‘healthy’ individuals 
without clinically established CVD 26, 34. A first CVD event may be either a non-
fatal or fatal event and up to 80% of premature CVD defined as premature CVD 
in the young is preventable 35. Primary prevention strategies focus on delaying 
the first CVD events, prolonging symptom-free life and reducing CVD mortality 
at diagnosis.  Current primary prevention programs recommended by 
guidelines regarding population level or individual level are cost-effective 36.  
Absolute CVD risk for primary prevention of CVD 
As major CVD risk factors cluster and interact together, moreover blood 
pressure (BP) and blood cholesterol have a continuous effect on CVD risk, a 
so-called ‘normal’ BP (systolic BP< 140 mmHg and diastolic BP < 90 mmHg) 
or a ‘normal’ blood lipid (total cholesterol (TC)<6.5 mmol/L) does not exclude 
an individual from increased CVD risk 49. Thus, a number of adults having CVD 
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events were not previously recommended for preventive treatment, whereas 
others are on treatment in spite of low CVD risk profiles.   
An absolute risk approach that aims at individuals most likely to have 
events is more cost-effective because this approach tends to prevent more 
CVD events with a lower number of patients needed to treat 37, 38. Compared to 
a risk factor counting model, an integrated risk model is advanced because it 
accounts for variability or intensity of risk factor levels and the progressive 
impact of age on total risk 39. Generally, most CVD risk score models 
incorporate a group of traditional risk factors that include age, sex, smoking 
status, systolic BP, total cholesterol (TC), high-density lipoprotein cholesterol 
(HDL-c) and diabetes mellitus (DM). Some recent scores added a family history 
of CVD, ethnicity, deprivation score, and diagnosis of atrial fibrillation or 
rheumatoid arthritis into the models (Table 1.1).  
Current guidelines for primary prevention of CVD 2, 5, 40, 41 are now mainly 
based on short-term absolute risk, the risk of having a CVD event in the next 5 
to 10 years for the treatment decision. The most validated and widely used risk 
score are Framingham risk score (FRS) 42-44 and SCORE45, however, these risk 
algorithms should be applied with caution because they were established using 
cohorts from the last decade with much higher CVD event rates, fewer 
preventive medications, less socioeconomically and ethnically diverse 
compared to current cohorts. The two most contemporary risk equations – 
QRISK 246 (2008) and the New Zealand Primary Prevention Equations  (2018) 
47 were developed from contemporary cohorts in the UK and New Zealand 
respectively, however they have not been comprehensively validated and 
calibrated in other regions. Most of the guidelines use 10-year CVD risk 
equations whereas the New Zealand and Australia guidelines adopt 5-year 
CVD risk equations 1, 2. Compared to 10-year risk, the 5-year risk is likely to be 
more practical because most of the current evidence for preventive medications 
is from randomised controlled trials (RCT) of 5 years or less follow-up and 
prevention strategies might change within 10 years.  
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Considerations on absolute risk assessment 
❖ Given that age is heavily weighted in the short-term absolute risk, such 
approach targets most of drug treatments to elderly populations. Thus, 
middle-aged individuals who have an extremely high value of a risk factor 
or significant comorbidities could have their risk underestimated and thus 
remain untreated (i.e. BP or lipid-lowering drug treatment). A new risk 
measure, a so-called ‘lifetime’ risk that estimates the incremental risk of 
having a CVD event during the rest of an individual’s life has been recently 
recommended 48. The JBS 3 guideline49 used high lifetime risk as an 
indicator for BP lowering drug treatment in mildly elevated BP (e.g. systolic 
BP 140-159 and/or diastolic BP 90-99  mmHg). Due to scant evidence for 
the effectiveness and cost-effectiveness of applying this guideline, the 
‘lifetime’ risk or ‘heart age’ should be considered for communicating risk 
and encouraging behaviour changes only 40, 50.  
❖ Most risk algorithms are validated for adults under 75 years. CVD risk of 
the elderly at 75 years or over is estimated as ‘minimal’ risk. There is a 
concern about the decreased association between metabolic syndromes 
(e.g. obesity), systolic and/or diastolic BP with CVD risk and mortality, 
particularly in very old and/or frail and multimorbid, polypharmacy 
individuals 51-56. 
❖ Some common conditions determine high-risk profiles: (1) renal 
dysfunction, CKD, (2) familial hypercholesterolemia, (3) DM accompanying 
with another RF (e.g. age). Other different conditions are specified in 
particular guidelines (Table 1.1).  
❖ Individuals with absolute risk score near the threshold of treatment decision 
may be screened for preclinical vascular damage (coronary artery calcium, 
atherosclerotic plaques) or other factors that were not included in CVD risk 
algorithms (e.g. BMI, family history of premature CVD) to improve the risk 
predictors and decision making. In ESC and NICE guideline 40, 57, the 
authors noted concerns about conditions that may contribute to increasing 
CVD risk such as cardiotoxicity in cancer patients with chemotherapy or 
radiotherapy, autoimmune disease (e.g. rheumatoid arthritis, systemic 
lupus erythematosus). 
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Table 1.1. Absolute risk assessment for primary prevention of cardiovascular disease 
Guidelines  Risk Score Risk threshold (%) Predicted 
outcomes 
Risk 
factors 
CVD risk equivalent 
(assumed to have high 
CVD risk) 
Age range for 
screening 
Low Moderate High 
NVDPA2  
2012, 
(Australia)  
5-year 
Framingham 
risk 44 
<10  10-15 >15 ‘Hard’ CHD + 
‘hard’ CVE +  
angina, HF, 
PVD, TIA. 
Sex-specific 
models. 
Traditional 
RFs + ECG-
LVH 
DM + age > 60 years, DM + 
microalbuminuria,  moderate 
or severe CKD, SBP ≥180 
and/or DBP ≥ 110 mmHg, 
TC> 7.5 mmol/L, TC/HDL-c 
≥ 8, FH, Aboriginal and 
Torres Strait Islander adults 
> 74 years. 
≥ 45 years,   
(Aboriginal and 
Torres Strait 
Islander peoples ≥ 
35 years) 
Australian 
NHF 2016 58 
(Australia) 
(As above + diagnosis of 
TOD) 
New 
Zealand 
2018 1 
5-year New 
Zealand CVD 
risk 47 
<5 5-15 >15 ‘Hard’ CHD + 
‘hard’ CVE+ 
angina, HF, 
PVD, TIA 
Sex-specific 
models. 
Traditional 
RFs+  
ethnicity, 
deprivation 
score, 
family 
history of 
premature 
CVD, 
history of 
AF, BP- / 
lipid- 
DM+ moderate CKD, severe 
CKD, FH, TOD 
Men 45-74 yrs, 
women  55-74 
years, (Maori, 
Pacific peoples or 
South-Asian 
peoples: men 30-
74 years, women 
40-74 years)  
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Guidelines  Risk Score Risk threshold (%) Predicted 
outcomes 
Risk 
factors 
CVD risk equivalent 
(assumed to have high 
CVD risk) 
Age range for 
screening 
Low Moderate High 
lowering 
medication, 
antithrombo
tic 
medication. 
ESC for 
CVD 
prevention 
2016 40, 
ESC for 
hypertensio
n 2018 
59(Europe) 
10-yr SCORE 
45 
<1 1-4 ≥ 5 Fatal CHD or 
fatal stroke. 
Versions for 
use in 
high and 
low-risk 
countries. 
Traditional 
RFs 
excluding 
DM. 
DM, moderate CKD, systolic 
BP ≥180 and/or diastolic BP 
≥ 110 mmHg, TC > 8 
mmol/L, FH. 
Men 40-65 yrs, 
Women 50-65 
years or post-
menopausal 
Canada 
guideline for 
hypertensio
n 20183 
10-year 
Framingham 
risk  
<15 ≥ 15 ‘Hard’ CHD + 
‘hard’ CVE + 
angina, HF, 
PVD, TIA. 
Sex-specific 
models. 
Traditional 
RFs+ BP- 
lowering 
medication, 
DM, CKD, age ≥ 75 Age 45-75 years 
Canada 
guideline for 
lipid 
manageme
nt 201660 
<10 10-20 ≥ 20 DM, CKD, FH, LDL-c ≥5 
mmol/l. 
NICE for 
hypertensio
10-year 
QRISK2 46 
<20 ≥20 Traditional 
RFs+ 
DM, albuminuria, CKD, FH 
or other inherited disorder of 
Adults 40-80 
years 
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Guidelines  Risk Score Risk threshold (%) Predicted 
outcomes 
Risk 
factors 
CVD risk equivalent 
(assumed to have high 
CVD risk) 
Age range for 
screening 
Low Moderate High 
n 2011 (UK)  
5 
‘Hard’ CHD + 
‘hard’ CVE + 
TIA. 
treated 
hypertensio
n, BMI, 
family 
history of 
premature 
CVD, 
deprivation 
score, 
ethnicity, 
rheumatoid 
arthritis, 
CKD, AF. 
lipid metabolism, presence 
of TOD 
<10 ≥10 Type 1 DM, albuminuria, 
CKD, FH or other inherited 
disorder of lipid metabolism, 
age ≥ 85 
Adults 40-84 
years 
NICE for 
lipid 
manageme
nt 2014 
(UK)57 
JBS 3 2014 
(UK) 49  
10-year JBS3 
risk calculator 
49 
<10 ≥10 DM+ age>40 years, 
moderate or severe CKD, 
FH, presence of TOD, 
significantly high lifetime 
risk, age ≥ 80. 
Adults 40-74 
years 
SIGN149 
2017 61 
(Scotland, 
UK) 
10-year 
ASSIGN 62  
<20 ≥20 CVD events are 
defined by ICD9 
and 10 (fatal or 
non-fatal events 
of the circulatory 
system)  
Sex-specific 
model. 
Traditional 
RFs + family 
history of 
premature 
CVD, 
rheumatoid 
arthritis, 
deprivation 
score.  
DM+ age>40yrs, DM + 
age<40yrs+ 
albuminuria/duration of 
DM≥20 years / proliferative 
retinopathy/ autonomic 
neuropathy/ TOD, severe 
CKD, microalbuminuria, FH, 
TC > 8 mmol/L, SBP ≥160 
and/or DBP ≥ 100 mmHg. 
Adults 40-74 
years (at any age 
for those with a 
family history of 
premature CVD or 
FH. 
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Guidelines  Risk Score Risk threshold (%) Predicted 
outcomes 
Risk 
factors 
CVD risk equivalent 
(assumed to have high 
CVD risk) 
Age range for 
screening 
Low Moderate High 
ACC/AHA  
for 
hypertensio
n 2017 (US) 
63  
10-year 
Pooled 
Cohort 
Equations64 
<10 ≥ 10 ‘Hard’ CHD + 
‘hard’ CVE 
Sex- and 
race-
specific 
model. 
Traditional 
risk factors+ 
BP lowering 
medications
. 
DM, CKD, age ≥ 75 Adults 40-75 
years 
ACC/AHA 
for lipid 
manageme
nt 2018 
(US)65  
<7.5 7.5-<20 ≥20 DM, LDL-c ≥ 190 mg/dl 
USPSTF for 
lipid 
manageme
nt 2016 
(US)66 
<7.5 7.5-10 >10 Not mentioned 
Abbreviations: ACC/AHA: American College of Cardiology/American Heart Association, AF: Atrial Fibrillation, CHD: Coronary Heart Disease, 
CVD: Cardiovascular disease, CVE: Cerebrovascular event, CKD: Chronic Kidney Disease, DBP: Diastolic blood pressure, DM: Diabetes 
Mellitus, ESH/ESC: European Society of Cardiology, FH: Familial Hypercholesterolemia, HDL-c: High Density Lipoprotein cholesterol, HF: Heart 
failure, JBS: Joint British Societies, LDL-c:  Low Density Lipoprotein cholesterol, LVH: Left Ventricular Hypertrophy, NHF: National Heart 
Foundation, NICE: National Institute for Health and Care Excellence, NVPDA: National Vascular Disease Prevention Alliance, PVD: Peripheral 
Vascular Disease, RF: Risk factor, SBP: Systolic blood pressure, SIGN: Scottish Intercollegiate Guidelines Network, TC: Total Cholesterol, TIA: 
Transient Ischemic attack, TOD: Target Organ Damage, USPSTF: US Preventive Services Task Force. 
* ‘Hard’ CHD refers to myocardial infarction and fatal CHD, ‘Hard’ cerebrovascular disease refers to stroke and fatal stroke. Traditional risk 
factors refer to age, sex, smoking status, systolic BP, TC/HDL-c and DM.  
 
11 
Chapter 1. Introduction  
BP lowering drug treatment in the primary prevention of CVD   
 In this thesis, BP lowering drug treatment is considered for primary 
prevention of CVD, thus management of complicated, resistant or secondary 
‘hypertension’ is not covered. BP value throughout this thesis refers to 
clinic/office BP. 
The effectiveness of BP lowering drug treatment  
The effect of BP lowering drug treatment for CVD risk reduction has been 
well established in many RCTs 67, 68. However, not all BP-lowering drugs are 
equal for CVD reduction. Alpha1-blockers, centrally acting antiadrenergic 
agents (a2-adrenoreceptor agonists and imidazoline receptor agonists), 
antialdosterone, and aliskiren effectively reduced BP, however, the benefits for 
CVD reduction, safety and tolerability of these agents have been unclear, thus 
these are only recommended as add-on therapies 69.  
In contrast, at standard doses of the five most commonly-used of BP 
lowering drugs, angiotensin-converting enzyme inhibitors (ACEI), angiotensin 
receptor blockers (ARB), dihydropyridine calcium channel blockers (CCB), β 
blockers and thiazides or thiazide-like diuretics (e.g. chlorthalidone) similarly 
reduce BP at a certain pre-treatment BP value. At higher pre-treatment BP 
value, therapeutic dose of BP lowering drug treatment produced a larger BP 
reduction 70. As Law et al estimated, at an average pre-treatment BP of 154/97 
mmHg, half or one standard dose of the five commonly-used BP lowering drugs 
reduced SBP by an average 7.1 mmHg and DBP by 9.1 mmHg over a 24 hours 
period 71. Every 10 mmHg reduction of systolic BP was associated with a 20% 
reduction of CVD over 5 years irrespective of drug class, age or sex 1, 49, 70, 72. 
The full effects of BP lowering drug regimens on CVD risk reduction were 
potentially achieved within one year 70, 73. Different BP lowering drug classes 
have modest benefits in cause-specific CVD outcomes40, 74 (Table 1.2), this 
difference in cause-specific outcomes may be attributable to small differences 
in BP reduction. The non-BP-related effect is also doubted, but no ‘pleiotropic’ 
effect has been identified 70, 75. Noticeably, due to inferior effects on stroke 
prevention and adverse effects on metabolism syndrome (weight gain, lipid 
metabolism and new on-set DM), β blockers are no longer recommended as an 
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initial therapy. Due to additive efficacy of BP lowering drug classes and the 
likelihood of adverse effect at high dose, a combination of low dose drugs at 
initiation is preferable to titrating a single agent to high dose 71, 76. 
Table 1.2. Effects of blood pressure lowering drug treatment on cause-specified 
outcomes and adverse effects. 
 
Inferior (-) 
/superior(+) 
effects on 
specific 
outcomes 
40, 74 
Compelling 
contraindic
ations 
Major adverse effects Caution 
DHP- 
CCB 
Stroke 
(+),heart 
failure (+) 
NA Peripheral vasodilation 
(peripheral oedema, flushing, 
headache, dizziness), postural 
hypotension, tachycardia, 
palpitations, chest pain, 
gingival hyperplasia 
NA 
TZ Heart failure 
(++) 
Gout Lipid metabolism, new on-set 
DM, sudden death with high 
dose (4x standard dose), 
postural hypotension, 
dizziness, hypokalemia, 
hyponatraemia, 
hyperuricemia, 
hyperglycaemia 
‘Triple 
whammy’ 
( 
ACEI/ARB 
+diuretic 
+NSAID) 
can cause 
acute 
kidney 
injury ACEI LVH (+), 
microalbumi
nuria (+), 
renal 
function (+). 
Pregnancy, 
bilateral 
renal 
artery 
stenosis, 
hyperkalae
mia 
Dry cough, hyperkalaemia, 
renal impairment, angioedema 
ARB Hyperkalaemia, renal 
impairment 
Abbreviation: ACE-I: Angiotensin Converting Enzyme Inhibitors, ARB: Angiotensin 
II Receptor Blockers, DHP-CCB: Dihydropyridine Calcium Channel Blocker, DM: 
Diabetes Mellitus, LVH: Left Ventricular Hypertrophy, NA: Not Applicable, NSAID: 
Nonsteroidal anti-inflammatory drugs, TZ: Thiazide or thiazide-like diuretics. 
 
When to initiate a BP-lowering drug?  
Historically, BP thresholds for drug treatment initiation heavily focussed 
on diastolic BP until the performance of Systolic Hypertension in the Elderly 
Program (SHEP) trials in the 1990s. Since then the focus was shifted to systolic 
BP ( Figure 1.3) 77. In a large study with 1.25 million participants aged 30 years 
or older, Rapsomaniki et al56 showed that systolic and diastolic BP were 
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differently associated with different types of CVD events. Systolic BP had a 
stronger association with stroke, CHD and CVD events whereas diastolic BP 
had a stronger association with abdominal aortic aneurysms.  
Figure 1.3 Blood pressure thresholds for drug treatment initiation. 
Figure adapted from Pfeffer et al. New England Journal of Medicine. 2016; 
375(18):1756-176677.  
In the past couple of years there have been significant changes to the 
BP thresholds for drug treatment initiation down to as low as 120-130 mmHg of 
systolic BP. Later trials and observational studies demonstrated a continuous, 
log-linear relationship between risk of CVD and BP even at a modest value of 
115/75 mmHg 78, 79.  Any commonly-used BP-lowering drug classes induce 
similar relative CVD risk reduction at any baseline BP threshold 70, 74, age80, 
sex81, diagnosis of DM82, CKD83 or not, and any baseline CVD risk 84 however, 
absolute risk reduction is greater in participants at higher baseline CVD risk 84, 
85. Thus, a risk approach is more beneficial and cost-effective than a BP-
threshold approach (e.g. BP ≥ 140/90 mmHg) that could undertreat those with 
high risk 84, 86, 87. Still, JNC 8 (2014) in the US heavily depends on age and BP 
thresholds41. As short-term absolute risks overweighted age in their 
calculations, young or middle age individuals with significantly elevated BP (e.g. 
BP ≥160/100 mmHg) tends to be underestimated as ‘low-moderate’ risk and 
remain untreated 86. In addition, most of the absolute risk algorithms account 
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for systolic BP only, thus, an absolute risk approach in conjunction with BP 
threshold is recommended. 
Current guidelines for BP lowering drug treatment (Table 1.3) 
High-risk settings 
In terms of the primary prevention of CVD, high-risk settings refer to 
individuals whose absolute risk exceed a threshold or those with the presence 
of CVD risk equivalents indicated by each guideline (Table 1.1). General 
recommendations for the high-risk population are substantially based on 
evidence that recommends an early initiation of pharmacotherapy 70, 74, 84, 88-93 
because the benefits of BP lowering drug treatment were recorded from a 
systolic BP of 130 mmHg or higher 92, 93.  
Guidelines in the UK 5, 49, 61  and Europe40 recommend a BP threshold of 
140/90 mmHg, whereas Australian2, 58 guidelines prompt an immediate 
treatment regardless of BP levels. The recent SPRINT trial showed that 
lowering systolic BP below 120 mmHg provided little further benefits in spite of 
no increased risk of CVD or mortality 90, 94, 95.  Others are concerned about 
serious adverse events of intensive pharmacotherapy including hypotension, 
syncope, electrolyte abnormalities, acute kidney injury, or acute renal failure. 
Recently guidelines from Canada (2018), New Zealand (2018) and ACC/AHA 
US (2017) have a BP threshold of 130/80 mmHg at which efficacy and safety 
are likely to be balanced 1, 3, 63, 94, 96.  
Low-moderate risk settings 
In general, most guidelines 1-3, 5, 49, 58, 61  consider that a persistent BP of 
160/100 mmHg is sufficiently high to establish a BP lowering drug treatment. In 
the HOPE-3 trial 97 pre-specified for intermediate risk population, no significant 
effect of BP lowering drug treatment was recorded, however substantial CVD 
reduction was observed in those whose BPs were higher than 143 mmHg. In a 
secondary analysis of HOPE-3 trial, Dagenais et al showed that such 
substantial benefits disappeared in participants with healthy lifestyles98. Thus, 
healthy lifestyle tended to sufficiently reduce CVD risk in an intermediate CVD 
risk setting, and benefits of BP lowering drug treatment in a low-moderate 
setting remains unclear, particularly in those with BP ranging from 140 to 159 
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mmHg. However, the US and European guidelines40, 63 persist with the 
traditional threshold of 140 mmHg of systolic BP.  
Table 1.3. Blood pressure thresholds to initiate blood pressure drug treatment 
according to absolute CVD risk stratification. 
 Guidelines Low risk 
Moderate 
risk 
High risk/CVD risk 
equivalent  
Australian hypertension 2016 
(Australia) 58 160/100 140/90 Any blood pressure level  
Canada guideline for 
hypertension 2018 (Canada) 3 
160/100 
(no risk 
factors) 140/90 
SBP ≥ 130 irrespective 
of DBP 
130/80 for DM 
NVDPA guideline for CVD 
prevention 2012 (Australia) 2 160/100  
Any blood pressure level 
70, 82 
New Zealand guideline 2018 1  160/100  130/80 
SIGN 2017 61 (Scotland) 160/100  
Any blood pressure level  
for DM, severe CKD, 
albuminuria, dialysis99, 
100 
140/90 70, 83-85, 89, 91, 99-101 
 NICE for hypertension 20115, 
JBS3 201449 (UK) 160/100  140/90 70 
ACC/AHA hypertension 2017 63 
(US) 140/90 79, 88, 102-104 130/80 70, 74, 84, 88-92 
ESC/ESH for CVD prevention 
2016 40, ESC/ESH for 
hypertension 2018 59 (Europe) 140/90 
Abbreviation: ACC/AHA: American College of Cardiology/American Heart 
Association, CKD: Chronic Kidney Disease, CVD: Cardiovascular disease, DM: 
Diabetes Mellitus, ESC: European Society of Cardiology, JBS: Joint British Societies, 
NICE: National Institute for Health and Care Excellence, NVPDA: National Vascular 
Disease Prevention Alliance, SIGN: Scottish Intercollegiate Guidelines Network 
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The effectiveness of BP lowering drug treatment in mildly elevated BP 
Two systematic reviews 88, 105 specifically focused on mildly elevated BP 
(SBP 140-159 mmHg and/or DBP 90-99 mmHg) have been conducted. (1) In 
a systematic review by Diao et al 105, no significant benefits for CVD or mortality 
were observed. The review was restricted to RCTs with the control group of 
placebo or untreated.  Only four studies (MRC, SHEP, VA-NHLBI and ANBP) 
of 8912 participants were included with a maximum follow-up of five years. A 
small number of CVD events were recorded in these trials, indicating the low-
risk profile of the participants. The review by Diao et al included the SHEP trial 
that required participants to have systolic BP exceeding 160 mmHg and a 
diastolic BP lower than 90 mmHg, though only 7 out of 4736 SHEP participants 
were included in this review. (2) In a larger systematic review of 11 RCTs 
(15266 participants) by BPLTTC 2015 88, a significant reduction of major CVD 
events, CVD and all-cause mortality was observed in the active or intensive 
treatment group. However, the BPLTTC review included RCTs with the 
continuation of previous BP lowering drug treatment (ADVANCE, Diabhycar, 
PART-2, BENEDICT and SCAT), thus baseline BP values were likely to be 
underestimated and misclassified as ‘mild hypertension’.  In Table 1.4, only 
RCTs with discontinuation of previous treatment were pooled and the treatment 
effects were also standardised to 10 mmHg reduction of systolic BP.  The effect 
on CVD and total death outcomes were no longer significant, however, the 
effect on stroke remained significant with OR 0.21 (0.07-0.64). However, the 
significant effects on stroke were exclusively observed in RCTs with 100% 
diabetic participants (ABCD and UKPDS), they were more likely to be at 
increased CVD risk. In a retrospective longitudinal cohort study106 on low risk 
participants (QRISK2<20%) with mild hypertension, no significant reduction on 
major CVD events or mortality were observed in treated participants, this group 
were more likely to have higher risk of adverse events such as hypotension, 
syncope, bradycardia, electrolyte abnormalities, falls and acute kidney injury. 
In contrast, a recent stratified meta-analysis by  Brunström et al107  found a 
significant reduction of  major CVD events with a RR 0.88 (0.80-0.96) in  a 
group of primary preventive trials with mean SBP ranging from 140-159 mmHg, 
yet these trials included at least 50% of participants with previous CVD. 
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Table 1.4. Summary of effects of BP lowering drug treatment in mildly elevated BP 88  
Characteristics ANBP  MRC VA-NHLBI PREVEND ABCD (H) ABCD (N) UKPDS Overall 
effects 
Comparison Chlorothiazid
e vs placebo 
Bendrofluazide 
/propranolol vs 
placebo 
Chlorthalidone 
+ reserpine vs 
placebo 
Enalapril 
vs placebo 
More vs less intensive; 
nisoldipine or enalapril 
More vs 
less 
intensive; 
captopril 
or atenolol 
NA 
No of 
participants/origi
nal trials 
1832/3427 6061/17354 1012/1012 212/864 213/470 143/480 453/1148 NA 
Mean/median 
follow-up (years) 
4 5 4.5 3.9 5.0 5.1 8.3 NA 
Mean BP mmHg NA NA NA 147/84 144/94 147/85 145/94 NA 
Previous BP 
lowering drug 
treatment (%) 
0 0 0 0 37 
(stopped) 
36 (stopped) 0 NA 
% DM 0 0 0 5 100 100 100 NA 
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Characteristics ANBP  MRC VA-NHLBI PREVEND ABCD (H) ABCD (N) UKPDS Overall 
effects 
SBP reduction 
mmHg 
NA NA NA 7.2 8.7 7.1 9.1 NA 
Outcomes RR         
CVD events NA 0.93  
(0.68-1.2) 
1.60  
(0.52-4.91) 
0.43  
(0.12-1.46) 
0.45  
(0.20-1.02) 
1.33  
(0.55-3.23) 
NA 0.88 
(0.68-1.15) 
Standardised  NA NA NA 0.30  
(0.06-1.68) 
0.40  
(0.16-1.03) 
1.49  
(0.43-5.21) 
NA 0.57  
(0.29-1.14)  
CHD event NA 1.08  
(0.76-1.55) 
1.60  
(0.52-4.91) 
NA 1.10  
(0.38-3.14) 
2.23  
(0.55-9.00) 
0.98  
(0.53-1.81)  
1.12  
(0.85-1.49) 
Standardised  NA NA NA NA 1.12  
(0.33-3.74) 
3.10  
(0.43-22.07) 
0.98  
(0.50-1.92) 
1.11 
(0.63-1.94) 
Stroke NA 0.50  
(0.24-1.08) 
NA 0.08  
(0.00-1.57) 
0.46  
(0.11-1.90) 
0.22  
(0.02-1.98) 
0.21  
(0.07-0.64) 
0.34  
(0.20-0.59) 
Standardised  NA NA NA 0.03  0.41  0.12  0.18  0.21  
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Characteristics ANBP  MRC VA-NHLBI PREVEND ABCD (H) ABCD (N) UKPDS Overall 
effects 
(0.00-1.62) (0.08-2.07) (0.01-2.61) (0.06-0.61) (0.08-0.51) 
CVD death NA NA NA 1.80  
(0.16-
20.16) 
0.11  
(0.01-0.90) 
2.36  
(0.44-12.57) 
NA 0.66  
(0.26-1.68) 
Standardised  NA NA NA 2.26  
(0.08-
64.82) 
0.08  
(0.01-0.89) 
3.35 
(0.32-35.36) 
NA 0.72  
(0.16-3.25) 
Total death* 1.20  
(0.58-2.46) 
0.76 
(0.54-1.07) 
7.35  
(0.46-117.60) 
0.89  
(0.28-2.84) 
0.30  
(0.11-0.81) 
1.62  
(0.47-5.53) 
0.81  
(0.44-1.49) 
0.81  
(0.63-1.04) 
Standardised  NA NA NA 0.85  
(0.17-4.27) 
0.22  
(0.06-0.83) 
2.02  
(0.34-12.16) 
0.79  
(0.41-1.53) 
0.71  
(0.42-1.20) 
Abbreviation: ABCD: Appropriate Blood pressure Control in Diabetes trial, ANBP: Australian National Blood Pressure study, BP: blood pressure, MRC: Medical 
Research Council trial, PREVEND-IT: Prevention of Renal and Vascular End stage Disease Intervention Trial, RR: Risk Ratio, SBP: Systolic blood pressure, 
UKPDS: UK Prospective Diabetes Study, VA-NHLBI: Veterans Administration-National Heart, Lung, and Blood Institute trial. 
Overall and standardised effects are recalculated from data provided in the 2015 BPLTTC review88. RCTs with the continuation of previous treatment were 
excluded due to BP underestimation. ¶ Standardised to a 10 mmHg reduction of systolic BP that is calculated by multiplying the log OR (and its standard error) 
by 10/average SBP reduction. Bold: statistically significant outcome. *: Used Peto OR due to 0 events in a controlled group of VA-NHLBI.
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Concerns about irreversible damage if BP lowering drug treatment is delayed 
As reported by Wilkins et al108, an individual with optimal risk profiles 
could delay CVD events by 8-14 years compared to those with at least two 
major risk factors.  Concern is around the high residual risk (after-treatment 
risk) despite intensive drug treatments or irreversible damage if reserving 
treatment to high-risk individuals only 85, 109-111. Thomopoulos et al 85 reported 
that ‘residual’ risk was higher in high-risk settings, in other words, treatment in 
high-risk profiles was more likely to fail. However, baseline CVD risks 
estimation in the Thomopoulos et al analysis was based on actual incidence 
death rates of CVD in controlled groups. Noticeably, the controlled groups were 
either placebo, no treatment or less intensive treatment regardless of whether 
previous BP lowering drug treatment was continued or not, thus the calculated 
CVD risk tended to be underestimated and patients misclassified. Besides, 
assessment of ‘residual risk’ is impacted by other concomitant preventive 
therapies (e.g. lifestyle modifications, lipid-lowering or antiplatelet treatment), 
drug adherence, achieved BP or visit-to-visit BP variation 112, 113. 
 In the paucity of evidence of short-term benefits or harms, the concern 
of BP lowering drug treatment in those with low-risk has been shifted to long-
term effects. As most of the RCTs were mainly followed-up to a maximum of 5 
years, after the end of the in-trial phase, some trials were extended. In the 
extended phase, all participants returned to usual care and were advised to 
receive active therapies. Outcomes were obtained by health records or national 
death index linkages. In Table 1.5, to minimize the impact of carry-over effects 
of previous treatments, some placebo-controlled RCTs without previous 
treatment or RCTs with wash-out previous treatment were reviewed to estimate 
the effect of treated versus untreated group114-123. In relatively low-risk RCTs 
(Oslo, PREVEND-IT), the 5-year follow-up phase observed a significantly low 
cerebrovascular event rate in the active treatment group compared to the 
placebo group. However, the beneficial effects disappeared in the long-term 
phase of both trials, noticeably, the 5-year and 10-year Oslo trial recorded a 
higher number of fatal CHD events in the active group compared to the placebo 
group but this was not statistically significant; in the 40-year Oslo trial the harm 
of active treatment on fatal CHD became significant HR 1.51 (1.01-2.26). 
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Participants in the Oslo trial were treated with a high dose of thiazide diuretic 
that is not recommended in current practice. As a high dose of a thiazide diuretic 
is highly relevant to a high risk of new onset diabetes mellitus (DM), DM with 
long duration may lead to increase CHD risk. In contrast, the SHEP and Syst-
Eur trial recorded a sustained reduction of CVD mortality in the active treatment 
group in both the short- and long-term phases. All participants in these trials 
tended to be at increased baseline CVD risk when inclusion criteria restricted 
to the elderly with highly elevated BP (systolic BP ≥ 160 mmHg). Most of the 
post-trial observational studies have a common limitation that information of 
post-trial treatment was not sufficiently recorded, however as a nature of 
randomisation, it is unlikely that the treatment regimens were uneven or more 
pronounced between the originally randomised groups. Generally, the concern 
about the long-term effects of BP lowering drug treatment in a low-risk setting 
with mildly elevated BP remained questionable.  
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Table 1.5. Summary of short- and long-term effects of blood pressure lowering drug treatment for primary prevention of cardiovascular 
disease 
Characteristics Oslo114-116 PREVEND-IT 117, 118 SHEP 119-121 Syst-Eur 122, 123 
Comparison Hydrochlorothiazide 50 mg vs 
placebo 
Fosinopril 20 mg vs 
placebo 
Chlorthalidone 12.5 mg vs 
placebo 
Nitrendipine 10 mg vs 
placebo 
% Active treatment in post-
trial phase 
80 (both groups)  Reported equal NA 75 (both groups) 
Mean age years 45 51 72 70 
Mean BP mmHg 156/97 127/74 170/76 174/85 
CVD history (%) 0 3 5% MI, 1.5% stroke 30 
DM (%) 0 3 10 10 
SBP reduction mmHg in-trial 
phase 
17 1 11 11 
‘Ethical’ roof to initiate 
treatment in placebo (mmHg) 
180/110  NA 240/115 (single visit) 
Sustained 220/90 
SBP 219 
Outcomes A: 407, P: 379 A:431, P:433 A:2365, P:2371 A:2398, P:2297 
5-yr (1972-1977) 
+CVE: 0 (A), 7 (P) 
+CHD: 20(A), 13 (P), NS. 
5-yr (1998 - 2003) 
+Nonfatal CVE: 1 
(A), 10 (P) 
5-yr (1985 - 1990) 
+CVE: RR 0.73 (0.57-
0.94) 
2-yr (1995 - 1997) 
+Stroke: RR 0.61 
(0.44-0.87) 
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Characteristics Oslo114-116 PREVEND-IT 117, 118 SHEP 119-121 Syst-Eur 122, 123 
+Fatal CHD: 6(A), 2 (P), NS 
+Total deaths: NS 
+Nonfatal: MI, HF, 
and PVD: NS. 
+ Fatal: CVD, total: 
NS 
 
+CHD: 0.75 (0.60-0.94) 
+CVD: 0.68 (0.58-0.79) 
+Fatal: stroke, CVD, total: 
NS 
 
 
+CVD: RR 0.74 
(0.60-0.91) 
+ MI, HF:NS 
+Fatal: CVD, cancer, 
total: NS 
 
 
10-yr (1972-1982) 
+Fatal CHD: 14 (A), 3 (P), NS 
+Total deaths: NS 
9.5-yr (1998-2008) 
+ Nonfatal: MI, HF, 
PVD, CVE, CVD: 
NS. 
+ Fatal: CVD, total: 
NS. 
14-yr (1985-2000) 
+Fatal CVD: HR: 0.86 
(0.76-0.97) 
+ Fatal: stroke, non-CVD, 
total: NS 
6-yr (1995-2001) 
+Stroke: RR 0.73 
(0.57-0.93) 
+CVD: RR 0.87 
(0.76-0.99) 
+ MI, HF:NS 
+Fatal: CVD, cancer, 
total: NS 
 
 
40-yr (1972-2011) 
+ Fatal MI: HR 1.51 (1.01-2.26) 
+Fatal: CVE, total: NS 
22-yr (1985-2006) 
+Fatal CVD: 0.89 (0.80-
0.99) 
+Fatal: CHD, stroke, total: 
NS 
Abbreviation: A: Active, CHD: Coronary Heart Disease, CVD: Cardiovascular disease, CVE: Cerebrovascular event, DM: Diabetes Mellitus, HF: 
Heart failure, MI: Myocardial Infarction, NS: Not statistically significant, P: Placebo, PREVEND-IT: Prevention of Renal and Vascular End-stage 
Disease Intervention Trial, RR: Risk Ratio, SBP: Systolic blood pressure, SHEP: Systolic Hypertension in the Elderly Program trial, SYST-Eur: 
Systolic Hypertension in Europe Trial
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Lipid-lowering drug treatment (LLT) in primary prevention of CVD  
In this thesis, lipid-lowering drug treatment (LLT) is considered for the 
purpose of primary prevention of CVD, thus management of complicated or 
secondary ‘dyslipidaemia’ is not mentioned.  
Lipid profiles include total cholesterol, HDL-c, LDL-c and triglyceride 
(TG). LDL-c is calculated by the Friedewald equation given that the ratio of total 
cholesterol and triglyceride is constant124. When TG exceeds 4.5 mmol/L or 
fasting tests are not available, non-HDL-c that is calculated by total cholesterol 
minus HDL-c obtained from a non-fasting test may be eligible for treatment 
decision. Despite HDL-c being strongly associated with CVD risk, treatment 
primarily aimed at improving HDL-c contributes modest effects to CVD 
reduction125, 126. In contrast, statins that primarily reduce LDL-c are associated 
with substantial major CVD reduction, thus are recommended as the first line 
therapy127.  
Statin 
  Different statins produced different magnitudes of LDL-c reduction at a 
certain dose, atorvastatin and rosuvastatin have higher lipid-lowering efficacy, 
and thus they are considered high potency statins (Table 1.6). Higher doses of 
statins are log-linearly associated with a larger LDL-c reduction, each doubling 
of the dose of statins obtains approximately a further 6% LDL-c reduction 
irrespective of pre-treatment LDL-c value 128. Based on the percentage of 
achieved LDL-c reduction, statins are classified as low, moderate and high 
intensity with LDL-c reduction of less than 30%, 30-40% and more than 40% 
respectively 57.   
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Table 1.6. Statin doses and effects on LDL-c reduction 128 
 
Given that any statins at any doses effectively reduced major CVD risk, 
every 1 mmol/L reduction of LDL-c was associated with 25% reduction of major 
CVD events during each year irrespective of pre-treatment  LDL-c or baseline 
CVD risk 130, although greater CVD risk populations obtained greater absolute 
risk reduction 127, 132, 133. The benefits of statins accumulate over years, longer 
treatments obtained larger absolute risk reduction 134. Thus, current guidelines 
encourage early initiation of moderate-high intensity statins in high CVD risk 
individuals at any level or at mildly elevated LDL-c 1, 2, 135 (Table 1.7). As 
adverse effects of statin are dose-dependent, a low-moderate dose of high 
potency statins is preferable. 
Daily dose (mg) Notes 
Statin 5 10 20 40 80  
Fluvastatin 10% 15% 21% 27% 33% Metabolised by 
cytochrome P450 
2C9-> cautious with 
drug interaction129 
Pravastatin 15% 20% 24% 29% 33%  
Lovastatin - 21% 29% 37% 45% Metabolised by 
cytochrome P450 3A4 
-> interact with potent 
cytochrome P450 3A4 
inhibitors, even 
grapefruit.129 
+ Simvastatin 80 mg 
may be harmful 
(greater risk of 
myopathy) 130 
+ High dose of 
atorvastatin increased 
liver enzyme level 
(reversible)131 
Simvastatin 23% 27% 32% 37% 42% 
Atorvastatin 31% 37% 43% 49% 55% 
Rosuvastatin 38% 43% 48% 53% 58%  
 
Low intensity        Moderate intensity        High intensity        
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Table 1.7 Initiation of statins based on absolute cardiovascular disease risk and serum cholesterol thresholds 
Guidelines Low risk Moderate risk High risk /CVD risk equivalent 
Canada guideline for lipid 
management 2016 60 
LDL-c ≥ 5  mmol/L LDL-c ≥ 3.5 or 
Non-HDL-c ≥ 4.3 or 
ApoB ≥ 1.2 g/l  
Any serum cholesterol level 
ESC 2016 (EU)40 LDL-c≥ 4.9  mmol/L LDL-c≥ 2.6  mmol/L *SCORE 5-9:  
LDL-c≥ 1.8 mmol/L 
*SCORE ≥ 10 
Any LDL-c level 
SIGN 2017 (Scotland) TC > 8  mmol/L Any serum cholesterol level 
NVDPA (2012) 2 TC>7.5 mmol/L or TC/HDLc ≥ 8 Any serum cholesterol level 
New Zealand 20181 TC/HDLc ≥ 8 Any serum cholesterol level 
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Guidelines Low risk Moderate risk High risk /CVD risk equivalent 
NICE for cholesterol 
management 201457, JBS3 
2014 (UK)49 
Not recommended Any serum cholesterol level 
USPTS for lipid management 
2016 (US) 66 
Not recommended Additional RFs (smoking, hypertension, DM, 
dyslipidaemia) 
ACC/AHA for lipid management 
2018 (US)65  
LDL-c>4.9  mmol/L 
LDL-c>1.8 mmol/L in 
DM. 
LDL-c ≥ 4.1 or  
Additional RFs  
LDL-c > 1.8 mmol/L 
Abbreviations:  ACC/AHA: American College of Cardiology/American Heart Association, DM: Diabetes Mellitus, ESC: European 
Society of Cardiology, HDL-c: High Density Lipoprotein cholesterol, JBS: Joint British Societies, LDL-c: Low Density Lipoprotein 
cholesterol, NICE: National Institute for Health and Care Excellence, NVPDA: National Vascular Disease Prevention Alliance, 
SIGN: Scottish Intercollegiate Guidelines Network, USPSTF: US Preventive Services Task Force 
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Adverse effects of statins 
Statin use is associated with myopathy, new-onset diabetes, elevated 
liver enzyme levels and haemorrhagic stroke. Statins at higher doses are 
associated with increased risk of adverse effects, noticeably simvastatin 80 mg 
was significantly associated with increased risk of myopathy130. Besides, most 
statins are metabolised through cytochrome P450 system (except pravastatin 
and rosuvastatin), thus they are more likely to have drug interactions. 
Simvastatin and atorvastatin are metabolised via cytochrome P450 3A4, 
concomitant use of cytochrome P450 3A4 inhibitor agents (e.g. ‘azole’ anti-
fungal agents, amiodarone, verapamil, diltiazem) or a less potent inhibitor such 
as grapefruit juice increases the plasma level of these statins and subsequently 
enhances the risk of adverse effects129.  At a moderate-high dose of statins, 
incidence rates of statin-related adverse effects are very low, in other words, 
the evident benefits on CVD outcomes substantially exceed potential harms of 
statin. As estimated by Collin et al134, treating 2000 healthy individuals with a 
statin would prevent 200 major CVD events and would cause one case of 
myopathy, one to two cases of haemorrhagic stroke and one to two cases of 
new-onset DM.  
Non-statin agents 
Other lipid-lowering agents including fibrates136-139, bile acid sequestrant 
140, ezetimibe141, 142  have modest effects on LDL-c or TC, inconsistent impacts 
on CVD outcomes and have higher adverse effects, thus they are not routinely 
recommended as monotherapy for the primary prevention of CVD (Table 1.8) 
135. Lack of evidence for the benefit of combinations of these drugs with statins 
has been found except for a combination of ezetimibe with simvastatin that 
yielded a substantial CVD risk reduction in people with advanced chronic kidney 
disease143, still titrating statins to the maximum tolerated dose is preferable. A 
combination with non-statin agents is reserved for a very high-risk setting (e.g. 
familial hypercholesterolemia) or those accompanying significant disorders of 
HDL-c or TG. Nicotinic acid (niacin) 144, 145 has no clear evident benefits on CVD 
outcome and potentially increases overall mortality, thus it is no longer 
recommended as a preventive therapy. A new LLT agent, proprotein 
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convertase subtilisin/kexin type 9 (PCSK9) was associated with a substantial 
LDL-c and MI reduction, however, the evidence base is a small number of 
studies with short-term follow-up146, 147.  Thus PCSK9 has not been widely 
recommended or used to date.   
Table 1.8. Summary effects of non-statin agents. 
Non-statin 
agents 
Beneficial 
effects on 
serum 
cholesterol 
Beneficial 
effects on 
CVD 
outcomes 
Major adverse 
effects 
Indications 
Fibrate 
(except 
gemfibrozil) 
 TG, 
LDL-c, 
HDL-c 
CVD148  Serum 
creatinine 
(reversible) 148 
Not tolerated/ 
contraindicated 
statins ± marked 
elevated TG,  
low HDL-c 
Bile acid 
sequestrants 
LDL-c CHD149  TG, GI 
irritation, 
constipation. 
149 
FH, not 
tolerated/ 
contraindicated 
statins. 
Ezetimibe LDL-c Unclear (no 
study on 
primary 
prevention) 
 Liver 
enzyme, 
myopathy150 
PCSK9 
inhibitors 
LDL-c, 
HDL-c 
MI (mixed 
with 
secondary 
prevention)146 
Potential 
neurocognitive 
dysfunction 
(mixed with 
secondary 
prevention)147 
Not tolerated to 
statins and 
other non-statin 
agents 
Nicotinic acid 
(niacin) 
HDL-c, 
TG, LDL-c 
No benefits 
(even for 
secondary 
prevention)144 
Harmful effects 
on GI bleeding 
and infection, 
potentially  
all-cause 
mortality144, 145 
Not 
recommended 
Abbreviation: CVD: Cardiovascular disease, GI: Gastrointestinal, HDL-c: High-
Density Lipoprotein cholesterol, LDL-c: Low-Density Lipoprotein cholesterol, MI: 
Myocardial Infarction, TG: Triglyceride, FH: Familial Hypercholesterolemia. 
 
Lipid-lowering drug treatment in the elderly 
Current guidelines recommend LLT (e.g. statins) following the absolute 
CVD risk approach for the elderly aged 65 years or over (Table 1.7).  As most 
30 
Chapter 1 Introduction 
of the CVD risk algorithms are heavily weighted for age, the elderly are more 
likely to have a high CVD risk prediction, even if they have otherwise optimal 
risk profiles. Thus, most of them are eligible for LLT, however evidence for 
their benefits is attributable from RCTs mixed with secondary prevention151 or 
with younger age settings152.  In the elderly subgroup analysis incorporated in 
the meta-analysis by Brugts et al153, no significant effects on major CHD, 
cerebrovascular events or all-cause mortality were recorded, although the 
authors did not report the specific outcomes of MI or stroke. It is doubtful that 
the effects on cerebrovascular events could be diminished by the adverse 
effects of statins on haemorrhage stroke. In a meta-analysis154 restricted to 
RCTs or subgroups of primary prevention in the elderly aged 65 years or over 
a significant reduction in MI RR 0.61 (0.63-0.93) and stroke RR 0.76 (0.63-
0.93) was observed, however, no survival benefits were accrued. As the 
included RCTs were followed up less than 5 years and some of the included 
studies (ASCOT-LLA155, CARDS156 and JUPITER152) terminated earlier than 
planned, the effects on MI and stroke may be overestimated and mortality 
outcomes may require longer observations.  In a recent meta-analysis157 of 
the elderly subgroups from JUPITER and HOPE-3 trial, rosuvastatin 
substantially reduced CVD with HR 0.51 (0.38-0.69) in subgroup aged 65 to 
younger than 70 years, HR 0.74 (0.61-0.91) in subgroup aged 70 years or 
over, still, no mortality outcomes were reported. Some RCTs were extended 
after study termination for long-term follow-up of mortality outcome, only two 
extended RCTs have a large number of elderly participants indicated by mean 
age at 65 years or over (Table 1.9). As presented in Table 1.9, no trials 
observed substantial effects on mortality outcomes both in-trial and post-trial 
phases, however both ALLHAT-LLT and PROSPER trial included more than 
40% of secondary prevention subsets. Mortality effects of statins or LLT for 
primary prevention of CVD in the elderly remained unclear.  STAREE is an 
ongoing RCT that will inform us of the benefits and harms of statins in the 
elderly over 70s.  
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Table 1.9. Summary of effects of statins on the elderly 
Characteristics ALLHAT-LLT158, 159 PROSPER 151, 160 
Comparison Pravastatin 40 mg vs 
usual care 
Pravastatin 40  mg vs placebo 
% Active treatment in 
post-trial phase 
Not reported  Not reported 
Mean age yrs 66 75 
Mean LDL-c mmol/L 3.8 3.8  
Age ≥ 65 yrs (%) 56.1 100 
CVD history (%) 44.7 43.2 
DM (%) 39.3 11 
LDL-c reduction 
mmol/L in-trial phase 
0.4 1.3 
Outcomes 6-year phase (1994-
2002) 
+Combined CHD/ 
stroke, heart failure, 
cancer: NS 
+All-cause/CVD 
mortality: NS. 
3-year phase (1997-2002) 
+Combined CVD HR 0.85 (0.75-
0.97), CHD HR 0.81 (0.69-0.94). 
+CHD death HR 0.76 (0.58-
0.99) 
+Stroke, heart failure, cancer: 
NS 
+All-cause/CVD mortality: NS. 
10-year phase (1994-
2006) 
+Combined CVD/CHD/ 
stroke, heart failure: NS 
+All-cause/CVD 
mortality: NS. 
9-year phase (1997-2009) 
+Combined CHD HR 0.81 (0.69-
0.95). 
+Combined CVD, stroke, 
cancer: NS 
+All-cause/CVD mortality: NS. 
Abbreviations: ALLHAT-LLT: Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial–Lipid-Lowering Trial, CHD: Coronary Heart Disease, DM: 
Diabetes Mellitus, HR: Hazard Ratio, LDL-c: Low Density Lipoprotein cholesterol, 
MI: Myocardial Infarction, NS: Not statistically significant, PROSPER: Pravastatin in 
elderly individuals at risk of vascular disease trial, TG: Triglyceride 
Aims and sources of data used in this thesis 
This thesis contributes to filling in the gaps around the effectiveness of BP 
and LLT for primary prevention of CVD according to absolute CVD risk. 
However, the research focuses on settings with low absolute CVD risk and 
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mildly elevated BP for BP lowering drug treatment and the elderly for lipid-
lowering drug treatment. Four studies incorporated in this thesis aim to: 
❖  Assess which group of individuals classified by absolute risk benefits 
from actively BP lowering drug treatment versus placebo for CVD 
events. (Chapter 2) 
Chapter 2 presents a post-hoc subgroup analysis of the Australian National 
Blood Pressure (ANBP) cohort, a seminal study establishing the efficacy of 
BP lowering in ‘mild hypertensive’ persons. ANBP is a community-based 
placebo-randomised controlled trial in 3244 participants aged 35 to 69 
years. ANBP was conducted between 1973 and 1979 and was selected 
because it was placebo-controlled and patients in the control arm of the 
study would not have been taking a BP lowering medication previously 
unless they had very high levels of BP. Thus, the effect of treated vs 
untreated or delayed BP lowering drug treatment according to absolute CVD 
risk could be assessed.  
All analyses were based on the modified ‘intention to treat’ principle. 
Treatment effects were assessed by hazard ratio (HR), absolute risk 
reduction (ARR) and number needed to treat (NNT). In a subgroup analysis, 
participants were stratified by tertile of the 5-year Framingham absolute risk 
score with low (<6%), moderate  (6% -17%) and high risk (>17%). Tests for 
interaction of treatment effect over the subgroups were obtained by the Cox 
regression model for the Hazard ratio and a Cochran’s Q test for the 
absolute risk reduction.  
Although the study in the ANBP maintained the randomisation, the subgroup 
analysis by absolute CVD risk would reduce the study power due to the 
reduced sample size in each subgroup. As multiple statistical tests were 
performed, the results should be interpreted carefully due to the risk of false-
positive results. 
❖ Investigate the short- and long-term effects of BP lowering therapy on 
those with elevated BP over a spectrum of absolute risk on all-cause and 
disease-specific mortality. 
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Chapter 3 presents a post-hoc observational study of the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 
ALLHAT is a comparative RCT of three treatment arms (diuretic, CCB, ACE-
I). 33,357 ALLHAT participants were recruited in 623 centres in the USA, 
Canada, Puerto Rico and the US Virgin Islands. In the current study, the 
participants would be reclassified to previous treatment and treatment naïve 
group based on their treatment status before enrolling in the ALLHAT trial. 
ALLHAT was selected due to its large sample size and extended follow-up 
including post-trial phase up to 17 years.  
A Cox proportional hazard model was used to estimate the effects of BP 
treatment naive on mortality outcomes. Treatment effects were adjusted for 
baseline and in-trial characteristics. Also, a subgroup analysis by estimated 
10-year Framingham risk score (FRS) was performed to stratify participants 
into low (<20%), moderate (20-30%) and high risk (>30%) group. In the 
subgroup analysis by absolute CVD risk, interaction among CVD subgroup 
was tested by a baseline treatment status x absolute CVD risk stratification 
term in Cox models. 
This study would be biased by ‘confounding by indication’. Participants in 
previous treatment were more likely to be at higher underlying CVD risk (e.g. 
subclinical vascular damages or family history of CVD) or they were 
exposed to uncontrolled BP with lifestyle modifications. Thus, the mortality 
rate in these participants were expected to be higher than ‘treatment naïve’ 
participants. This issue should be put into consideration when interpreting 
the results. There are several methods to handle the confounding by 
indication such as propensity score, instrumental variable and multivariate 
adjusted models. Adjustment model was chosen because we wanted to 
present results from models with progressively larger sets of covariates, 
since there was not consensus about where some variables were on the 
causal pathway, and results with and without adjustment of such variables 
would be valuable.  
❖ Investigate short- and long-term effects of BP lowering pharmacotherapy 
in middle-aged individuals with mildly elevated BP stratified by absolute 
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risk for primary prevention of CVD with a particular focus on the low risk 
(<10% absolute risk over 5 years) group: a systematic review and meta-
analysis. 
Chapter 4 presents a systematic review meta-analysis of RCTs post-trial 
studies in middle-aged individuals with mildly elevated BP. We compared 
the effects of delayed  BP treatment (placebo/untreated during the trial or 
no previous treatment at trial entry) versus early treatment (actively treated 
during the trial or previous BP treatment at trial entry) on mortality in the 
short-term (5-year in-trial period) and long-term (≥10 years in total period). 
The data were pooled using Peto odds ratio . A subgroup analysis by 10-
year Framingham risk score was performed. Vigorous efforts in accessing 
individual data was put in to identify eligible participants.  
❖ Examine the relationship between the use of LLT at randomization and 
short- (4 years) and long-term (11 years) all-cause and CVD mortality by 
absolute CVD risk in those aged 65 years or over. 
Chapter 5 presents a post-hoc observational analysis of the Second 
Australian National Blood Pressure Study (ANBP2). ANBP2 is a 
comparative trial of two treatment arms (diuretic and ACE-I) with an 
open-labelled design with the blinded end-point assessment. The 
participants would be reclassified to LLT and no LLT group based on 
their treatment status before enrolling in the ANBP2 trial. ANBP2 was 
selected due to its large sample size and extended follow-up including 
post-trial phase up to 11 years. 
Cox proportional hazard models were used to estimate the hazard ratios 
and corresponding 95% confidence interval (CIs) for outcomes for 
participants in the ‘‘LLT’’ group compared with those in ‘‘no LLT’’ group. 
All of the analyses were adjusted by baseline and in-trial characteristics. 
A subgroup analysis was conducted using the tertile of 5-year FRS. The 
Cox regression models were used to test for interaction of treatment in 
the subgroup analyses. 
Similar to the study conducted in chapter 3, the results of this study were 
impacted by the risk of ‘confounding by indication’ where physicians 
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tended to prescribe lipid lowering drug treatment on those with higher 
underlying CVD risk.  The results should be interpreted carefully. 
Structure of this thesis 
Chapter 1: Introduction 
Chapter 2: Effectiveness of Blood Pressure-Lowering Drug Treatment by 
Levels of Absolute Risk: Post-hoc analysis of the Australian National Blood 
Pressure Study. 
Chapter 3: Legacy effect of baseline blood pressure ‘treatment naivety’ on all-
cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT). 
Chapter 4: Legacy effect of delayed blood pressure lowering drug treatment in 
middle-aged adults with mildly elevated blood pressure: systematic review and 
meta-analysis. 
Chapter 5: Short- and long-term association of lipid-lowering drug treatment 
and cardiovascular disease by estimated absolute risk in the Second Australian 
National Blood Pressure Study (ANBP2). 
Chapter 6: Summary, implications, future directions and conclusions 
Concluding remarks 
This chapter provides some backgrounds on the burden and primary 
prevention of CVD.  Generally, this chapter points out that (1) Primary 
prevention based on absolute risk approach is more cost-effective than 
traditional risk approach with threshold alone (e.g. blood pressure or blood 
cholesterol) (2) BP lowering drug treatment is reserved to the high-risk setting 
with BP threshold of 130/90 mmHg or higher. Benefits and harms of drug 
treatment in individuals at low-moderate risk with or without mildly elevated BP 
are controversial.  (3) Lipid-lowering drug treatment, particularly statins are 
generally prescribed in elderly populations due to its dominant effects on non-
fatal CVD outcomes whereas the survival benefits are less clear. (4) Most of 
the current evidence is attributable to studies with less than five years of follow-
up. The preventive treatment is a lifelong therapy, thus its long-term effects 
should be taken into consideration. 
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Chapter 2  Effectiveness of Blood Pressure-Lowering Drug 
Treatment by Levels of Absolute Risk: A Post-hoc analysis of 
the Australian National Blood Pressure Study. 
 
Preface 
In an attempt to assess which group of ‘mild hypertensive’ individuals 
classified by absolute risk benefits from actively BP lowering drug treatment, 
this chapter presents an analysis on the Australian National Blood Pressure 
study (ANBP), a seminal study in ‘mild hypertensive’ persons in 1970s. ANBP 
was a randomised placebo-controlled trial that provided a great opportunity to 
compare the impacts of early versus delayed treatment. This could not be done 
in modern clinical trials when placebo-controlled is unlikely to be ethical.  
The following text in this chapter was published in the journal BMJ Open 
2018; 8(3):e017723. 
Abstract 
Objectives: In many current guidelines, blood pressure (BP)-lowering drug 
treatment for primary prevention of cardiovascular disease (CVD) is based on 
absolute risk. However, in clinical practice, therapeutic decisions are often 
based on BP levels alone. We sought to investigate which approach was 
superior by conducting a post hoc analysis of the Australian National Blood 
Pressure (ANBP) cohort, a seminal study establishing the efficacy of BP 
lowering in ‘mild hypertensive’ persons. 
Design: A post hoc subgroup analysis of the ANBP trial results by baseline 
absolute risk tertile. 
Setting and participants: 3244 participants aged 35–69 years in a community-
based randomised placebo-controlled trial of blood pressure-lowering 
medication. 
Interventions: Chlorothiazide500 mg versus placebo. 
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Primary outcome measures: All-cause mortality and nonfatal events (non-
fatal CVD, congestive cardiac failure, renal failure, hypertensive retinopathy or 
encephalopathy). 
Results Treatment effects were assessed by HR, absolute risk reduction and 
number needed to treat. Participants had an average 5-year CVD risk in the 
intermediate range (10.5±6.5) with moderately elevated BP (mean 
159/103mmHg) and were middle-aged (52±8 years). In a subgroup analysis, 
the relative effects (HR) and absolute effects (absolute risk reduction and 
number needed to treat) did not statistically differ across the three risk groups 
except for the absolute benefit in all-cause mortality (p for heterogeneity=0.04). 
With respect to absolute benefit, drug treatment significantly reduced the 
number of events in the high-risk group regarding any event with a number 
needed to treat of 18 (10 to 64), death from any cause with 45 (25 to 196) and 
major CVD events with 23 (12 to 193).  
Conclusion: Our analysis contributed further evidence that the benefit of 
treatment was substantial only in the high-risk tertile, reaffirming the rationale 
of treating elevated blood pressure in the setting of all risk factors rather than 
in isolation. 
Introduction 
For decades, cardiovascular disease (CVD) has remained the greatest 
burden of disease in the developed world and now also in the developing world 
161, 162.  In 2012, CVD was responsible for 17.5 million deaths in the world and 
more than twenty thousand deaths in Australia161, 163. Noticeably, nearly 50% 
of deaths from CVD are attributable to high blood pressure (BP), the 
commonest modifiable population risk factor164.  Drug therapy for primary 
prevention of CVD is now recommended to be based on absolute CVD risk, 
where BP lowering drug treatment is determined by BP level together with other 
major CVD risk factors (e.g. sex, age, total cholesterol, high-density lipoprotein 
cholesterol, diabetes and smoking status) as an integrated score2, 3, 40, 165, 166. 
39 
Chapter 2. BP lowering drug treatment by absolute CVD risk 
Yet clinicians are reticent to treat systolic BP in those below 140 mmHg at high 
risk as well as not treating patients at low risk with blood pressure above this 
threshold. There is a paucity of literature on the effects of lowering BP in low to 
moderate CVD risk individuals with Grade 1 hypertension (systolic BP from 140 
mmHg to 159 mmHg and/or diastolic BP from 90 to 99) and some debate 
regarding its benefit105. Guidelines from the US and Europe tend to promote 
early drug treatment due to the potential benefits of earlier intervention and 
potential adverse effects of delayed intervention 40, 41, 59, 63, 165-168. However  JNC 
8 41 recommends initiating drug treatment at the threshold of 150 mmHg systolic 
BP or 90 mmHg diastolic BP for the general population at 60 years or older. 
This revised recommendation has caused controversy amongst clinicians who 
argue that drug treatments need to be initiated at a lower systolic BP of 140 
mmHg, as previously recommended in JNC 7169, otherwise patients are 
exposed to increased risk110, 170-172. Similarly, the 2018 European Society of 
Cardiology guidelines recommends considering BP lowering drug treatment 
when systolic BP is greater than 140 mmHg and/or diastolic BP is greater than 
90 mmHg after a reasonable period of time with lifestyle choice59. Recently, the 
SPRINT (Systolic Blood Pressure Intervention trial)92 reported a significant 
benefit from intensive treatment to a target BP of 120 mmHg rather than 140 
mmHg. However, this benefit was observed in those at high CVD risk without 
diabetes. In agreement with the findings from the SPRINT trial, guidelines in 
Australia2, New Zealand1, UK166 and Canada3  recommend BP lowering 
medication based on absolute CVD risk, recommending  BP lowering treatment 
as soon as possible in high CVD risk individuals, but not in the low to moderate 
risk population unless BP persistently exceeds 160/100 mmHg.  
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Other groups173 have recommended early drug treatment of grade 1 
hypertension even in patients at low risk with the exception of patients with 
grade 1 “isolated” hypertension, based on a meta-analysis by Thomopolous et 
al89 and the HOPE-3 study97. In contrast, a Cochrane review by Diao et al105 
concluded that there was no statistically significant effect of BP treatment in 
individuals who had grade 1 hypertension. The 2015 Blood Pressure Lowering 
Treatment Trialists Collaboration88 (BPLTTC) meta-analysis reported a 
statistically significant benefit of BP lowering drug treatment in grade 1 
hypertension in terms of stroke and all-cause mortality.  However, the effects 
seen in the BPLTTC analysis could reflect differences in the BPLTTC sample 
that included participants who had diabetes, had a higher baseline risk and had 
previously received drug treatment. In another analysis of the BPLTTC  
individual patient data84  by absolute CVD risk at baseline showed a 
continuously increasing benefit with baseline risk. The BPLTTC study, 
however, included participants who both did and did not have a history of CVD.  
Thus, we sought to reanalyse a seminal study used to justify treating 
individuals with elevated BP to see if stratification by baseline CVD risk would 
be a superior method for identifying candidates for BP-lowering medication in 
a treatment-naïve population. In this study, we compared the effectiveness of 
BP lowering drug treatment by a post-hoc subgroup analysis of the Australian 
National Blood Pressure study174 (ANBP). We restricted the analysis group to 
individuals with no history of CVD or diabetes, and who were naïve to BP 
lowering treatment. We selected this historic study because it was placebo-
controlled and patients in the control arm of the study would not have been 
taking a BP lowering medication previously unless they had very high levels of 
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BP. Our aim was to assess which group of individuals classified by absolute 
risk benefited from active treatment vs. placebo for CVD events within this 
seminal study that underwrote the treatment of elevated BP by BP thresholds. 
Methods 
Study design and population 
We performed a post-hoc analysis of the Australian National Blood 
Pressure study (ANBP)174. ANBP was conducted between 1973 and 1979 in 
Melbourne, Perth and Sydney and was a multicentre, single-blind placebo 
randomised controlled trial. ANBP enrolled participants who had not been on 
treatment for hypertension in the past three months and had no history of CVD 
or diabetes. In the 1970s, ‘mild hypertension’ was defined as a screening 
diastolic BP of 95 to 109 mmHg with a systolic BP lower than 200 mmHg.  At 
the screening phase, mean of two BP readings were assessed at two separate 
visits at 1-2 weeks intervals. The measurements were conducted by non-
medical staffs using random-zero sphygmomanometers at standardised 
criteria. 104171 participants were screened, 3931 eligible participants were 
initially randomised, then 504 participants were excluded because their BP 
throughout the study did not meet the criteria for starting drug treatment (entry 
or follow-up diastolic BP higher than 95 mmHg and/or entry or follow-up systolic 
BP higher than 200 mmHg) (Figure 2.1)  
Included participants were randomised to chlorothiazide 500mg or 
placebo that was identical in appearance with the active agent, with 
stratification by age and sex. When a systolic BP or diastolic BP exceeded 200 
and 110 mmHg respectively at three visits within 6 weeks, participants in the 
placebo group would be prescribed active treatment. The study intervention 
remains applicable to current practice as thiazide diuretics (e.g. 
hydrochlorothiazide) are still first line BP lowering agents2, 3, 40, 166, 175. The first 
step of active treatment was 500 mg chlorothiazide daily, then the dose was 
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increased to 500 mg chlorothiazide twice daily or second agents (e.g. alpha-
methyldopa, propranolol or pindolol) or thirds agents (e.g. hydralazine or 
clonidine) were added to achieve the treatment target of 80 mmHg of diastolic 
BP. All participants were advised on weight, diet and exercise.  
The primary endpoints were all-cause mortality and non-fatal events 
(non-fatal CVD, congestive cardiac failure, renal failure, hypertensive 
retinopathy or encephalopathy)174.   
Risk stratification 
In this analysis, the baseline absolute CVD risk was calculated according 
to the 5-year Framingham absolute risk score43. The Framingham score was 
chosen because it is currently recommended in the National Vascular Disease 
Prevention Alliance (NVDPA) guidelines2 in Australia. The sample was 
restricted to 3,244 participants who were older than 35 years and was stratified 
by tertile of estimated 5-year CVD risk score (Figure 2.1). We also classified all 
participants with very high BP (systolic BP ≥ 180 mmHg and/or diastolic BP ≥ 
110 mmHg) or total cholesterol (> 7.5 mmol/l) values the highest risk tertile 
regardless of their risk score, as per the Australian guidelines2.  The ANBP 
dataset included all variables required for CVD risk calculation except high-
density lipoprotein cholesterol (HDLc).  The HDLc value was imputed from the 
Australian National Heart Foundation risk factor prevalence study as this was 
near contemporaneous with the ANBP176.  Mean value of HDLc was 
categorised by age and sex. In a sensitivity analysis, we stratified the sample 
by GLOBORISK score177, a CVD risk score that does not require HDLc value 
and is validated in individuals over 40 years.  The equation for the Australian 
population was obtained by personal contact with the author (Peter Ueda, 
unpublished data, 2016).  This analysis excluded 471 participants younger than 
40 years. Less than 1% of the study participants had data missing for total 
cholesterol, weight and/or height and these missing data were managed by 
multiple imputations using chained equations. 
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Figure 2.1. Trial profile. 
 
Statistical analysis 
All analyses were based on the modified ‘intention to treat’ principle.  We 
included participants who had withdrawn from the study by their group 
allocation at randomisation in all analyses. The differences in baseline 
characteristics between ‘active group’ and ‘placebo group’ were tested by 
ANOVA test for continuous variables and Chi-square test for categorical 
variables.  Treatment effects were assessed by hazard ratio (HR), absolute risk 
reduction (ARR) and number needed to treat (NNT).  The HRs and 
corresponding 95% confidence intervals were estimated by Cox proportional 
hazard model after adjusting for clustering of participants within community-
based centers and potential risk factors including baseline characteristics.  The 
proportional assumption was checked by the test for interaction of HR with time.  
ARR and NNT were estimated from Kaplan-Meier curves at the median of 
follow-up time (4.4 years)178. Tests for interaction of treatment effect over the 
subgroups were obtained by the Cox regression model for the Hazard ratio and 
a Cochran’s Q test for the absolute risk reduction. The threshold for significance 
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for treatment effect was set at 0.05 for the main analysis and subgroup analysis. 
Only one subgroup analysis with related outcomes was conducted, thus 
multiplicity was not likely to affect our results. 
Ethics approval. This study was approved by the Tasmanian Health and 
Medical Human Research Ethics Committee (H0015252). 
Results 
Patient characteristics 
Table 2.1 provides baseline characteristics of the participants stratified 
by the tertile of the CVD risk score. On average, study participants had 
intermediate 5-year CVD risk as referred in the NVDPA guideline (10.5 ± 6.5) 
with moderately elevated BP (mean 159/103 mmHg) and were middle-aged 
(52± 8). The tertiles had estimated 5-year CVD risks of less than 6.1% (low), 
6.1 to 17.0% (moderate) and more than 17.0% (high). These values are similar 
to the thresholds recommended by the Australian NVDPA guideline2 for low 
(<10%), moderate (10-15%) and high-risk categorisation (>15%). A 
stratification by these cut-off points was attempted, but the number of 
participants in each subgroup were substantially imbalanced (2757 low risk 
participants, 422 moderate risk participants and 65 high risk participants) and 
the number of events in the high risk group were not high enough to run an 
analysis. The distribution of baseline characteristics by treatment assignment 
was not significantly different except for body mass index (BMI) in the total 
population, the number of smokers in the low-risk group, systolic BP and BMI 
in the moderate risk group. 
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Table 2.1. Baseline characteristics stratified by tertile of baseline CVD risk 
score. 
SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body - mass index. Bold 
p<0.05 based on the distribution of baseline characteristics by treatment assignment. 
Approximately one-third of the participants (34.5%) prematurely 
stopped study treatment due to decisions by clinics, participants’ doctors, and 
the participant themselves, or for unknown reasons (Table 2.2). Participants’ 
doctors were more likely to stop placebo treatment in all three risk groups, 
whereas clinics withdrew more BP-lowering drug-randomised participants in 
the low-risk group and the high- risk group. No substantial difference in 
baseline characteristics between the two randomised treatment groups was 
recorded in any risk group.  
 Group variable Total 
Low 
(<6.1 %) 
Moderate 
(6.1 – 17.0%) 
High 
(>17.0%) 
Sample, N 3244 1082 1081 1081 
Randomised to active 
treatment, N (%) 1622 (50%) 559 (51.7%) 513 (47.5) 550 (50.9) 
Age, years 51.7 ± 8.1 46.0 ± 6.2 54.5 ± 6.5 54.6 ± 8.1 
Male sex, N (%) 2017 (62.2) 567 (52.4) 804 (74.4) 646 (59.8) 
Current smoker, N (%) 801 (24.7) 115 (10.6) 352 (32.6) 334 (30.9) 
SBP, mmHg 159.5 ± 17.5 148.4 ± 12.2 157.3 ± 12.2 172.6 ± 17.9 
DBP, mmHg 102.9 ± 6.8 100.0 ± 3.8 100.8 ± 4.4 107.9 ± 8.2 
Total cholesterol, mmol/l 6.0 ± 1.1 5.5 ± 0.9 6.0 ± 0.9 6.5  ± 1.3 
BMI, kg/m2 26.6 ± 3.9 26.6 ± 4.0 26.5 ± 3.6 26.7 ± 4.1 
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Table 2.2. Characteristics of those who prematurely stopped study regimen. 
 Group variable Total 
Low 
(<6.1%) 
Moderate 
(6.1-17.0%) 
High 
(>17.0%) 
 Sample, N 1119 404 346 369 
Randomised to active 
treatment, N (%) 531 (47.5) 204 (50.5) 151 (43.6) 176 (47.7) 
Age, years 51.2 ±  8.3 45.9 ± 6.4 54.1 ± 7.0 54.2 ± 8.5 
Male sex, N (%)  626 (55.9) 188 (46.5) 243 (70.2) 195 (52.9) 
Current smoker, N (%) 321 (28.7) 58 (14.4) 143 (41.3) 120 (32.5) 
SBP, mmHg 159.1 ±  18.1 147.6 ± 12.9 157.0 ± 11.9 173.7 ± 17.7 
DBP, mmHg 102.9 ±  6.8 100.0 ± 4.0 100.6 ± 4.2 108.1 ± 8.2 
Total cholesterol, 
mmol/l 6.0 ±  1.1 5.5 ± 0.9 6.0 ± 0.9 6.4 ± 1.3 
BMI, kg/m2 26.7 ±  4.1 26.7 ± 4.0 26.6 ± 3.9 26.8 ± 4.5 
Reason for stopping 
  
Clinic, N (%) 204 (18.2) 74 (18.3) 75 (21.7) 55 (14.9) 
Local doctor, N (%) 287 (25.7) 98 (24.3) 87 (25.1) 102 (27.6) 
Participants, N (%) 548 (49.0) 204 (50.5) 162 (46.8) 182 (49.3) 
Not known, N (%) 80 (7.2) 28 (6.9) 22 (6.4) 30 (8.1) 
SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body - mass index.  Bold 
p<0.05 based on the distribution of baseline characteristics by treatment assignment. 
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Effect of BP lowering drug treatment on the total study population 
During a median follow-up of 4.4 years (IQR 1.0 – 5.9), 257 major CVD 
events (7.9%) were observed, in which ischemic heart disease accounted for 
203 events (6.3%), stroke 48 events (1.5%) and congestive heart failure 6 
events (0.2%).  
After adjustment for sex, age, BMI, smoking, systolic BP at baseline 
and study centres, BP lowering treatment was associated with a 15% 
reduction in non-fatal events and a 25% reduction in all-cause mortality 
(Figure 2.2), although the treatment effects were not statistically significant. 
Similar effects were found in the secondary endpoints including any events 
HR 0.82 (0.65 – 1.03), major CVD events HR 0.83 (0.65 – 1.07) and non-fatal 
CVD events HR0.87 (0.67 – 1.13). We identified a marginally significant effect 
in stroke HR 0.55 (0.3 – 1.001). 
 
Figure 2.2. Effect of treatment in the overall study population. 
*Adjusted for age, sex, body-mass index, screening centres, smoking and 
systolic blood pressure. Bold p<0.05. CVD for cardiovascular disease, CHD for 
coronary heart disease. 
Effect of BP lowering drug treatment on 5 year-CVD risk groups 
In the subgroup analysis, the magnitude of relative treatment effect 
increased from low to high CVD risk group, though the benefits were not 
statistically significant in the high-risk group in terms of all-cause mortality 0.60 
(0.26 - 1.40) and major CVD event with HR 0.76 (0.52 - 1.10). 
48 
Chapter 2. BP lowering drug treatment by absolute CVD risk 
The increasing trend for the benefit was also observed when comparing 
the absolute treatment effects absolute risk reduction – ARR among the three 
risk groups. No evidence of heterogeneity was observed except the effect in 
all-cause mortality. Substantial effects of BP lowering treatment were produced 
in the high-risk group regarding any trial endpoints (ARR 5.6 (1.6, 9.6)), all-
cause mortality (ARR 2.2 (0.5, 3.9)) and any CVD event (ARR 4.3 (0.5, 8.1)) 
(Table 2.3). Treating 18 high-risk participants for 4 years prevented one trial 
event, treating 45 prevented one death and treating 23 prevented one CVD 
event. In contrast, treating low or moderate risk participants needed much 
higher numbers to prevent one event or possibly caused net harm (Table 2.3). 
Similarly, in the subgroup analysis by tertile of baseline SBP (Appendix),  active 
treatment group was also associated with significant absolute risk reduction on 
any trial endpoint (ARR 4.8  (0.9, 8.8)), all-cause mortality (ARR1.9 (0.3, 3.6)) 
and any CVD event (ARR 4.1 (0.4, 7.8)), however no statistically significant 
heterogeneity was recorded in any outcomes. Also, a sensitivity analysis by 
using the GLOBORISK score177 which does not require HDLc was consistent 
with our original findings, except that the absolute risk reduction in major CVD 
event is no longer statistically significant with ARR 3.4% (-0.4,7.3, p = 0.08). 
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Table 2.3. Effect of treatment by tertile of baseline CVD risk score. 
     Active             Placebo       
  Event (rate per 1000 patient-yr) 
Adjusted HR   
(95% CI)* 
ARR % 
(95% CI)** NNT** 
Any event 
Low  22 (8.9) 23 (10.0) 
0.94 (0.52 - 1.70) 
-0.3 (-2.7, 2,1) -370 (-37, 47) 
Moderate  56 (26.1) 67 (28.0) 
0.93 (0.65 - 1.33) 
1.1 (-2.9, 5.2) 87 (-34, 19) 
High  59 (24.8) 75 (33.2) 
0.75 (0.53 - 1.06) 
5.6 (1.6, 9.6) 18 (10, 64) 
p - value - - 0.64 0.05 - 
All-cause mortality 
Low  6 (2.4) 6 (2.5) 
0.96 (0.30-3.01) 
-0.5 (-1.6, 0.7) -213 (-63, 153) 
Moderate  10 (4.4) 13 (5.1) 
0.81 (0.35 - 1.86) 
0.2 (-1.7, 2.1) 476 (-60, 48) 
High  9 (3.5) 14 (5.7) 
0.60 (0.26 - 1.40) 
2.2 (0.5, 3.9) 45 (25, 196) 
p – value - - 0.78 0.04 - 
Non-fatal event  
Low  16 (6.4) 17 (7.4) 
0.93 (0.47 - 1.87) 
0.2 (-1.9, 2.3) 476 (-52, 43) 
Moderate  46 (21.3) 54 (22.2) 
0.96 (0.65 - 1.43) 
0.9 (-2.8, 4.5) 118 (-35, 22) 
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     Active             Placebo       
  Event (rate per 1000 patient-yr) 
Adjusted HR   
(95% CI)* 
ARR % 
(95% CI)** NNT** 
High  50 (20.9) 61 (26.6) 
0.80 (0.55- 1.16) 
3.3 (-0.4, 7.0) 30 (-249, 14) 
p – value - - 0.77 0.36 - 
Major CVD event 
Low  17 (6.8) 18 (7.8) 
0.98 (0.50 - 1.91) 
0.2 (-1.9, 2.3) 476 (-52, 43) 
Moderate  50 (23.2) 58 (24.0 
0.98 (0.67 - 1.43) 
0.6 (-3.2, 4.5) 164 (-31, 22) 
High  50 (20.9) 64 (28.0) 
0.76 (0.52 - 1.10) 
4.3 (0.5, 8.1) 23 (12, 193) 
p - value - - 0.62 0.17 - 
Any CHD           
Low  17 (6.8) 14 (6.0) 
1.21 (0.59 - 2.48) 
-0.4 (-2.4, 1.6) -256 (-41, 61) 
Moderate  39 (17.9) 47 (19.2) 
0.93 (0.60 - 1.42) 
1.1 (-3.0, 5.1) 94 (-33, 19) 
High  41 (17.0) 45 (19.2) 
0.90 (0.59 - 1.37) 
1.9 (-1.4, 5.3) 52 (-72, 19) 
p - value - - 0.83 0.47 - 
CVD: cardiovascular disease, CHD: coronary heart disease, HR: hazard ratio, CI: confidence interval, ARD: absolute risk difference, NNT: number 
needed to treat. NNTB: number needed to treat (benefit). NNTH: number needed to treat (harm).p-value indicated p for interaction. 
* Adjusted for age, sex, body-mass index, smoking, screening centres and systolic blood pressure. ** As estimated by the Kaplan-Meier curve. 
Bold p<0.05 
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Discussion 
Our study population had an overall moderate 5-year CVD risk (10.5%) 
and moderately elevated systolic BP (mean 159/103 mmHg) by modern 
definitions.  The ANBP study aimed to treat ‘mild hypertension’ (according to 
the old definition) that was primarily defined by diastolic BP.  Some randomised 
participants were excluded from the original analysis because they did not meet 
the criteria for starting BP lowering drug treatment post-randomisation. This 
would not be seen in modern clinical trials. In our reanalysis, we found that BP 
lowering drug treatment reduced the risk of major CVD events and all-cause 
mortality, but the effect was not statistically significant. This is likely to be due 
to reduced power as the cohort was analyses by tertile of absolute risk, as well 
as by the two groups of randomised therapy. The original study found a 
statistically significant reduction in the incidence of CVD mortality and all trial 
endpoints, using the full dataset and a risk ratio rather than time-to-event 
analysis174. 
In our analysis of subgroups defined by CVD risk score, the magnitude 
of relative treatment effects (relative risk reduction) on all-cause mortality and 
major CVD events increased across all three CVD risk group from low to high 
risk, without statistically significant heterogeneity (p = 0.78 for all-cause 
mortality and p = 0.62 for the major CVD event) (Table 2.3). It is expected that 
the p value for interaction does not reach significance here, due to the low 
number of events, and the requirement for a much larger sample for adequate 
power to detect subgroup interactions than for a main effect 179. All relative 
treatment effects in our analysis measured by HRs were adjusted by age, sex, 
body-mass index, smoking, screening centres and systolic BP. However, no 
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significant difference was observed between adjusted and unadjusted HRs 
probably because randomisation successful balanced these characteristics 
between groups.  In terms of absolute benefits, risk reduction linearly increased 
across the CVD risk group from low to high risk.  .  BP lowering drug treatment 
produced an unclear benefit in the low and intermediate CVD risk group, and a 
clinically meaningful benefit in the high CVD risk group 
Regarding the benefit of BP lowering drug treatment in the low to 
intermediate CVD risk population, our results from main and subgroup analyses 
match well with the study outcomes from the HOPE-3 trial97, the Diao review105 
and a retrospective observational study by Sheppard et al106.  In the HOPE-3 
trial97, no benefit of intensive drug treatment was established in the 
intermediate-risk persons with HR 0.98 (0.84-1.14) for all-cause mortality and 
HR 0.92 (0.79 – 1.06) for major CVD events referred as a first secondary 
outcome in the paper.  At baseline, the HOPE-3 participants were older (65 
years) and had a lower level of BP (138.1/81.9 mmHg) compared to the ANBP 
participants.  One reason for the lower blood pressures may be due to the 4-
week run-in phase in which all of the HOPE-3 participants received active BP 
lowering drug treatment before randomisation and one-fifth of all eligible 
participants had previously received drug treatment before the trial.  Similarly, 
Sheppard et al also observed a non-signification association between BP 
lowering drug treatment and mortality or major CVD event with a RR 1.02 (0.88-
1.17) and a RR 1.09 (0.95-1.25) respectively in a low risk population. 
Participants in this study had a lower average BP 146/89 mmHg than our 
participants. However, the BP value in the treated group was likely to be 
underestimated. In 2012, Diao et al reviewed placebo randomised controlled 
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trials in grade 1 hypertension and also found no beneficial effect of drug 
treatment with a risk ratio (RR) 0.85 (0.63 – 1.15) for all-cause mortality and RR 
0.97 (0.2 – 1.32) for major CVD events105.  The participants in the Diao review 
were likely to have a lower CVD risk than those in the ANBP and the HOPE-3 
trials, with major CVD events occurring in only 2.4% of participants in the 
placebo group.  Following a similar approach, in 2015, The Blood Pressure 
Lowering Treatment Trialists’ Collaboration (BPLTTC)88 reviewed randomised 
controlled trials in grade 1 hypertension but extended to trials comparing active 
or more intensive regimens and placebo or less intensive regimens. In line with 
the findings from the 2015 BPLTTC study, we identified a marginally significant 
effect on stroke, yet our effect estimates with an HR 0.75 (0.45 – 1.36) for total 
deaths and an HR 0.83 (0.65 – 1.07) for major CVD events slightly differed from 
the 2015 BPLTTC study’s results with an OR 0.78 (0.67-0.92) and an OR 0.86 
(0.74-1.01) correspondingly.  The differences in confidence intervals may be 
due to the difference in sample sizes and baseline characteristics.  It is more 
likely that the 2015 BPLTTC participants had higher CVD risk and higher BP 
value at baseline when about 40% of 15,266 participants had diabetes and 
about 23% had previously received BP lowering drug treatment.  Our study and 
the 2015 review confirm the absolute benefits of BP lowering drug treatment in 
high CVD risk population in terms of total deaths with ARR 2.2% (0.5, 3.9, 
p=0.01) for the ANBP and ARR 1.4% (0.5, 2.2) for the review.  Furthermore, 
the benefit was also recorded in major CVD event with ARR 4.3% (0.5, 8.1, 
p=0.03) in the ANBP, whereas the 2015 BPLTTC observed a non-significant 
effect with ARR 1.0% (-0.1, 1.9).  The difference can be explained in part by the 
study design when more than 50% of participants with systolic BP higher than 
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160 mmHg in eligible studies in the 2015 BPLTTC were excluded.  The 
distribution of these excluded participants might not be even between active 
arm and control arm, thus biasing the treatment effects.  
In another subgroup analysis stratified by tertile of baseline systolic BP 
(Appendix), the mean value of CVD risk varied from low to high corresponding 
to the lowest and the highest tertile.  The relative treatment benefits were not 
statistically significant, but in terms of absolute effects, BP lowering drug 
treatment substantially reduced any trial events, all-cause mortality and major 
CVD events within the highest tertile.  The findings were in line with what we 
found in the CVD risk-stratified subgroup when all participants in the highest 
BP-stratified tertile had a high CVD risk score (20.7 ± 9.5). However, the 
heterogeneity of treatment effects among the three subgroups in the analysis 
by baseline systolic BP was no longer significant as it was in the subgroup 
analysis by CVD risk score. Further, the trend of lower to higher absolute benefit 
from low to high-risk groups that was seen for CVD risk was not apparent when 
groups are defined by BP alone. Thus, in this study, the CVD risk score 
identified those who most benefited from BP lowering drug treatment. 
Limitations 
There are a number of limitations of our study.  Firstly, statistical power 
is unavoidably decreased in a post-hoc subgroup analysis. The multivariate 
Framingham risk score used in our analysis has not been well validated within 
the Australian population180, however it remains the most well-established and 
accepted method for CVD risk assessment181.  Using a multivariate score for 
stratification is known to increase the power to detect heterogeneity in absolute 
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risk benefit over subgroup analyses that are based on individual risk factors182.  
A prospective study to address the issue of whether there is an advantage in 
treating blood pressure by AR is unlikely to be performed, because of the very 
large sample size and very long follow-up time required, particularly in patients 
at low risk. Therefore, re-analysis of the early placebo-controlled trials seems 
to be the most feasible approach for assessing the effects of delayed versus 
early drug treatment in individuals with varying CVD risk together and elevated 
BP. A large scale observational data may be another optimal approach.  
Secondly, the estimation of HDLc from the 1980s national survey may 
alter the CVD risk score, but we do not believe this method greatly affected the 
risk stratification because a 0.4 difference in the HDL estimate only results in a 
0.01 difference in CVD risk score.  Furthermore, no association between HDLc 
and BP has been observed183, 184.  The sensitivity analysis using GLOBORISK 
score177 without HDLc showed similar results as our main analysis. Although 
the ARR is no longer statistically significant, this result is likely due to the 
smaller sample size and subsequent number of events. In conclusion, the 
sensitivity analysis supports our main analysis.   
Thirdly, the paucity of trial endpoints in each CVD risk group prevented 
us from comparing the effects in some specific outcomes with respect to stroke 
and deaths from CVD. In addition, approximately one-third of the participants 
prematurely stopped randomised drug treatment. However, this pattern likely 
reflects the typical situation to occur in actual clinical practice, and this analysis 
is conducted on an intention-to-treat basis, so any difference in the estimate of 
treatment effect due to non-adherence is deliberately retained. Most 
participants were followed throughout the trial, except those with an unknown 
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reason for stopping - loss to follow-up (7.2%). An analysis with further 
adjustment by variable ‘premature stopped study treatment’ did not 
substantially change our findings, except effects on stroke in general population 
became statistically significant (0.55, 95%CI 0.30-0.99, p=0.05). This is 
because non-adherence is balanced between the allocated treatment groups.  
In conclusion, our research has contributed further evidence that drug 
treatment in patients with elevated BP should be directed to those at high risk 
of incident CVD events.  This reinforces the guidelines recommendation to treat 
based on absolute (or global) CVD risk, rather than according to BP thresholds 
alone2, 3, 40, 166, 175.  
Postscripts 
This chapter contributed justifications for treating high blood pressure 
established on an absolute risk approach that accounts for other major CVD 
risk factors. The next chapter examined the 14-year ‘legacy effect’ of not 
treating high blood pressure in individuals without established CVD.   
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Appendix 
Table appendix 2.1. Baseline characteristics stratified by tertile of baseline 
systolic blood pressure 
 
 Group variable 
1st tertile 
(113-151 mmHg) 
2nd tertile  
(152 – 165 mmHg) 
3rd tertile 
(166 – 225 mmHg) 
Sample, N 1156 1014 1074 
Age, years 48.8 ± 7.3 51.4 ± 7.8  55.1 ± 7.8 
Male sex, N (%) 803 (69.5) 645 (63.6) 569 (53.0) 
Current smoker, N (%) 285 (24.7) 251 (24.8) 265 (24.7) 
SBP, mmHg 142.1 ± 7.0 158.2 ± 3.9 179.3 ± 11.7 
DBP, mmHg 99.7 ± 4.1 102.7 ± 6.0 106.5 ± 8.0 
Total cholesterol, mmol/l 5.9 ± 1.1 6.0 ± 1.1 6.1 ± 1.2 
BMI, kg/m2 26.7 ± 3.6 26.5 ± 3.7 26.6 ± 4.4 
CVD risk (%) 7.9 ± 8.7 12.8 ± 9.6 20.7 ± 9.5 
SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body - mass index, CVD: 
cardiovascular disease. 
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Table appendix 2.2 Effect of treatment by tertile of baseline systolic blood pressure 
  Event (%)       
  Active Placebo 
Adjusted HR   
(95% CI)* 
ARR % 
(95% CI) NNT 
Any event           
113-151 mmHg 34 (5.6) 43 (7.8) 
0.71 (0.45 -1.11) 
2.5 (-0.7,5.6) 41 (-135, 18) 
152 – 165 mmHg 49 (9.8) 46 (9.0) 
1.07 (0.71 - 1.61) 
-1.2(-5.0, 2.7) -87 (-20, 37) 
166 – 225 mmHg 54 (10.5) 76 (3.6) 
0.73 (0.51-1.03) 
4.8  (0.9, 8.8) 21 (11, 112) 
p-value - - 0.25 0.1 - 
All-cause mortality 
113-151 mmHg 5 (0.8) 10 (1.8) 
0.49 (0.17-1.46) 
0.7  
(-0.2, 1.7) 
139  
(-468, 60) 
152 – 165 mmHg 11 (2.2) 8 (1.6) 
1.30 (0.51 - 3.28) 
-0.9 (-2.7, 0.9) -110 (-36, 108) 
166 – 225 mmHg 9 (1.7) 15 (2.7) 
0.64 (0.28 - 1.46) 
1.9 (0.3, 3.6) 52 (28, 372) 
p – value - - 0.26 0.08 - 
Non-fatal event  
113-151 mmHg 29 (4.8) 33 (6.0) 
0.77 (0.47 - 1.28) 
1.2 (-1.7, 1.5) 86 (-59, 25) 
152 – 165 mmHg 38 (7.6) 38 (7.4) 
1.00 (0.63 - 1.58) 
-0.2 (-3.6, 1.7) -455 (-27, 31) 
166 – 225 mmHg 45 (8.7) 61 (10.9) 
0.76 (0.52 - 1.13) 
2.9 (-0.8, 1.8) 35 (-133, 15) 
p – value - - 0.58 0.48 - 
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  Event (%)       
  Active Placebo 
Adjusted HR   
(95% CI)* 
ARR % 
(95% CI) NNT 
Major CVD event 
113-151 mmHg 31 (5.1) 35 (6.3) 
0.79 (0.48 - 1.28) 
1.6 (-1.3, 1.5) 61 (-74, 22) 
152 – 165 mmHg 41 (8.2) 40 (7.8) 
1.04 (0.67 - 1.61) 
-0.4 (-4.0; 3.1) -227 (-25, 32) 
166 – 225 mmHg 45 (8.7) 65 (11.7) 
0.73 (0.50 - 1.06) 
4.1 (0.4, 7.8) 24 (13, 242) 
p - value - - 0.39 0.22 - 
Any CHD           
113-151 mmHg 30 (5.0) 29 (5.3) 
0.93 (0.56 - 1.56) 
0.4 (-2.4, 3.1) 286 (-42, 32) 
152 – 165 mmHg 29 (5.8) 30 (5.9) 
0.95 (0.57-1.59) 
-0.1 (-3.1, 2.9) -1250 (-32, 34) 
166 – 225 mmHg 38 (7.4) 47 (8.4) 
0.87 (0.57-1.34) 
2.0 (-1.4, 5.4) 51 (-71, 19) 
p - value - - 0.89 0.65 - 
CVD: cardiovascular disease, CHD: coronary heart disease, HR: hazard ratio, CI: confidence interval, ARD: absolute risk difference, NNT: number needed 
to treat. p-value indicated p for interaction. 
* Adjusted for age, sex, body-mass index, smoking, screening centres and systolic blood pressure. Bold p<0.05 
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Chapter 4 Legacy effect of delayed blood pressure lowering 
drug treatment in middle-aged adults with mildly elevated 
blood pressure: systematic review and meta-analysis. 
Preface 
The previous chapter showed no significantly increased risk of all-cause 
and CVD mortality of baseline BP treatment naivety over a 5 and 14-year 
periods at any level of CVD risk stratification. This chapter would investigate 
the ‘legacy effects’ of no BP lowering drug treatment in a relatively lower risk 
population who had mildly elevated BP at middle age.  
Abstract 
Objective 
To investigate if there is evidence for a ‘legacy effect’ for blood 
pressure lowering treatment, that is worse health outcomes from not initiating 
drug treatment at a systolic blood pressure (SBP) threshold of 140 mmHg in 
middle-aged adults. 
 Methods 
We systematically reviewed post-trial studies comparing the effects of 
delayed  BP treatment (placebo/untreated during the trial or no previous 
treatment at trial entry) versus early treatment (actively treated during the trial 
or previous BP treatment at trial entry) on mortality in the short-term (5-year 
in-trial period) and long-term (≥10 years in total period). The data were pooled 
using Peto odds ratio . A subgroup analysis by 10-year Framingham risk 
score was performed. 
 Results 
Three studies (ALLHAT, Oslo and PREVEND-IT) involving 4746 
participants were included. The results were heavily influenced by the 
ALLHAT trial. We found no significant difference in all-cause mortality 
between ‘delayed BP’ and ‘early treatment’ in the short-term OR 0.95 (95% CI 
0.68- 1.32) or long-term OR 0.90 (95%CI 0.78-1.04), with similar results for 
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mortality from cardiovascular disease (CVD). The effects of delayed BP 
lowering treatment on long-term all-cause and CVD mortality did not vary with 
baseline risk of CVD. 
Conclusion 
The review showed no clinically adverse ‘legacy effect’ on mortality or 
major CVD event from not treating middle-aged adults at a systolic BP 
threshold of 140 mmHg or over. The results were consistent for all CVD risk 
subgroups. Although these studies are non-randomised post-hoc analyses, 
they may allay concerns that early treatment of elevated SBP is necessary to 
prevent CVD events.  
Introduction 
The effectiveness of blood pressure lowering drugs to prevent 
cardiovascular disease (CVD) has been well established in trials of patients 
with diabetes, the elderly, or those with a SBP of ≥160 mmHg or over (for 
example SHEP, Syst-Eur, HYVET and UKPDS). However, there remains a lack 
of evidence for the effects of BP lowering pharmacotherapy in middle-aged 
adults with mildly elevated BP. A recent systematic review by Diao et al 105 on 
participants with systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg  
found a no statistically significant effect of active treatment on the reduction of 
CVD or deaths. However, a similar review by the Blood Pressure Lowering 
Treatment Trialist’s Collaboration (BPLTTC)88 observed significant reductions 
in stroke, CVD and all-cause deaths. Although the BPLTTC review included 
more trials with larger number of participants, the review included trials with 
less versus more intensive treatments and trials with new blood pressure 
treatment added to pre-existing medication and so the comparison was not 
restricted to active versus placebo/no treatment as in the Diao et al review. In 
line with the finding in the Diao et al review105, most of the placebo trials117, 187,
195-199 in which previous treatments were not permitted or were withdrawn did
not observe substantial effects of active drug treatment on major CVD events, 
CHD, stroke or all-cause deaths within the trial period.  
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Concerns have been raised around a so called ‘legacy effect’: that is an 
irreversible pathological damage due to delaying treatment after a patient 
reaches a SBP threshold of 140 mmHg Two systematic reviews185, 186 have 
been conducted of blood pressure lowering trials with a post-trial follow-up of 
up to ten years and shown a significantly reduced risk of CVD and all-cause 
mortality in the participants randomly allocated to active treatment. However, 
these two reviews included patients with pre-existing cardiovascular disease. 
Therefore, the ‘legacy effect’ of delayed drug treatment in individuals with mildly 
elevated SBP without cardiovascular disease remains uncertain. As there are 
no trials that addressed this specific question, the aim of this review is to 
investigate if there are any adverse ‘legacy effects from not initiating drug 
treatment at a systolic BP threshold of 140 mmHg in ‘healthy’ middle-age adults 
using post-hoc analyses of existing trials with long-term follow-up. 
Methods 
Protocol and registration 
The review protocol was published in the Journal of Medical Internet 
Research200 and can be accessed via 
https://www.researchprotocols.org/2017/9/e177/. The review was registered in 
PROSPERO International Prospective Register of Systematic Reviews: 
CRD42017058414 
Criteria for considering studies for this review 
Population 
Trials including men and non-pregnant women from 30 to 65 years of 
age, where at least 80% of participants in the trial had mildly elevated BP at 
baseline (defined as a SBP of 140 – 159 mmHg) and no history of CVD 
(myocardial infarction, angina pectoris, coronary bypass surgery, coronary 
angioplasty, stroke, transient ischaemic attack, carotid endarterectomy, surgery 
for peripheral vascular disease, intermittent claudication or renal failure 
(creatinine > 1.5 times the upper limit of normal) at baseline were eligible. 
Where trials included participants different to those of interest (e.g. in secondary 
prevention populations, in participants with moderately or highly elevated BP or 
older than 65 years), we attempted to access individual patient data from trial 
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investigators and subsequently included only participants meeting our criteria 
in the analyses. 
Intervention 
The study included all types of BP-lowering drugs, except for some types 
that have limited clinical use due to the risk of side effects and availability (eg, 
ganglion blockers, reserpine, rauwolfia). 
Comparison 
We included studies that used a placebo or untreated control comparator 
or another active BP lowering treatment where it was possible to determine 
participants who had previously been taking blood pressure lowering treatment 
(previous treatment) or no pre-existing treatment (treatment naïve).  
Outcomes 
The primary outcome of the review was all-cause mortality, with 
secondary outcome of CVD mortality and CVD events (defined as fatal and 
non-fatal stroke, fatal and non-fatal CHD, fatal and non-fatal heart failure).  
Study design 
The current review included randomised controlled trials (RCTs) with at 
least 1-year post-trial follow-up. 
Data sources and searches 
We searched Medline via Ovid (1946 to Sept 2018), Embase via Ovid 
(1974 to Sept 2018) and the Cochrane Register of Controlled Trials (CENTRAL) 
(Sept 2018). We combined text word and MeSH/Emtree terms related to BP 
lowering drug agents with hypertension terms and follow-up studies. We used 
the  Cochrane Highly Sensitive Search Strategy for identifying randomised trials 
(sensitivity and precision maximising 2008 revision) in Medline201. No language 
restrictions were applied.  The search strategies are provided in Table appendix 
4.1. We modified the search strategy from the published protocol200 as the 
planned method identifying trials and then searching for follow-up studies was 
considered inadequate to identify potentially eligible RCTs. 
We searched reference lists of known systematic reviews on post-trial 
studies of BP lowering drug treatment (Kostis 2010185 and Hirakawa 2017186) 
or meta-analyses on trials of middle-aged adults with mildly elevated BP88, 105, 
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202, 203. We contacted corresponding authors of relevant papers regarding any 
further published or unpublished work. 
Study selection 
Two reviewers (CH and SS) independently scanned the results of the 
title and abstract search and any potentially relevant articles were obtained in 
full text. Two reviewers then screened the full text of  potentially relevant articles 
against the reviews inclusion criteria. Discrepancies were resolved through 
discussion with a third reviewer 
Data extraction 
Data extraction were independently performed by two reviewers (CH 
and SS). If any disagreement arises, two reviewers discussed or consulted with 
the third reviewer (JD). Generally, the extraction form included details of study 
characteristics, participant characteristics, interventions and settings, outcome 
data, type of analysis used in the studies, follow-up years. 
Assessment of risk of bias in included studies 
Two review authors (CH and SS) independently assessed risk of bias 
using the Cochrane Risk of bias in non-randomised and /randomised studies of 
interventions tools 206, 207. The ALLHAT study was assessed using the tool for 
non-randomised studies as data from the original randomised trial was 
reanalysed to compare non-randomised groups (treatment naïve vs previous 
treatment) based on data collected at trial baseline. Risk of bias assessment in 
both non-randomised31,208 and /randomised studies30, 209 included consideration 
of four mutual domains: bias due to deviations from intended interventions, bias 
due to missing data, bias in measurement of outcomes and bias in selection of 
the reported. Risk of bias assessment in non-randomised controlled studies 
required consideration of three further criteria: bias due to confounding, bias in 
selection of participants into the study and bias in classification of intervention. 
For randomised studies, risk of bias assessment also included consideration of 
bias arising from the randomisation process. For the non-randomised studies, 
each risk of bias domain was assessed as low, moderate, serious or critical risk 
of bias with a no information response when insufficient data were reported to 
permit a judgment. For the randomised studies, each risk of bias domain was 
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assessed as low, some concerns and high risk of bias. The domain level 
judgments provide the basis for an overall risk of bias judgment for each study. 
An assessment of potential publication bias was not performed due to the small 
number of included studies.  
Data analysis 
We compared outcomes in the short-term (average 5-year in-trial period) 
and long-term (an overall period of at least 10 years cumulative in- and post-
trial period) between ‘delayed treatment’ and ‘early treatment’ groups. The 
‘early treatment’ group included who had been previously treated with blood 
pressure lowering treatment at trial entry and the ‘delayed treatment’ group 
included participants who were treatment naïve using individual patient data 
from the trial. This approach has been used previously by Nelson et al188.  
Due to the small number of included studies, fixed effect Peto odds ratio 
(OR) was used to estimate the pooled effects 210,27-29. As recommended, we 
also used other methods to test the robustness of the results in sensitivity 
analyses. Heterogeneity of treatment effects in different trials were tested by 
the I2 statistic. Statistical heterogeneity was recorded when the p value of the 
test of heterogeneity was 0.1 or lower or the I2 value was 0.5 or greater. In a 
post-hoc analysis of the ALLHAT trial, the effects of ‘no previous treatment’ 
versus ‘previous treatment’ (PT) for high BP by hazard ratio were estimated 
using a Cox proportional hazard model. As this analysis was a comparison of 
non-randomised groups, the two groups were adjusted for an imbalance in 
baseline characteristics (e.g. age, race, sex, diabetes mellitus, education, body 
mass index, smoking, aspirin, randomised group, blood pressure, total 
cholesterol, serum glucose and creatinine), as per Nelson et al in the ANBP2 
study188. The observed (O), expected event (E) and variance (V) in ALLHAT 
were estimated from adjusted HR as recommended by Tierney et al 211 and 
then pooled with the corresponding O, E and V in Oslo and PREVEND-IT. The 
threshold of a significant effect was set at 0.05.  
We conducted a subgroup analysis based on baseline risk of CVD where 
data were available. Included participants were stratified by the baseline 
estimated 10-year Framingham risk score (fatal and non-fatal CVD events).  
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Due to inconsistent thresholds of 10-year Framingham risk score 2, 3, 
conventional thresholds of lower than 20%, 20-30% and higher than 30% were 
chosen to stratify participants into low, moderate and high risk groups 
correspondingly in this study. We estimated the relative risk for all-cause and 
CVD mortality in each group and tested for difference between the groups. Data 
synthesis and analyses were run on Review Manager 5 212. We extracted data 
based on intention-to-treat principles. 
Sensitivity analysis  
An analysis restricted to placebo/untreated controlled RCTs was 
performed to investigate the impact of the observational study on the pooled 
outcomes. Different statistical methods were used to check the robustness of 
the results27-29. 
Results 
Result of the searches 
The database searches identified 6012 records and three articles were 
identified from other sources (Figure Appendix 4.1 shows the flowchart of 
studies). After removal of duplicates 4090 articles were screened. Eighty nine 
articles were screened in full-text and 3 studies (Oslo, PREVEND-IT and 
ALLHAT) from 11 articles were included in the review. Aggregate unpublished 
data from the ALLHAT and individual data of PREVEND-IT trial were provided 
by the trial investigators.  
One trial excluded from the review included participants with mildly 
elevated diastolic BP (90-115 mmHg): USPHS 1977204, 205.   Although USPHS 
did not have a post-trial phase, the trial was followed for up to 10 years. No 
information on the proportion of participants with mildly elevated systolic BP 
was reported. Based on the baseline systolic BP148±15 mmHg, it is likely that 
less than 80% of participants had systolic BP less than 160 mmHg. The 
intervention was a combination of a diuretic and rauwolfia serpentine that had 
limited clinical use in current practice because of the risk of side effects and 
availability. Thus USPHS was excluded in the current systematic review and 
meta-analysis. 
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Characteristics of included studies and risk of bias 
The review included published data of the Oslo trial, unpublished 
aggregate data of ALLHAT and individual data of the PREVEND-IT trial. As 
ALLHAT is a randomised active-controlled trial, we used data based on whether 
participants had previously been treated with BP lowering agents or not, that is 
a comparison on a difference in treatment status at baseline between the two 
groups rather than a randomised comparison. ALLHAT participants were 
followed for a mean of 4.9 years in the in-trial period and 14 years over the in- 
and post-trial period.  As the original ALLHAT trial 189 reported beneficial effects 
from BP lowering treatment within the trial period, the majority of participants 
from all arms of the trials received active treatment in the post-trial phase, so 
there is likely to be little cross-over between the early treatment and delayed 
treatment comparison groups. Although some participants in the Oslo trial may 
have diastolic BP exceeding 110 mmHg, nearly 80% of Oslo participants had 
systolic BP lower than 160 mmHg, so we included the published data of this 
trial. Oslo reported 10-year116 and 40-year115 follow-up of all-cause mortality 
and coronary heart disease (CHD) deaths, thus the results of the 40-year study 
were included in the review. In PREVEND-IT trial, participants were originally 
randomised either to active treatment (Fosinopril 20 mg) or placebo. The mean 
follow-up period ranged from 3.3-4.4 years for the in-trial phase and 9.4-10.7 
years for the overall period.  
The baseline risk for participants in ALLHAT was higher than the other 
two trials as it included participants with elevated BP and at least one other 
CVD risk factor (e.g. history of type 2 diabetes, current cigarette smoking, high-
density lipoprotein cholesterol of less than 0.91 mmol/L). PREVEND-IT 
included healthy subjects from general population with persistent 
microalbuminuria, and the Oslo trial was restricted to men with mildly elevated 
BP defined as systolic BP 150-179 mmHg and diastolic BP less than 110 
mmHg. The median follow-up period ranged from 3.8-5.5 years for the in-trial 
phase and 9.5-40 years for the overall period. More details on characteristics 
of included studies were provided in Table appendix 4.2. 
94 
Chapter 4. Legacy effect of not treating mildly elevated BP  
The baseline characteristics of the participants included in the review 
showed no significant differences between study groups in the PREVEND-IT 
and Oslo trials (Table 4.1).  ALLHAT participants had a higher proportion of 
patients with diabetes and contributed to a higher proportion of participants with 
early treatment having type 2 DM. Participants with early treatment in the 
ALLHAT trial were more likely to be black, female, non-smoker and had type 2 
DM  and had higher estimated 10-year CVD risk scores. These imbalance 
characteristics were adjusted in multivariable models. Noticeably, Oslo 
restricted to men only and were likely to have higher systolic BP than other two 
trials. 
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 Table 4.1.Baseline characteristics of included participants 
Characteristics Delayed Early 
 ALLHAT PREVEND-IT Oslo ALLHAT PREVEND-IT Oslo 
Number of observations, 
n 
509 70 379 3303 79 406 
Age (mean + SD, years) 59.5 + 2.9 52.3±8.0 45.2±2.8 59.5 + 2.9 50.3±8.2 45.3±2.9 
Black, % 34.6* 0 NA 43.6 1.3 NA 
Male, % 52.8* 64.3 100 46.3 65.8 100 
Current Smoker, % 43.8* 32.9 42.5 34.6 34.2 40.9 
BMI (mean + SD, kg/m2)† 29.9 + 5.9* 28.1± 4.2 NA 31.3 +7.1 27.7±4.7 NA 
Diabetes† (%) 41.7* 2.9 0 51.1 2.5 0 
SBPs (mean + SD, 
mmHg): 
147+ 7* 147± 6 
155±8 
146 + 8 148±6 
156±7 
DBPs (mean + SD, 
mmHg): 
88+7* 84±8 
96±7 
87+7 85±7 
97±7 
Fasting Serum Glucose† 
(mmol/L) 
7.2+ 3.5* 5.3±1.4 
6.0±0.6 
7.6 + 3.8 5.3±1.8 
6.0±0.6 
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*: p<0.05. ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-
IT: Prevention of Renal and Vascular Endstage Disease Intervention Trial. NA: not available. SBP: Systolic Blood Pressure, DBP: 
Diastolic Blood Pressure, BMI: Body Mass Index, HDL: High Density Lipoprotein cholesterol, FRS: Framingham Risk Score. 
 
Total cholesterol 
(mmol/L) 
5.6 + 1.1 6.1±1.1 7.1±1.2 5.7 + 1.2 6.1±0.9 7.1±1.2 
HDL-c† (mmol/L) 1.2 + 0.4 1.0±0.3 NA 1.2 + 0.4 1.0±0.3 NA 
Serum Creatinine† 
(umol/L) 
82.2 + 27.4 82.4±14.0 96.9±13.7 84.0 + 27.4 84.8±14.5 97.2±14.0 
10-year FRS, mean (SD) 27.7 + 12.8* 20±12 NA 34.2 + 15.5 21±16 NA 
97 
Chapter 4. Legacy effect of not treating mildly elevated BP  
Risk of bias (Table 4.2) 
We assessed the ALLHAT data to be at serious risk of bias due to 
residual confounding as a result of the use of post-hoc non-randomised data 
from the trial, and this resulted in a grading for the overall risk of bias of ALLHAT 
of  ‘serious risk’. Although the outcome measurements in the post-trial phase 
of the PREVEND-IT and Oslo trials were unblinded, the primary outcomes 
considered in this analysis are generally objective (all-cause and 
cardiovascular mortality). Thus, the overall risk of bias for PREVEND-IT and 
Oslo trial was judged as ‘Low risk’.  Analyses in all three trials were based on 
the ‘Intention to treat’ principle since this was appropriate for the research 
question which related to ‘assignment of intervention’. More details on each 
criterion was presented in Table appendix 4.3   
 
 Table 4.2 Risk of bias 
Risk of bias domain ALLHAT 
1994 
PREVEND-IT 
1998 
Oslo 1972 
Bias arising from the 
randomisation process 
NA Low risk Low risk 
Bias due to deviations 
from intended 
interventions 
NI Low risk Low risk 
Bias due to missing 
outcomes 
NI Low risk Low risk 
Bias in measurement of 
the outcomes 
Low risk Low risk Low risk 
Bias in selection of the 
reported results 
NA Low risk Low risk 
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Risk of bias domain ALLHAT 
1994 
PREVEND-IT 
1998 
Oslo 1972 
Bias in selection of 
participants into the study 
Low NA NA 
Bias in classification of 
intervention 
Moderate risk NA NA 
Bias due to confounding Serious risk NA NA 
Overall risk of  bias Serious risk Low Low 
NA: not applicable, NI: no information, ALLHAT: Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, 
PREVEND-IT: Prevention of Renal and Vascular Endstage Disease 
Intervention Trial. 
 
Short- and long-term all-cause and CVD mortality  
The analyses on short- and long-term all-cause mortality and short-term 
CVD mortality included 4746 participants from three trials, with 80% originating 
from the ALLHAT trial. As Oslo separately reported aggregate data of CHD and 
stroke, Oslo was excluded in the analysis of long-term CVD mortality, leaving 
3961 participants in the analysis. There were 301 total deaths, in which 102 
deaths due to CVD were recorded in the in-trial period and increased to 1871 
total deaths and 312 CVD deaths during the post-trial period (Table appendix 
4.5).  
We observed no statistically significant difference in all-cause mortality 
in either the short- or long-term (short-term OR 0.95, 95%CI 0.68-1.32; long-
term OR 0.90, 95%CI 0.78-1.04) for those with delayed BP lowering treatment 
relative to those with earlier treatment. Similarly, no difference was found for 
CVD mortality (short-term OR 0.90, 95%CI 0.51-1.59; long-term OR 0.79, 95% 
CI 0.55-1.14). (Figure 4.1) 
Major CVD events  
 Two trials (Oslo and PREVEND-IT) including 934 participants contributed 
to the analysis of major CVD events in the short-term, with 69 events recorded 
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in the in-trial phase of Oslo and PREVEND-IT trial (Table appendix 4.5). 
However only PREVEND-IT (149 participants, 19 events) recorded long-term 
outcomes. Delayed’ drug treatment was associated with a modest, though not 
statistically significant, increased risk of major CVD events with OR 1.35 (0.83-
2.21) for the short-term phase. There was no evidence for long-term effects in 
PREVEND-IT with OR 1.02 (0.39-2.66) (Figure 4.1) 
 
 
 
 
(A) All-cause mortality during the in-trial and overall follow-up 
 
(B) Cardiovascular disease death during the in-trial and overall follow-up 
 
 
(C) Major cardiovascular disease during the in-trial and overall follow-up. 
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Figure 4.1. Forest plot for outcomes during the in-trial and overall follow-up. 
CI: Confidence interval, ALLHAT: Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: 
Prevention of Renal and Vascular Endstage Disease Intervention Trial. 
 
Subgroup analysis by 10-year Framingham risk score (Figure 4.2 and 
Figure 4.3) 
Data were available to stratify participants in ALLHAT and PREVEND-IT 
into low, moderate and high risk of CVD. More than half of the included 
participants were in the high risk group, primarily due to the inclusion criteria of 
the ALLHAT study. The effects of delayed BP lowering drug treatment were 
consistent among the three groups (p=0.46 and p=0.79 for the test of subgroup 
differences in overall all-cause and CVD mortality respectively) 
Figure 4.2. Forest plot for overall all-cause mortality in subgroup by 10-year 
Framingham risk score.  
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CI: Confidence interval, ALLHAT: Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: 
Prevention of Renal and Vascular Endstage Disease Intervention Trial. 
 
Figure 4.3. Forest plot for overall CVD mortality in subgroup by 10-year 
Framingham risk score.  
CI: Confidence interval, ALLHAT: Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: 
Prevention of Renal and Vascular Endstage Disease Intervention Trial. 
 
Sensitivity analysis  
Using different methods (DerSimonian‐Laird between‐study variance 
estimator and Wald‐type confidence intervals , DerSimonian‐Laird between‐
study variance estimator  and  Hartung‐Knapp‐Sidik‐Jonkman  adjusted 
confidence intervals, Paule‐Mandel between‐study variance estimator and 
Hartung‐Knapp‐Sidik‐Jonkman confidence intervals) to pool the aggregate 
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data did not change the main findings in all-cause and CVD mortality as 
presented in Table appendix 4.6. 
An analysis restricted to the data from the randomised trials only 
(PREVEND-IT and Oslo), were similar to the main analyses, with no statistically 
significant difference in for short-term all-cause mortality (OR 0.99, 95% CI 
0.43-2.27) or long-term all-cause mortality (OR 0.94, 95% CI 0.70-1.28) or 
short- or long-term CVD mortality (short-term OR 1.26, 95% CI 0.42 - 3.76; 
long-term OR 2.23, 95%CI 0.23-21.84) (Table appendix 4.7).  
A sensitivity analysis adjusting for baseline differences, showed no 
substantial difference between the adjusted and crude hazard ratio for any 
outcome (Table appendix 4.8). 
 Discussion 
The present systematic review and meta-analysis of studies with 
extended post-trial phase recorded no significant different in risk of all-cause 
and CVD mortality for participants with ‘delayed’ drug treatment at a systolic BP 
threshold of 140 mmHg in middle-aged adults even when the follow-up was 
extended for more than ten years. Due to the small number of events in the in-
trial period, subgroup analyses were performed only for long-term all-cause and 
CVD mortality. No heterogeneity of ‘delayed’ treatment effects was found 
across the three risk subgroups.  
Our findings are similar to two earlier systematic reviews in middle-aged 
adults without previous CVD213 and in middle-aged adults both with and without 
previous CVD 202. Trials in these reviews had follow-ups of approximately five 
years, except for the USPHS study205. The USPHS was followed for 7-10 years 
and recorded a non-significant association between ‘early’ treatment and 
reduced all-cause mortality with a RR 0.51 (0.09-2.74). Results from USPHS 
may not be considered relevant to current populations, however, as this trial 
used rauwolfia, which is no longer recommended treatment. Similar to our 
short-term results, the SHEP119 and Syst-Eur123 trials did not record any 
substantial benefits of ‘early’ treatment for all-cause or CVD mortality after an 
in-trial follow-up of five and two years respectively. However, the effects on 
CVD mortality became statically significant with a HR 0.86 (0.76-0.97) when the 
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SHEP trial was extended to 14 years120 and such a ‘legacy effect’ remained 
significant at the 22-year follow-up214. The mortality effects in Syst-Eur 
remained non-statistically significant after a total follow-up of 6 years215, 
indicating that a longer time for follow-up is required to observe  significant 
‘delayed benefits’. The SHEP and Syst-Eur trials had an actual ‘placebo’ arm 
when participants experienced ‘placebo’ run-in or withdrawal phase, however 
these trials were aimed at the elderly with much higher BP value of 160 mmHg 
or over compared to our included participants.  
Benefits of ‘active treatment’ or harms of ‘no treatment’ may require 
longer than ten years to become evident, particularly on mortality outcomes in 
middle-aged adults with mildly elevated BP who are likely to be at low CVD risk. 
This is the group that where treatment with blood pressure lowering medication 
is not clearly of benefit. We have attempted in this review to determine if 
treatment can safely be delayed in this treatment group. In this review, the 
average Framingham risk score was >20%, and so is higher than the low risk 
patients we would consider where treatment could be delayed. Even in this 
review, however, no clear evidence of early treatment was observed. The 
included ALLHAT and Oslo trial115 were extended to 14 and 40 years 
respectively, with no substantial adverse ‘legacy effect’  on all-cause or CVD 
mortality  of delayed treatment observed, and we observed consistent results 
across the low, moderate and high CVD risk subgroups.    
Strengths and limitation 
This is the first study to systematically review the medical evidence to 
determine if delaying BP lowering treatment for middle-aged adults with a 
systolic BP between 140 and 159 mmHg results in an increase in all-cause or 
cardiovascular mortality in the short or long term.   
In spite of vigorous efforts in accessing individual data to identify eligible 
participants, only three studies with 4746 participants could be included in the 
current review. Given the much larger sample size of ALLHAT trial, the overall 
results were heavily influenced by the results of the ALLHAT trial. In the 
ALLHAT trial, information on how long before the start of the trial participants 
had been on BP lowering treatment was not collected and even if it was, we 
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could not truly know how long someone was hypertensive before it was noted. 
Also, the study design of ALLHAT (post-hoc observational) is different from the 
other two randomised controlled trials (PREVEND-IT and Oslo). However, in 
sensitivity analysis on short- and long-term all-cause mortality, the results of 
analyses excluding the ALLHAT trial were generally consistent with the overall 
results.  
This review did not examine CHD and stroke mortality separately. Given 
the small number of studies and the potential for CHD and stroke to be affected 
by different classes of BP lowering medication 40, 74, we were only able to 
assess overall and total CVD mortality. 
The three included trials lacked BP lowering drug treatment information 
in the post-trial phase, except that an equal percentage of participants receiving 
drug therapy were reported in PREVEND-IT and Oslo trial. Given the ‘positive’ 
findings of the original ALLHAT trial, we believe it is likely that a substantial 
proportion of both arms of the trial would have used BP lowering therapy after 
the trial period.  
We used the Peto method for meta-analysis because of the small 
number of included studies. While it is true that the Peto method is open to bias 
when including studies with imbalance in the comparison groups, this only 
becomes apparent in combination with a large treatment effect210. Also, 
different statistical methods provided similar pooled effects as provided in Table 
appendix 4.6.  
Due to the above limitations, the results should be carefully interpreted. 
‘Legacy effects’ in low risk population with mild hypertension should be 
investigated in further studies,  however a long-term trial in such a low risk 
population is not likely to be feasible due to time commitment, money and other 
practical issues. A large observational study with the use of electronic health 
records should be considered.    
One of the barriers to adopting the absolute risk approach for decisions 
regarding BP lowering treatment is the concern that early treatment of mildly 
elevated BP is necessary to prevent pathological changes that result in CVD 
events. The current systematic review and meta-analysis showed no evidence 
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of an association between delayed treatment and CVD or death in middle-aged 
adults at a systolic BP threshold of 140 mmHg or over at any CVD risk 
subgroup. This study contributes to an area of major concern raised by many 
clinicians that early treatment of mildly elevated BP is necessary to prevent 
CVD events.  
Postscript 
The findings in this study and previous chapters manifested the non-
significant benefits or harms of delaying or untreating BP lowering drug 
treatment in low or moderate CVD risk, particularly middle-aged adults with 
mildly elevated BP.  Similarly, the next chapter will investigate the effect of 
lipid lowering drug treatment versus no treatment in the elderly across the 
CVD risk subgroup.  
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Appendix 
Table appendix 4.1 Search strategy  
 
            
           
MEDLINE search strategy 
Database: Ovid MEDLINE(R) 1946 to Present with Daily Update 
Search Date: 24 Sept 2018 
-------------------------------------------------------------------------------- 
1     exp Antihypertensive Agents/ (259590) 
2     (antihypertensive$ adj (agent$ or drug)).tw. (11275) 
3     exp Thiazides/ (16149) 
4     exp Sodium Chloride Symporter Inhibitors/ (14961) 
5     exp Sodium Potassium Chloride Symporter Inhibitors/ (14368) 
6     ((ceiling or loop) adj diuretic?).tw. (2922) 
7     (amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or 
chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or 
hydroflumethiazide or methyclothiazide or metolazone or polythiazide or 
trichlormethiazide or veratide or thiazide?).tw. (36600) 
8     (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or 
oxodoline or thalitone or hygroton or indapamide or metindamide).tw. (2551) 
9     exp Angiotensin-Converting Enzyme Inhibitors/ (44128) 
10     angiotensin converting enzyme inhibit$.tw. (19920) 
11     (ace adj2 inhibit$).tw. (19752) 
12     acei.tw. (3311) 
13     (alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or 
ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or 
enalaprilat or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or 
idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or 
omapatrilat or pentopril$ or perindopril$ or pivopril or quinapril$ or ramipril$ or 
rentiapril or saralasin or s nitrosocaptopril or spirapril$ or temocapril$ or teprotide or  
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trandolapril$ or utibapril$ or zabicipril$ or zofenopril$ or Aceon or Accupril or Altace or 
Capoten or Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril).tw. 
(28628) 
14     exp Angiotensin Receptor Antagonists/ (21660) 
15     (angiotensin adj3 (receptor antagon$ or receptor block$)).tw. (13192) 
16     arb?.tw. (6139) 
17     (abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan 
or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or 
tasosartan or telmisartan or valsartan or zolasartan or Atacand or Avapro or Benicar 
or Cozaar or Diovan or Micardis or Teveten).tw. (17067) 
18     exp Calcium Channel Blockers/ (83927) 
19     (amlodipine or aranidipine or barnidipine or bencyclane or benidipine or bepridil 
or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or efonidipine or 
elgodipine or etafenone or fantofarone or felodipine or fendiline or flunarizine or 
gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or lomerizine or 
manidipine or mibefradil or nicardipine or nifedipine or niguldipine or nilvadipine or 
nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or semotiadil or 
terodiline or tiapamil or verapamil or Cardizem CD or Dilacor XR or Tiazac or Cardizem 
Calan or Isoptin or Calan SR or Isoptin SR Coer or Covera HS or Verelan PM).tw. 
(65375) 
20     (calcium adj2 (antagonist? or block$ or inhibit$)).tw. (41141) 
21     (methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit 
or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit 
or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or 
aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or 
mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or 
dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl 
dopa).mp. (16483) 
22     (clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or 
chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine  
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or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or 
duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or 
klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno 
timelets).mp. (21355) 
23     exp Hydralazine/ (4913) 
24     (hydralazin$ or hydrallazin$ or hydralizine or hydrazinophtalazine or 
hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine 
or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-
hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin 
or alphapress or alazine or idralazina or lopress or plethorit or praeparat).tw. (4755) 
25     exp Adrenergic beta-Antagonists/ (87205) 
26     (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or 
atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or 
bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or 
bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol 
or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol 
or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol 
or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or 
hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or 
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or 
levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or 
metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or 
pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or 
pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol 
or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or 
sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or 
tolamolol or toliprolol or tribendilol or xibenolol).tw. (67238) 
27     (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw. (104465) 
28     exp Adrenergic alpha-Antagonists/ (52071) 
29     (alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or 
silodosin or tamsulosin or terazosin or tiodazosin or trimazosin).tw. (15051) 
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30     (adrenergic adj2 (alpha or antagonist?)).tw. (20736) 
31     ((adrenergic or alpha or receptor?) adj2 block$).tw. (61684) 
32     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 
(560290) 
33     exp Hypertension/ (252124) 
34     hypertens$.tw. (405123) 
35     ((high or elevat$ or rais$) adj2 blood pressure).tw. (28379) 
36     exp Cardiovascular Diseases/pc [Prevention & Control] (187726) 
37     33 or 34 or 35 or 36 (636841) 
38     randomized controlled trial.pt. (497432) 
39     controlled clinical trial.pt. (99269) 
40     randomized.ab. (434110) 
41     placebo.ab. (202971) 
42     clinical trials as topic/ (195636) 
43     randomly.ab. (299164) 
44     trial.ti. (196020) 
45     38 or 39 or 40 or 41 or 42 or 43 or 44 (1212939) 
46     animals/ not (humans/ and animals/) (4646041) 
47     Pregnancy/ or Hypertension, Pregnancy-Induced/ or Pregnancy Complications, 
Cardiovascular/ or exp Ocular Hypertension/ (916617) 
48     (pregnancy-induced or ocular hypertens$ or preeclampsia or pre-eclampsia).ti. 
(17005) 
49     45 not (46 or 47 or 48) (1081328) 
50     exp Follow-Up Studies/ (627771) 
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51     (1$ year follow up or 2$ year follow up or 3$ year follow up or 4$ year follow up 
or 5$ year follow up or 6$ year follow up or 7$ year follow up or 8$ year follow up or 
9$ year follow up).tw. (56294) 
52     follow$.tw. (3159033) 
53     (post trial or posttrial or post-trial or after trial or long term or longterm or long-
term or extension or extended or observation$ or passive or longitudinal).tw. 
(2075721) 
54     52 and 53 (506270) 
55     50 or 51 or 54 (1049694) 
56     32 and 37 and 49 and 55 (2681) 
57     (legacy adj effec$).tw. (183) 
58     56 or 57 (3038) 
Appendix 2. EMBASE search strategy 
Database: Ovid Embase <1974 to 2017> 
Search Date: 24 Sept 2018 
-------------------------------------------------------------------------------- 
1 exp Antihypertensive Agents/ (648405)  
2 (antihypertensive$ adj (agent$ or drug)).tw. (14296)  
3 exp thiazide diuretic agent/ (52373)  
4 exp loop diuretic agent/ (67171)  
5 ((ceiling or loop) adj diuretic?).tw. (4074)  
6 (amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or 
chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or 
hydroflumethiazide or methyclothiazide or metolazone or polythiazide or 
trichlormethiazide or veratide or thiazide?).tw.  (42735)  
7 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or 
oxodoline or thalitone or hygroton or indapamide or metindamide).tw. (3789)  
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8 exp dipeptidyl carboxypeptidase inhibitor/ (159353)  
9 angiotensin converting enzyme inhibit$.tw. (23320)  
10 (ace adj2 inhibit$).tw. (27469)  
11 acei.tw. (6301)  
12 (alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or 
ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or 
enalaprilat or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or 
idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or 
omapatrilat or pentopril$ or perindopril$ or pivopril or quinapril$ or ramipril$ or rentiapril 
or saralasin or s nitrosocaptopril or spirapril$ or temocapril$ or teprotide or 
trandolapril$ or utibapril$ or zabicipril$ or zofenopril$ or Aceon or Accupril or Altace or 
Capoten or Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril).tw. 
(37069)  
13 exp Angiotensin Receptor Antagonists/ (79298)  
14 (angiotensin adj3 (receptor antagon$ or receptor block$)).tw. (18175)  
15 arb?.tw. (11361)  
16 (abitesartan or azilsartan or candesartan or elisartan or embusartan or 
eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or 
saprisartan or tasosartan or telmisartan or valsartan or zolasartan or Atacand or 
Avapro or Benicar or Cozaar or Diovan or Micardis or Teveten).tw. (25409)  
17 exp calcium channel blocking agent/ (208343)  
18 (amlodipine or aranidipine or barnidipine or bencyclane or benidipine or bepridil 
or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or efonidipine or 
elgodipine or etafenone or fantofarone or felodipine or fendiline or flunarizine or 
gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or lomerizine or 
manidipine or mibefradil or nicardipine or nifedipine or niguldipine or nilvadipine or 
nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or semotiadil or 
terodiline or tiapamil or verapamil or Cardizem CD or Dilacor XR or Tiazac or Cardizem 
Calan or Isoptin or Calan SR or Isoptin SR Coer or Covera HS or Verelan PM).tw. 
(79546)  
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19 (calcium adj2 (antagonist? or block$ or inhibit$)).tw. (47871)  
20 (methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit 
or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit 
or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or 
aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or 
mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or 
dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl 
dopa).mp. (28741) 
21 (clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or 
chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine 
or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or 
duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or 
klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno 
timelets).mp. (46100)  
22 exp Hydralazine/ (18331)  
23 (hydralazin$ or hydrallazin$ or hydralizine or hydrazinophtalazine or 
hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine 
or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-
hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin 
or alphapress or alazine or idralazina or lopress or plethorit or praeparat).tw. (6395)  
24 exp beta adrenergic receptor blocking agent/ (273269)  
25 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or 
atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or 
bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or 
bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or 
carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or 
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or 
dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or 
flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or 
hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or 
isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or 
mepindolol or methylthiopropranolol or  
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metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or 
pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or 
pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol 
or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or 
sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or 
tolamolol or toliprolol or tribendilol or xibenolol).tw. (80953)  
26 (beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw. (119505)  
27 exp alpha adrenergic receptor blocking agent/ (131347)  
28 (alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or 
silodosin or tamsulosin or terazosin or tiodazosin or trimazosin).tw. (16958)  
29 (adrenergic adj2 (alpha or antagonist?)).tw. (18457)  
30 ((adrenergic or alpha or receptor?) adj2 block$).tw. (73216)  
31 or/1-30 (979528)  
32 exp Hypertension/ (633764)  
33 hypertens$.tw. (553609)  
34 ((high or elevat$ or rais$) adj2 blood pressure).tw. (37199)  
35 32 or 33 or 34 (817103)  
36 Random:.tw.  (1253377)  
37 Placebo:.mp. (408004)  
38 Double-blind:.tw. (183950)  
39 36 or 37 or 38 (1496703)  
40 follow*.tw. (4064909)  
41 (post trial or posttrial or post-trial or after trial or longterm or long term or long-
term or extension or extended or observation* or passive or longitudinal).mp. [mp=title, 
abstract, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword, floating subheading word]  (2664945)  
42 40 and 41 (726994)  
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43 31 and 35 and 39 and 42 (1728)  
44 (legacy adj effect$).tw. (191)  
45 43 or 44 (2021) 
CENTRAL search strategy 
Database: Cochrane Central Register of Controlled Trials on Wiley  
Search Date: 23 October 2017 
-------------------------------------------------------------------------------- 
1 MeSH descriptor: 1 explode all trees (7669) 
2 (antihypertensive* near (agent* or drug)):ti,ab  (2327) 
3 MeSH descriptor: [Thiazides] explode all trees (2350) 
4 MeSH descriptor: [Sodium Chloride Symporter Inhibitors] explode all trees
 (368) 
5 MeSH descriptor: [Sodium Potassium Chloride Symporter Inhibitors] explode 
all trees (49) 
6 ((ceiling or loop) next diuretic*):ti,ab (417) 
7 (amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or 
chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or 
hydroflumethiazide or methyclothiazide or metolazone or polythiazide or 
trichlormethiazide or veratide or thiazide*):ti,ab  (5283) 
8 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or 
oxodoline or thalitone or hygroton or indapamide or metindamide):ti,ab (974) 
9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 (13928) 
10 MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees
 (3961) 
11 angiotensin converting enzyme inhibit*:ti,ab (5281) 
12 (ace near/2 inhibit*):ti,ab (3222) 
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13 acei:ti,ab (697) 
14 (alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or 
ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or 
enalaprilat or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or 
idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or 
omapatrilat or pentopril* or perindopril* or pivopril or quinapril* or ramipril* or rentiapril 
or saralasin or s nitrosocaptopril or spirapril* or temocapril* or teprotide or trandolapril* 
or utibapril* or zabicipril* or zofenopril* or Aceon or Accupril or Altace or Capoten or 
Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril):ti,ab 
 (7926) 
15 #10 or #11 or #12 or #13 or #14  (11126) 
16 MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees
 (2005) 
17 (angiotensin near/3 (receptor antagon* or receptor block*)):ti,ab (2387) 
18 arb*:ti,ab (2739) 
19 (abitesartan or azilsartan or candesartan or elisartan or embusartan or 
eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or 
saprisartan or tasosartan or telmisartan or valsartan or zolasartan or Atacand or 
Avapro or Benicar or Cozaar or Diovan or Micardis or Teveten):ti,ab (5211) 
20 #16 or #17 or #18 or #19  (8123) 
21 MeSH descriptor: [Calcium Channel Blockers] explode all trees (2871) 
22 (amlodipine or aranidipine or barnidipine or bencyclane or benidipine or 
bepridil or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or 
efonidipine or elgodipine or etafenone or fantofarone or felodipine or fendiline or 
flunarizine or gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or 
lomerizine or manidipine or mibefradil or nicardipine or nifedipine or niguldipine or 
nilvadipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine 
or semotiadil or terodiline or tiapamil or verapamil or Cardizem CD or Dilacor XR or 
Tiazac or Cardizem Calan or Isoptin or Calan SR or Isoptin SR Coer or Covera HS 
or Verelan PM):ti,ab (11734) 
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23 (calcium near/2 (antagonist* or block* or inhibit*)):ti,ab (4515) 
24 #21 or #22 or #23 (13375) 
25 (methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit 
or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit 
or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or 
aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or 
mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or 
dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl 
dopa):ti,ab  (596) 
26 (clonidine or adesipress or arkamin or caprysin or catapres* or catasan or 
chlofazolin or chlophazolin or clinidine or clofelin* or clofenil or clomidine or clondine 
or clonistada or clonnirit or clophelin* or dichlorophenylaminoimidazoline or dixarit or 
duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or 
klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno 
timelets):ti,ab,kw  (3423) 
27 MeSH descriptor: [Hydralazine] explode all trees (309) 
28 (hydralazin* or hydrallazin* or hydralizine or hydrazinophtalazine or 
hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine 
or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-
hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin 
or alphapress or alazine or idralazina or lopress or plethorit or praeparat):ti,ab (450) 
29 #25 or #26 or #27 or #28  (4463) 
30 MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees (4506) 
31 (acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or 
atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or 
bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or 
bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or 
carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or 
cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or 
dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or 
flestolol or flusoxolol or  
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hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or 
iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or 
levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or 
metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or 
pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or 
pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol 
or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or 
sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or 
tolamolol or toliprolol or tribendilol or xibenolol):ti,ab (14371) 
32 (beta near/2 (adrenergic* or antagonist* or block* or receptor*)):ti,ab 
 (9274) 
33 #30 or #31 or #32  (18895) 
34 MeSH descriptor: [Adrenergic alpha-Antagonists] explode all trees (1215) 
35 (alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or 
silodosin or tamsulosin or terazosin or tiodazosin or trimazosin):ti,ab  (2223) 
36 (adrenergic near/2 (alpha or antagonist*)):ti,ab  (1068) 
37 ((adrenergic or alpha or receptor*) near/2 block*):ti,ab (6598) 
38 #34 or #35 or #36 or #37  (9280) 
39 #9 or #15 or #20 or #24 or #29 or #33 or #38  (54477) 
40 MeSH descriptor: [Hypertension] explode all trees (15677) 
41 hypertens*:ti,ab  (37742) 
42 ((high or elevat* or rais*) near/2 blood pressure):ti,ab  (2392) 
43 MeSH descriptor: [Cardiovascular Diseases] explode all trees and with 
qualifier(s): [Prevention & control - PC] (16513) 
44 #40 or #41 or #42 or #43  (55008) 
45 #39 and #44  (20752) 
46 MeSH descriptor: [Follow-Up Studies] explode all trees (54281) 
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47 follow*:ti,ab  (269231) 
48 ("post trial" or posttrial or post-trial or "after trial" or "long term" or longterm or 
long-term or extension or extended or passive or longitudinal):ti,ab  (92679) 
49 #47 and #48 (40334) 
50 (1* next year next "follow up"):ti,ab or (2* next year next "follow up"):ti,ab or (3* 
next year next "follow up"):ti,ab or (4* next year next "follow up"):ti,ab or (5* next year 
next "follow up"):ti,ab or (6* next year next "follow up"):ti,ab or (7* next year next "follow 
up"):ti,ab or (8* next year next "follow up"):ti,ab or (9* next year next "follow up"):ti,ab  
(12590) 
51 #49 or #50  (48897) 
52 #45 and #51  (862) 
53 (legacy near effect*):ti,ab  (15) 
54 #52 or #53  (953) 
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Figure appendix  4.1. Study flow diagram 
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Table appendix 4.2. Characteristics of included studies 
Trials 
Trial entry 
criteria In-trial comparison 
Comparison in this 
review 
Number of 
participants in 
this analysis* / 
in-trial sample 
size 
Follow-up 
% Receiving 
BP drug 
treatment in 
post-trial 
phase 
Sources of 
mortality 
outcomes in 
post-trial 
phase 
In-trial 
(Mean 
years) Overall 
ALLHAT 
Untreated 
SBP<180 or 
treated SBP 
<160 mmHg 
+≥ 1 CVD 
risk factors. 
Chlorthalidone 12.5 
to 25 mg/d vs 
amlodipine 2.5 to 
10 mg/d vs lisinopril 
10 to 40mg/d  
‘previous treatment’ 
(early) vs ‘treatment 
naïve’ (delayed) 3872/ 33357 4.9 14 Not reported.  
National 
Death Index, 
Social 
Security 
Administration 
databases 
and 
confirmatory 
death 
certificate 
PREVEND-
IT 
BP < 
160/100 
mmHg, no 
BP lowering 
medication + 
persistent 
albuminuria. 
Fosinopril 20 mg vs 
placebo 
Fosinopril 20 mg 
(early) vs placebo 
(delayed) 149/864 4 10 
Reported 
“rate of ACE 
inhibitor…use 
remained 
similar in all 
former 
randomised 
groups”  
Municipal 
register and 
Dutch Central 
Bureau of 
Statistics 
Oslo 
Men, systolic 
BP 150-179 
mmHg and 
diastolic BP 
Hydrochlorothiazide 
50 mg vs untreated 
Hydrochlorothiazide 
50 mg (early) vs 
untreated (delayed) 785/785 5.5 40 Not reported 
Statistics 
Norway 
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Trials 
Trial entry 
criteria In-trial comparison 
Comparison in this 
review 
Number of 
participants in 
this analysis* / 
in-trial sample 
size 
Follow-up 
% Receiving 
BP drug 
treatment in 
post-trial 
phase 
Sources of 
mortality 
outcomes in 
post-trial 
phase 
In-trial 
(Mean 
years) Overall 
< 110 
mmHg. 
(propranolol or 
methyldopa were 
added to regimen if 
required) 
ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid-Lowering Trial, PREVEND-IT: Prevention of 
Renal and Vascular Endstage Disease Intervention Trial. * Included participants referred to those who were at middle-age, had no history of 
CVD and had systolic BP ranging 140-159 mmHg. 
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Table appendix 4.3. Risk of bias in included studies 
ALLHAT 
Risk of bias 
Bias Reviewer' judgement Support for judgement 
Bias due to 
confounding 
Serious risk 
 
In this review, data from the randomised trial comparing active 
treatments was re-analysed and outcomes for participants were 
compared based on participants treatment status (‘treatment naïve’ or 
‘previously treated’ with blood pressure lowering medications) at entry 
to the original trial. Although treatment effects in this re-analysis were 
adjusted for the baseline characteristics age, gender, race, diabetes 
mellitus, education BMI, smoking, aspirin, randomisation group, 
systolic and diastolic BP, total cholesterol and glucose, some 
important residual or unmeasured confounders may be present such 
as dose and duration of previous treatment, the duration of elevated 
BP or subclinical vascular damage. 
Bias in selection of 
participants into the 
study 
Low risk 
 
This analysis included participants in the original trial who did not 
have CVD at trial entry. Selection into the analysis was not based on 
participant characteristics observed after the start of the intervention. 
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Bias Reviewer' judgement Support for judgement 
Bias in classification 
of intervention 
Moderate risk 
 
For this review data from the original trial which compared active 
blood pressure lowering treatment groups was reanalysed and the 
outcomes for participants who were ‘treatment naïve’ and ‘previously 
treated’ at entry into the original trial are compared. Information on 
treatment received at trial enrolment would have been obtained at 
two pre-randomisation visits and/or by chart review at clinical sites. 
The accuracy of recording of treatment status is uncertain and 
misclassification of participants to the treatment naïve and previous 
treatment comparison groups is possible.   
Bias due to 
deviations from 
intended 
interventions 
No Information 
 There is no information about  the care provided to ‘treatment naïve’ 
and ‘previous treatment’ groups beyond the assigned  in-trial 
interventions.   
Bias due to missing 
data 
No Information 
 
The analysis only includes participants who have post-trial follow up 
outcome data. The amount of missing data is not known and whether 
there were differences in missing data between the treatment naïve 
and previous treatment groups is unknown.  
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Bias Reviewer' judgement Support for judgement 
Bias in measurement 
of outcomes 
Low risk 
 
Outcomes in the original trial were documented by a checklist 
completed at follow-up visits supplemented by death certificates and 
hospital discharge summaries. Mortality was the primary endpoint. 
Participants and care providers were not blind to treatment allocation.  
Outcomes in the post-trial period were ascertained from the National 
Death Index using social security number, name, sex and date of 
birth as matching criteria.  
Whether outcome measurement was influenced by knowledge of 
previous treatment or treatment naivety at baseline in the original trial 
is not known. Mortality is objective so not likely to be bias in 
measurement. 
Bias in selection of 
the reported result 
Low risk The review outcomes were unpublished and obtained by contacted 
with the correspondence author. 
Overall risk of bias Serious risk  The study is judged to be a serious risk of bias due to the potential for 
bias from confounding and bias in classification of the (post hoc) 
‘intervention’.  
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PREVEND-IT 
Risk of bias 
Bias Reviewer' judgement Support for judgement 
Bias arising from the 
randomization 
process (random 
sequence generation, 
allocation 
concealment) 
Low risk The allocation sequence was random:  
“Randomisation was performed in blocks of 20 based on a computer 
generated randomization list by the pharmacy of Academic Hospital 
Groningen,…” 
There is no information on whether the allocation sequence was 
concealed until participants were enrolled and assigned to 
interventions.  However, baseline characteristics in the drug treatment 
and control group are similar. 
Bias due to 
deviations from 
intended 
interventions 
Low risk Participants, carers and personnel are likely to be unaware of 
intervention group: “Subjects are randomised to fosinopril 20 mg or 
matching placebo…”.  (Diercks et al 2000). Participants appear to 
have been analysed according to the intervention received for the 
primary study endpoint.  
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Bias Reviewer' judgement Support for judgement 
Bias due to missing 
outcome data (intrial 
and post trial period) 
Low risk Data on the primary outcome appears to be available for all 
randomised participants.  “Every surviving participant had a final visit 
3 months after the end of the active trial period” (Brouwers et al 2011) 
and Table 5 in Asselbergs.   
During the post-trial follow \-up only “2 subjects (0.2%) were lost to 
follow-up” 
Bias in measurement 
of the outcomes 
Low risk Outcome assessors were not aware of intervention assignment. The 
primary endpoint in the in-trial period was the combined incidence of 
cardiovascular mortality and hospitalization for cardiovascular 
morbidity. “An independent end-point committee reviewed all 
endpoints. The members of this end-point committee had no 
knowledge of the subject’s treatment assignment”. 
For the post -trial period The composite primary end point was 
“similar to the active trial”. Of the surviving participants at the end of 
the in-trial period data outcome data was obtained from clinic visits, 
personal communication and electronic hospital files. “Data on 
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Bias Reviewer' judgement Support for judgement 
mortality was retrieved from the municipal register….” “The 
independent end point committee of the active trial period reviewed 
all end points, and the members had no knowledge of subject’s 
treatment assignments”. (Brouwers 2011) 
Bias in selection of 
the reported results 
Low risk Reported outcome data not selected on the basis of results from 
multiple outcome measurements or multiple analysis of the data 
Overall risk of bias Low risk  
 
 
Oslo 
Risk of bias 
Bias Reviewer' judgement Support for judgement 
Bias arising from the 
randomization 
process (random 
Low 
The allocation sequence was random: 
“The randomisation was performed by a “random number table,”…”  
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Bias Reviewer' judgement Support for judgement 
sequence generation, 
allocation 
concealment) 
There is no information on whether the allocation sequence was 
concealed until participants were enrolled and assigned to 
interventions.  However, baseline characteristics in the drug treatment 
and control group are similar.  
Bias due to 
deviations from 
intended 
interventions (effect 
of assignment to 
intervention) 
Low During the in-trial period participants and clinicians were aware of 
treatment allocation: “The control subjects did not receive a placebo.”. 
Deviations from the intended intervention were present: drug 
treatment was started in the control group when a specified blood 
pressure threshold was reached. In the active treatment group 
additional or different blood pressure lowering treatments may have 
been used if the specified systolic blood pressure threshold was not 
achieved or if there were side effects. though 17% of the control 
group commenced blood pressure lowering therapy These deviations 
reflect usual practice. Participants were analysed according to the 
group to which they were randomised.   
129 
Chapter 4. Legacy effect of not treating mildly elevated BP  
Bias Reviewer' judgement Support for judgement 
Bias due to missing 
outcome data (short- 
and long-term 
outcomes) 
Low risk At the end of the intrial period 1.7% of participants did not attend for 
regular examinations but answered a mailed questionnaire (and 
provided outcome data) at the end of the study period. 
Data on mortality at long term followup were obtained from “Statistics 
Norway”. Data on mortality at long term follow up are available for all 
participants randomised in the original trial (406 in the treatment 
group and 379 in the control group)(Table 3 of Holme et al  2015). 
Bias in measurement 
of the outcome 
Low risk The outcomes reported at the end of the intrial period included total 
mortality, cardiovascular mortality, coronary and cerebrovascular 
events. “The incidence of cardiovascular disease was based on 
hospital records”. Possible nonfatal cerebrovascular events were 
evaluated by a diagnostic board with diagnostic criteria in accordance 
with WHO recommendations. Coronary events were evaluated by a 
“blind” diagnostic board of two independent cardiologists based on 
established criteria. The assessment of the outcome of total mortality 
is not likely to be influenced by knowledge of the intervention 
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Bias Reviewer' judgement Support for judgement 
received. Assessment of coronary events requires some judgment 
but this was performed by individuals blind to intervention status.  
The outcomes reported at long term follow up include total mortality 
and mortality at first MI. This data was obtained from “Statistics 
Norway”. Observers reporting mortality during the post-trial period are 
unlikely to be aware of in-trial allocation. 
Bias in selection of 
the reported results. 
Low risk It is not possible to tell whether all reported results correspond with 
intended outcome measurements, however, outcomes cannot be 
measured in multiple ways (meaning no opportunity to select from 
multiple measures) and there is only one way the outcome domain 
can be analysed. 
Overall risk of bias Low  
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Table appendix 4.4. Excluded studies and main reasons for exclusion 
Trials (year) Main reason for exclusion 
VA-II 
1970216, 217 
Double blind, randomised placebo controlled trial with no post-
trial phase in men with mildly elevated diastolic BP (90-114 
mmHg). Follow-up: 3.7 years.  
VA-NHLBI 
1977218, 219   
Double blind, randomised placebo controlled trial with no post-
trial phase in middle-aged participants with mildly elevated 
diastolic BP (90-114 mmHg). Follow-up: 3.7 years. 
USPHS 
1977204, 205   
Double blind, randomised placebo-controlled trial with no post-
trial phase in middle-aged participants with mildly elevated 
diastolic BP (90-115 mmHg). However the in-trial follow-up was 
7-10 years. Baseline BP 148±15 mmHg, thus less than 80% of 
participants had mildly elevated BP. The intervention was a 
combination of a diuretic and rauwolfia serpentine that have 
limited clinical use because of the risk of side effects and 
availability. 
MRC-TMH 
1985220, 221 
 
Single blind, randomised placebo controlled trial with post-trial 
phase in middle aged participants with mildly elevated diastolic 
BP. Post-trial random allocation to continued medication or 
stopped medication. 
SOLVD-
Prevention 
1992222, 223   
 
Double blind, randomised placebo controlled trial with post-trial 
phase in participants with asymptomatic left ventricular 
dysfunction. Previous BP lowering drug treatment were 
continued on top of the randomised regimens. Control group 
included non-specific antihypertensive therapy. There was no 
placebo/untreated/treatment naive group. 
TOMHS 
1995224 
 
Double blind, randomised placebo controlled trial with no post-
trial phase in participants with mildly elevated diastolic BP 
(<100 mmHg). Follow-up: 4 years. 
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Trials (year) Main reason for exclusion 
HOPE 2000 
225-227 
 
Double blind, randomised placebo-controlled trial with post-trial 
phase in participants aged > 55 years with history of CVD or 
diabetes and at least one other CVD risk factors. Previous BP 
lowering drug treatment were continued on top of the 
randomised regimens. Control group included non-specific 
antihypertensive therapy. There was no 
placebo/untreated/treatment naive group. 
AASK 
2002228-230 
 
Single blind randomised active controlled trial with post-trial 
phase in African American with hypertensive renal disease. 
There was no placebo/untreated/treatment naive group. 
Benedict 
2004231-233 
 
Double blind, randomised placebo controlled trial with post-trial 
phase in participants aged ≥ 40 years with type 2 diabetes 
mellitus. Previous BP lowering drug treatment were continued 
on top of the randomised regimens. Control group included 
non-specific antihypertensive therapy. There was no 
placebo/untreated/treatment naive group. 
ADVANCE 
2007234-238 
 
Double blind, randomised placebo controlled trial with post-trial 
phase in participants aged > 55 years with type 2 diabetes 
mellitus and at least one other CVD risk factors. However, 
previous BP lowering drug treatment were continued on top of 
the randomised regimens. Control group included non-specific 
antihypertensive therapy. There was no 
placebo/untreated/treatment naive group. 
CASE-J 
2008239-242   
 
Single blind randomised active controlled trial with post-trial 
phase. This trial recruited only those in the age range of interest 
(45-65) whose SBP was >=160mmHg. 
UKPDS 39 
2008243 
 
Randomised active controlled trial with post-trial phase in 
participants with type 2 diabetes mellitus. There was no 
placebo/untreated/treatment naive group. 
VA: The  Veterans Administration, VA-NHLBI: The Veterans Administration-National 
Heart, Lung, and Blood Institute Study Group, USPHS: The United States Public 
Health Service Hospitals Intervention Trial, MRC-TMH: The Medical Research Council 
trial of treatment of mild hypertension, SOLVD-Prevention: The Studies of Left 
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Ventricular Dysfunction, TOMHS: Treatment Of Mild Hypertension Study, HOPE: 
Heart Outcome Prevention Evaluation, AASK: The African American Study of Kidney 
Disease and Hypertension, Benedict: The Bergamo Nephrologic Diabetes 
Complication Trial, ADVANCE: The Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evaluation, CASE-J: 
Candesartan Antihypertensive Survival Evaluation in Japan, UKPDS: The UK 
Prospective Diabetes Study.  
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Table appendix 4.5 Number of events and participant numbers in this review versus 
total number in the trials. 
Events Delayed  Early  
 No. of events N No. of events N 
Short-term all-cause mortality     
ALLHAT 34 509 244 3303 
Oslo 9 379 10 406 
PREVEND 2 70 2 79 
Long-term all-cause mortality     
ALLHAT 159 509 1141 3303 
Oslo 272 379 296 406 
PREVEND 5 70 6 79 
Short-term CVD mortality     
ALLHAT 10 509 79 3303 
Oslo 6 379 6 406 
PREVEND 1 70 0 79 
Long-term CVD mortality     
ALLHAT 32 509 277 3303 
Oslo NR 379 NR 406 
PREVEND 2 70 1 79 
Short-term major CVD events     
ALLHAT NR 509 NR 3303 
Oslo 34 379 25 406 
PREVEND 4 70 6 79 
Long-term major CVD events     
ALLHAT NR 509 NR 3303 
Oslo NR 379 NR 406 
PREVEND 9 70 10 79 
ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and Vascular Endstage 
Disease Intervention Trial, NR: Not Reported. 
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Table appendix 4.6 Estimation of effects of delayed b lowering drug using different 
statistical methods 
Methods  Delayed vs Early  
Short-term all-cause mortality   
HKSJ, RE (k=3) RR 0.95 (0.86-1.05), I2=0.0% (0.0%;0.0%) 
DLRE, RE (k=3) RR 0.94 (0.0.65-1.36), I2=0.0% (0.0%;0.0%) 
PMHK, RE (k=3) RR 0.95 (0.86-1.05), I2=0.0% (0.0%;0.0%) 
Long-term all-cause mortality  
HKSJ, RE, (main analysis) (k=3) RR 0.96 (0.85-1.09), I2=0.0% (0.0%;82.7%) 
DLRE, RE (k=3) RR 0.96 (0.89-1.04) ), I2=0.0% (0.0%;82.7%) 
PMHK, RE (k=3) RR 0.96 (0.85-1.09), I2=0.0% (0.0%;82.7%) 
Short-term CVD mortality  
HKSJ, RE (k=3) RR 0.90 (0.43-1.87) ), I2=0.0% (0.0%;70.5%) 
DLRE, RE (k=3) RR 0.90 (0.51-1.57), I2=0.0% (0.0%;70.5%) 
PMHK, RE (k=3) RR 0.90 (0.43-1.87), I2=0.0% (0.0%;70.5%) 
Long-term CVD mortality  
HKSJ, RE (k=2) RR 0.79 (0.10-6.42), I2=0.0% 
DLRE, RE (k=2) RR 0.79 (0.55-1.14), I2=0.0% 
PMHK, RE (k=2) RR 0.79 (0.10-6.42), I2=0.0% 
DLRE: DerSimonian‐Laird between‐study variance estimator and Wald‐type 
confidence intervals (standard random effect model), HKSJ: DerSimonian‐Laird 
between‐study variance estimator  and  Hartung‐Knapp‐Sidik‐Jonkman  adjusted 
confidence intervals, PMHK: Paule‐Mandel between‐study variance estimator and 
Hartung‐Knapp‐Sidik‐Jonkman confidence intervals, RE: random effect, FE: fixed 
effect, k: number of studies included in the analysis.  
ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and Vascular Endstage 
Disease Intervention Trial 
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Table appendix 4.7 Estimation of effects of delayed BP lowering drug in randomised 
controlled trials 
Methods  Delayed vs Early  
Short-term all-cause mortality   
Oslo and PREVEND-IT Peto OR 0.99 (0.43-2.27) 
Long-term all-cause mortality  
Oslo and PREVEND-IT Peto OR 0.94 (0.70-1.28) 
Short-term CVD mortality  
Oslo and PREVEND-IT Peto OR 1.26 (0.42, 3.76) 
Long-term CVD mortality  
PREVEND-IT Peto OR 2.23 (0.23-21.84) 
PREVEND-IT: Prevention of Renal and Vascular Endstage Disease Intervention 
Trial, OR: Odd Ratio. 
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Table appendix 4.8 Short- and long-term effects in post-hoc analysis of ALLHAT trial 
Outcomes Unadjusted 
HR (95% CI) 
Adjusted 
HR (95% CI)* 
O-E V 
In-Trial (1994-2002, median time 4.9 years): 
All-cause mortality 0.94 (0.66-1.35) 0.94 (0.65-1.35) -1.78 28.77 
CVD mortality 0.86 (0.45-1.67) 0.84 (0.43-1.64) -1.50 8.57 
Post-Trial (1994-2011, median time 14.1): 
All-cause mortality 0.90 (0.76-1.06) 0.89 (0.76-1.06) -16.18 39.26 
  CVD mortality 0.74 (0.52-1.07) 0.77 (0.53-1.11) -7.35 28.12 
*: Adjusted for age, race, sex, diabetes mellitus, education, body mass index, smoking, 
aspirin, randomised group, systolic blood pressure, diastolic blood pressure, total 
cholesterol, serum glucose, creatinine. HR: Hazard ratio, O-E: Observed-Expected 
events, V: Variance. O-E and V was estimated as recommended by Tierney et al211. 
ALLHAT: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
Lipid-Lowering Trial, PREVEND-IT: Prevention of Renal and Vascular Endstage 
Disease Intervention Trial 
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Chapter 5  Short- and long-term association of lipid-lowering 
drug treatment and cardiovascular disease by estimated 
absolute risk in the Second Australian National Blood Pressure 
study (ANBP2). 
 
Preface 
BP and lipid lowering drug treatment (LLT) has substantively improved 
the major adverse cardiovascular event incidence and mortality that is 
attributable to the ageing population in the modern world. BP lowering drug 
treatment is clearly superior in the old age population who are more likely to 
have high CVD risk profiles than general population. Similarly, LLT is evidently 
superiority in the reduction of CVD incidence, however the effects on mortality 
in the elderly were less clear. This chapter examined the short- and long-term 
effect of LLT on all-cause and CVD mortality in the elderly by conducting a post-
hoc analysis in the Second Australian National Blood Pressure study (ANBP2). 
Abstract 
Background  
There is currently insufficient evidence to support the use of lipid-
lowering drug treatment (LLT) for primary prevention of cardiovascular disease 
(CVD) in the elderly. 
Objectives 
We examined the relationship of early initiation of LLT with short- and 
long-term all-cause and CVD mortality in persons older than 65 years in this 
post-hoc study from the Second Australian National Blood Pressure study 
(ANBP2). 
Methods 
In- and post-trial observational study. 4257 hypertensive participants 
aged 65 to 84 years within Australian family practices were randomized to an 
angiotensin converting enzyme-inhibitor or a diuretic treatment group. After 
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excluding participants with a prior history of CVD, the cohort was stratified into 
‘LLT’ and ‘no LLT’ subgroups based on LLT status at randomization. 
Results 
At randomization the participants had a mean age of 72 years, average 
blood pressure (BP) of 168/91 mmHg and estimated 5-year CVD risk of 18.7 ± 
8.3%. In the overall study population, the association of LLT with long-term (11-
years) all-cause and non-CVD mortality was significant (HR 0.78 (95% CI 0.66-
0.92, p=0.003) and HR 0.70 (95% CI 0.54-0.90, p=0.006) respectively). 
Magnitudes of the association of LLT with long-term mortality and the 
association with short-term mortality were similar, however, no statistically 
significant association with short-term mortality was observed. In the subgroup 
analysis by baseline 5-year CVD risk, LLT participants in the highest risk tertile 
had a substantially lower relative risk for short-term all-cause mortality (HR 
0.31, 95% CI 0.13-0.71, p for interaction 0.02), compared to those with lower 
estimated CVD risk. All analyses were adjusted for baseline and in-trial 
characteristics. 
Conclusion 
Our study showed a strong association between LLT and reduced long-
term all-cause mortality. Thus, our findings support recommendations of the 
use of LLT in patients over 65, particularly those with high CVD risk who were 
more likely to obtain additional benefits in the short-term. The findings also 
suggested that mortality benefits of LLT for the elderly may take longer to 
become evident. 
Introduction 
The global population is ageing. In 2015 there were 617 million (8.5%) 
people aged over 65 years and this is likely to reach 1.6 billion (17%) by 2050 
244. Cardiovascular disease (CVD) remains the leading burden of disease in this 
age group, being 30% of the total245. Lipid-lowering drug treatment (LLT), 
particularly statins, plays a key role in the prevention of CVD130, 246, 247. More 
than 40% of the Australian and US populations aged 75 and over are currently 
taking LLT248, 249 and this number is projected to grow as most of the LLTs come 
off patent and are therefore available at lower cost.  
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Most of the evidence for benefits from the use of LLT in those 65 years 
or over are from trials of secondary prevention of CVD or in mixed populations 
of those with younger age 151, 152, 155, 156, 250-254, insufficient evidence is available 
to support the use of LLT for primary prevention in the elderly255-258. In a recent 
meta-analysis of individual patient data by the Cholesterol Treatment Trialist’ 
Collaboration with a follow-up of 4.9 years 259, statin therapy or a more intensive 
statin regimen was associated with a trend of smaller relative risk reductions of 
major CVD events with increasing age in participants without history of CVD. In 
a subgroup of participants aged 65 to ≤70, statin treatment was associated with 
a significant reduction of major CVD with a RR 0.61 (0.51-0.73) per 1 mmol/L 
reduction in low density lipoprotein cholesterol, whereas no significant benefit 
was found in a subgroup of participants older than 70 years old. No analysis on 
CVD mortality or all-cause mortality in primary prevention populations was 
conducted in this review.  A systematic review and meta-analysis by Savarese 
et al154 related predominantly to primary prevention reported no significant 
mortality benefit of statin treatment in individuals aged 65 and over, although 
there were significant reductions in myocardial infarction (MI) and stroke. The 
average follow-up in the studies in this analysis was 3.5 years (range: 1.0 – 5.2 
years): 151, 152, 155, 156, 254, 260 ): this may not be long enough for the mortality 
benefit to reach a significant level.  
A prospective cohort study with 7.3 years follow-up 261 found substantial 
effects of early statin use (on-treatment versus no treatment at baseline) on 
major CVD events and all-cause mortality in the elderly (≥ 65 years) without 
CVD at baseline. This result stands despite a possible dilution of effects due to 
13% of non-drug users at baseline initiating treatment during the study. In 
contrast, another elderly cohort262 with median follow-up at 9.1 years found no 
benefits for CVD or CHD events except stroke.  
Evidence for both short- and long-term benefits of LLT in older adults 
thus remains inconsistent. From patients’ perspectives, other considerations in 
this age group impacting on chronic drug therapy are drug adherence, the 
possibility of adverse drug effects and the potential for consideration of 
medication discontinuation when other issues such as frailty and life 
expectancy become dominant263, 264. In this current post-hoc study in a cohort 
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of hypertensive elderly from the Second Australian National Blood Pressure 
study (ANBP2)265, we have examined the relationship between the use of LLT 
at randomization and short- (4 year) and long-term (11 year) all-cause and CVD 
mortality in those aged 65 years or over. 
Methods 
Study design and population 
We conducted a post-hoc analysis relating to a cohort from the Second 
Australian National Blood Pressure study (ANBP2) 265. ANBP2 was conducted 
in 1995 and was designed as a trial of a Prospective Randomized Open-label 
with Blinding of Endpoint assessment (PROBE). Participants aged 65-84 years 
at enrolment were randomized into an angiotensin-converting enzyme 
treatment group (enalapril recommended) or a thiazide diuretic treatment group 
(hydrochlorothiazide recommended) within Australian family practices. At entry, 
eligible participants had an average randomized blood pressure (BP) of 160/90 
mmHg or over. Short-term mortality outcomes were followed for a median 4.1 
years (from 1995 to 2001) as described by Wing et al265. A blinded independent 
endpoint committee adjudicated all study endpoints. An extended observation 
relating to survival status was conducted to a median 10.8 years (4.1-years in-
trial and 6.7 years post-trial) using linkage to the Australian National Death 
Index as described by Nelson et al188  to investigate longer term all-cause or 
CVD mortality. In this study, fatal cardiovascular events were comprised of 
sudden cardiac deaths, fatal stroke, fatal myocardial infarction, and ‘other’ 
cardiovascular causes of death. 
To focus on primary prevention, as presented in Figure 5.1, we excluded 
participants who had previous CVD events at baseline (n=705) and those who 
were initiated on LLT (n=1292) during the clinical trial period because we were 
uncertain whether they were prescribed LLT due to a CVD occurrence or an 
increased cholesterol level. Participants were re-stratified by LLT status at 
entry. Subsequently, we compared the outcomes between those who were on 
LLT (LLT group) and those who were not (no LLT) at randomization (baseline) 
regardless of their randomized treatment. 
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Figure 5.1 Flow chart of included participants in the analysis 
LLT: Lipid lowering drug treatment, CVD: Cardiovascular disease. 
Subgroup by CVD risk 
To investigate how the effect of LLT was affected by baseline CVD risk, 
we performed a subgroup analysis stratified by tertile of 5-year predicted CVD 
risk score at entry. The risk score was calculated by the Framingham absolute 
risk equation as used in the Australian National Vascular Disease Prevention 
Alliance (NVDPA) guideline2. As per the guideline, participants were 
automatically scored at high risk (>15%) if they had systolic BP ≥ 180 mmHg 
and/or diastolic BP ≥ 110 mmHg, total cholesterol > 7.5 mmol/l, diabetes and/or 
estimated glomerular filtration rate<45 ml/min/1.73 m2. For participants over 75 
years of age, the age value was set at 74 in the risk calculation. 
Statistical analysis 
The differences between the ‘LLT’ and ‘no LLT’ groups for baseline 
characteristics were tested by t-tests for continuous variables and Chi-square 
 
(-) Participants with CVD history 
(-) LLT in-trial initiation 
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tests for categorical variables. Cox proportional hazard models were used to 
estimate the hazard ratios (HRs) and corresponding 95% confidence interval 
(CIs) for outcomes for participants in the ‘LLT’ group compared with those in 
‘no LLT’ group. Participants were followed-up from entry to the time of event 
(deaths) or loss of vital status or the end of the follow-up (maximum 6 years for 
the short-term analysis and 11 years for the long-term analysis). Those who did 
not have an event throughout the observed time scale were considered as 
censored on 30 Sep 2001 for the short-term and 31 Oct 2009 for the long-term 
follow-up phase. The proportional hazard assumption was checked by a test 
for interaction of LLT group with time. All of the analyses were adjusted for 
baseline characteristics (age, sex, family history of CVD, non-HDL cholesterol, 
diabetes, anti-platelet use), in-trial characteristics (number of assigned in-trial 
BP lowering drugs), and clustered on the general practice clinic from which 
participants originated. Considering the multiple co-linearity issue, further 
adjustment models including W-H ratio and previous BP lowering treatment, 
systolic BP and diastolic BP at randomization were tested in sensitivity analysis. 
In addition, we conducted subgroup analyses stratified by age, sex and 
diabetes at baseline to investigate the impacts of these factors on the 
association of LLT and mortality outcomes.  The Cox regression models were 
used to test for interaction of treatment in the subgroup analyses. The 
significance of treatment effect was set to 0.05. Data management for all 
analyses was performed by using Stata version 12 for Windows.  
Ethics approval. ANBP2 was approved by the ethics committee of the Royal 
Australian College of General Practitioners and the post-trial cohort by the 
Monash University Standing Committee on Ethics in Research Involving 
Humans. The current cohort study was performed on non-identifiable dataset; 
thus an ethics approval was unnecessary. 
Results 
Patient characteristics 
Our study included 4257 out of the original ANBP2 cohort of 6083 
participants, approximately 70% of the total ANBP2 cohort. As shown in Table 
5.1, at study entry, participants had a mean age of 72 years, mean BP of 168/91 
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mmHg, mean plasma total cholesterol of 5.5 ± 0.9 mmol/l and HDL cholesterol 
of 1.4 ± 0.5 mmol/l. Compared with the ‘no LLT’ group, more female and 
younger participants were on LLT at baseline. Also, LLT participants were more 
likely to have a family history of CVD, diagnosed diabetes mellitus, and be on 
antiplatelet and previous BP lowering drug treatment. Although these 
participants were on LLT, they still had higher average plasma total cholesterol 
level and non-HDL cholesterol. This may be attributable either to insufficient 
adherence to LLT or to the non-specific treatment target recommended at the 
time (1995-2001) for primary prevention. In general, based on the estimated 
risk over 5-year, all participants were at high risk of CVD – mean risk: 18.7% ± 
8.3% using the Anderson equation43 as per the Australian NVDPA guideline2. 
The estimated CVD risk score of the no LLT group (18.9% ± 8.3%) was slightly 
higher than the LLT group, suggesting that LLT was prescribed based on the 
participant’s cholesterol level, not on absolute CVD risk. 
 
Table 5.1 Baseline characteristics by lipid-lowering drug treatment. 
  
Total 
(N=4257) 
No LLT 
(n=3609) 
LLT 
(n=648) 
p-value 
Age (mean ± SD in years)  72.0 ± 5.0 72.1 ± 5.0 71.0 ± 4.4 <0.001 
Female sex n (%)  2195 (51.6) 1789 (49.6) 406 (62.7) <0.001 
Current smoker n (%)  305 (7.2) 260 (7.2) 45 (6.9) 0.81 
Systolic BP at randomization 
 (mean ± SD, mmHg) 167.6 ± 12.6 167.7 ± 12.6 167.4 ± 12.3 
 
0.58 
Diastolic BP at randomization 
(mean ± SD, mmHg) 90.8 ± 8.1 90.8 ± 8.1 90.8 ± 7.9 
 
0.89 
TC (mean ± SD, mmol/l) 5.5 ± 0.9 5.5 ± 0.9 5.8 ± 1.1 <0.001 
HDL-c (mean ± SD, mmol/l) 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 0.48 
Non-HDL cholesterol  
(mean ± SD, mmol/l) 4.2 ± 1.0 4.1 ±  0.9 4.4 ± 1.1 
 
<0.001 
BMI (mean ± SD, kg/m2) 27.0 ± 4.2 27.0 ±   4.2 27.2 ±   4.1 0.18 
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Total 
(N=4257) 
No LLT 
(n=3609) 
LLT 
(n=648) 
p-value 
5-year Framingham risk score 
(mean ± SD, %) 18.7 ± 8.3 18.9 ±8.3 17.8 ± 8.1 
 
<0.001 
Diabetes mellitus n (%) 275 (6.5) 217 (6.0) 58 (9.0) 0.01 
Waist circumference  
(mean ± SD, cm) 94.4 ± 12.1 94.6 ± 12.2 93.6 ± 11.8 
 
0.07 
W-H ratio 0.90 ± 0.08 0.90 ± 0.08 0.89 ± 0.08 0.004 
Current alcohol consumption 
n (%) 3126 (73.4) 2660 (73.7) 466 (71.9) 
 
0.34 
Physically active n (%) 3332 (78.3) 2815 (78.0) 517 (79.8) 0.31 
Education n (%) 
   
0.57 
Primary school 997 (23.4) 854 (23.7) 143 (22.1)  
High school not completed 1853 (43.5) 1560 (43.2) 293 (45.2)  
Competed high school or 
higher 1407 (33.1) 1195 (33.1) 212 (32.7) 
 
Socio-economic status n (%) 
   
0.66 
1st quartile (most 
advantaged) 1085 (25.5) 915 (25.4) 170 (26.2) 
 
2nd quartile 1151 (27.0) 969 (26.9) 182 (28.1)  
3rd quartile 1365 (32.1) 1171 (32.5) 194 (29.9)  
4th quartile (most 
disadvantage) 656 (15.4) 554 (15.4) 102 (15.7) 
 
Family history of CVD n (%)    <0.001 
Yes 1986 (46.7) 1604 (44.4) 382 (59.0)  
Unknown 496 (11.7) 423 (11.7) 73 (11.3)  
Random blood glucose  
(mean ± SD, mmol/l) 5.5 ± 1.8 5.5 ± 1.8 5.6 ± 1.9 
 
0.33 
Serum creatinine  
(mean ± SD, µmol/l) 90.8 ± 19.2 90.8 ± 19.2 90.8 ± 18.9 
 
0.96 
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Total 
(N=4257) 
No LLT 
(n=3609) 
LLT 
(n=648) 
p-value 
Antiplatelet use n (%) 433 (10.2) 341 (9.5) 92 (14.2) <0.001 
Previous BP lowering 
treatment, n (%) 2556 (60.0) 2077 (57.6) 479 (73.9) 
 
<0.001 
LLT: lipid-lowering drug treatment, BP: blood pressure, HDL-c: high-density 
lipoprotein cholesterol, TC: total cholesterol, BMI: body mass index, W-H ratio: 
waist-hip ratio, CVD: cardiovascular disease. Bold p<0.05 
 
For in-trial characteristics (Table 5.2), there was no significant difference 
between the number of ‘LLT’ and ‘no LLT’ participants randomized to either 
ACE-I or diuretic-based therapy. However, LLT participants were more likely to 
receive a higher number of randomized drugs and had a lower average on-
treatment diastolic BP. 
Table 5.2 In-trial characteristics by LLT stratification. 
  
Total 
(N=4257) 
No LLT 
(n=3609) 
LLT 
(n=648) 
p-value 
Randomized to ACE-I n (%) 2117 (49.7) 1782 (49.4) 355 (51.7) 0.28 
BP lowering-drug compliance n 
(%) 1828 (67.2) 1532 (67.3) 296 (66.2) 
 
0.64 
Average on-treatment systolic BP  
(mean ± SD, mmHg) 145.6 ± 9.9 145.6 ± 9.9 145.4 ± 9.6 
0.49 
Average on-treatment diastolic BP  
(mean ± SD, mmHg) 80.8 ± 5.5 80.8 ± 5.5 80.3 ± 5.2 
 
0.02 
Number of assigned in-trial BP lowering drugs n (%) <0.001 
0 195 (4.6) 175 (4.9) 20 (3.1)  
1 2183 (51.6) 1902 (53.0) 281 (43.4)  
2 1640 (38.7) 1336 (37.3) 304 (46.7)  
≥3 216 (5.1) 174 (4.9) 42 (6.5)  
LLT: lipid-lowering drug treatment, ACE-I: Angiotensin Converting Enzyme-
Inhibitor, BP: blood pressure.  Bold p<0.05 
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Association of LLT and mortality in the total cohort  
263 deaths (106 CVD deaths including 13 fatal myocardial infarction, 28 
fatal stroke and 65 other CVD deaths) occurred during the in-trial period 
(median 4.1 years/’short-term’). These numbers increased to an overall 1250 
deaths (622 CVD deaths including 124 fatal myocardial infarction, 122 fatal 
stroke and 376 other CVD deaths) by the end of the extended phase (median 
10.8 years/’long-term’). Accumulative incidences of events according to LLT 
were presented in KM curves in Figure 5.2 and Figure appendix 5.1). 
In the long-term (10.8 years), LLT participants had a significantly lower 
adjusted risk of all-cause mortality HR 0.78 (95% CI 0.66-0.92, p=0.003). 
Noticeably, most of the survival benefits were attributable to the effects on long-
term non-CVD deaths HR 0.70 (95% CI 0.54-0.90, p=0.006), particularly cancer 
deaths HR 0.62 (95% CI 0.44-0.88, p=0.007) (Table 5.3). Also, magnitudes of 
the association of LLT with long-term mortality and the association with short-
term mortality were similar, however, no statistically significant association on 
short-term mortality was observed (Table 5.3 and Table 5.4).  In terms of CVD 
mortality, there was no significant difference between the LLT and no LLT 
groups in either the short (HR 0.86, 95% CI 0.46-1.61) or long term (HR 0.87, 
95% CI 0.68-1.11). 
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 (A) Short-term all-cause mortality 
 
(B) Long-term all-cause mortality 
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(C) Short-term CVD mortality 
 
(A) Long-term CVD mortality 
Figure 5.2 Cumulative incidence of all-cause and CVD mortality according to 
LLT (Kaplan Meier curve) in short- and long-term follow-up. 
 LLT: lipid-lowering treatment, CVD: cardiovascular disease. 
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Table 5.3 Association between LLT and long-term mortality in tertiles by estimated 5-year CVD risk and in the total cohort. 
  
Number of 
events % (n) 
Event 
 (rate per 1000 
person-year) Univariate Adjusted * 
Tertiles by estimated 5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
All-cause mortality 
    
1st tertile (2-14.5%)  7.0 (297) 11.5 22.5 0.51 (0.35-0.74) 0.64 (0.44-0.94) 
2nd tertile (14.5-22.6%) 9.3 (398) 21.7 29.6 0.72 (0.53-0.98) 0.85 (0.62-1.16) 
3rd tertile (22.6-59.8%)  13.1 (557) 30.7 43.3 0.70 (0.53-0.91) 0.85 (0.65-1.11) 
Total  29.4 (1252) 20.6 31.6 0.64 (0.54 - 0.76) 0.78 (0.66-0.92) 
p for interaction - - - 0.29 0.29 
CVD mortality    
  
1st tertile (2-14.5%)  3.3 (141) 5.9 10.5 0.56 (0.33-0.95) 0.74 (0.43-1.26) 
2nd tertile (14.5-22.6%) 4.6 (196) 10.9 14.5 0.74 (0.48-1.14) 0.86 (0.53-1.38) 
3rd tertile (22.6-59.8%)  6.6 (282) 17.9 21.4 0.82 (0.58-1.16) 0.98 (0.69-1.38) 
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Number of 
events % (n) 
Event 
 (rate per 1000 
person-year) Univariate Adjusted * 
Tertiles by estimated 5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
Total  14.5 (619) 11.1 15.4 0.71 (0.56 - 0.91) 0.87 (0.68-1.11) 
p for interaction - - - 0.5 0.46 
Cancer death    
  
1st tertile (2-14.5%)  2.0 (87) 2.4 6.8 0.35 (0.15-0.80) 0.40 (0.17-0.93) 
2nd tertile (14.5-22.6%) 2.9 (125) 7.1 9.3 0.76 (0.44-1.29) 0. 86(0.50-1.47) 
3rd tertile (22.6-59.8%)  3.7 (157) 6.9 12.5 0.55 (0.32-0.95) 0.62 (0.35-1.08) 
Total  8.7 (369) 5.3 9.5 0.55 (0.39 - 0.78) 0.62 (0.44-0.88) 
p for interaction - - - 0.27 0.28 
Non-CVD death    
  
1st tertile (2-14.5%)  3.7 (156) 5.5 11.9 0.46 (0.27-0.80) 0.57 (0.33-0.98) 
2nd tertile (14.5-22.6%) 4.7 (202) 10.9 15.1 0.71 (0.46-1.09) 0.84 (0.55-1.30) 
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Number of 
events % (n) 
Event 
 (rate per 1000 
person-year) Univariate Adjusted * 
Tertiles by estimated 5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
3rd tertile (22.6-59.8%)  6.5 (275) 12.9 21.8 0.58 (0.39-0.87) 0.72 (0.48-1.08) 
Total  14.9 (633) 9.5 16.2 0.57 (0.44-0.74) 0.70 (0.54-0.90) 
p for interaction - - - 0.47 0.48 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. * Age, sex, family history of CVD, non-HDL-C, diabetes, anti-platelet 
use, clustering effect by general practice, number of assigned in-trial BP lowering drugs. Bold p<0.05. 
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Table 5.4 Association between LLT and short-term mortality in tertiles by estimated 5-year CVD risk and in the total cohort. 
  
Number of 
events % (n) 
Event (rate per 
1000 person-year) Univariate Adjusted * 
Tertile by estimated 5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
All-cause mortality           
1st tertile (2-14.5%)  1.2 (52) 7.0 9.3 0.76 (0.34-1.67) 0.92 (0.41-2.07) 
2nd tertile (14.5-22.6%) 1.8 (76) 14.7 12.5 1.17 (0.64-2.12) 1.39 (0.74-2.60) 
3rd tertile (22.6-59.8%)  3.1 (134) 6.9 24.9 0.28 (0.12-0.64) 0.32 (0.14-0.75) 
Total  6.2 (262) 9.4 15.7 0.60 (0.40-0.90) 0.71 (0.47-1.07) 
p for interaction - - - 0.01 0.02 
CVD mortality  
    
1st tertile (2-14.5%)  0.4 (15) 2.0 2.8 0.70 (0.16-3.08) 1.12 (0.23-5.39) 
2nd tertile (14.5-22.6%) 0.8 (32) 7.9 5.1 1.54 (0.67-3.56) 1.78 (0.71-4.47) 
3rd tertile (22.6-59.8%)  1.3 (57) 3.5 10.4 0.33 (0.10-1.07) 0.35 (0.11-1.14) 
Total  2.4 (104) 4.3 6.2 0.71 (0.39 - 1.29) 0.86 (0.46-1.61) 
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Number of 
events % (n) 
Event (rate per 
1000 person-year) Univariate Adjusted * 
Tertile by estimated 5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
p for interaction - - - 0.09 0.1 
Cancer death  
    
1st tertile (2-14.5%)  0.5 (23) 3.0 4.0 0.74 (0.22-2.49) 0.77 (0.23-2.55) 
2nd tertile (14.5-22.6%) 0.8 (35) 5.6 5.9 0.96 (0.37-2.48) 1.14 (0.44-3.00) 
3rd tertile (22.6-59.8%)  1.1 (48) 2.3 8.9 0.26 (0.06-1.08) 0.27 (0.06-1.18) 
Total  2.5 (106) 3.6 6.3 0.58 (0.30-1.11) 0.60 (0.31-1.17) 
p for interaction - - - 0.26 0.28 
Non-CVD death  
    
1st tertile (2-14.5%)  0.9 (37) 5.0 6.4 0.78 (0.30-2.00) 0.85 (0.33-2.18) 
2nd tertile (14.5-22.6%) 44 (1.0) 6.8 7.4 0.91 (0.39-2.16) 1.12 (0.46-2.73) 
3rd tertile (22.6-59.8%)  1.8 (77) 3.5 14.5 0.24 (0.08-0.77) 0.29 (0.09-0.96) 
Total  3.7 (158) 5.1 9.5 0.53 (0.31-0.93) 0.61 (0.35-1.06) 
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Number of 
events % (n) 
Event (rate per 
1000 person-year) Univariate Adjusted * 
Tertile by estimated 5-year CVD risk 
 
LLT No LLT HR (95%CI) HR (95%CI) 
p for interaction - - - 0.13 0.17 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. * Age, sex, family history of CVD, non-HDL-C, diabetes, anti-platelet 
use, clustering effect by general practice, number of assigned in-trial BP lowering drugs. Bold p<0.05. 
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Association of LLT and mortality in a subgroup by 5-year estimated CVD 
risk  
In the subgroup analysis by estimated absolute CVD risk at baseline 
(Table 5.3 & Table 5.4), heterogeneity was found for short-term all-cause 
mortality, but no other outcomes. In the highest risk tertile, LLT group had a 
reduced risk of short-term all-cause mortality (HR 0.32, 95% CI 0.14-0.75) with 
p for interaction of 0.02, compared to the low and moderate risk tertile. There 
was no effect seen in other outcomes in the short or long-term.  
Sensitivity analysis 
  In subgroup analyses stratified by age, sex and diabetes status at 
baseline (Table appendix 5.1 and Table appendix 5.2), regarding long-term and 
short-term associations between LLT and mortality outcomes, the associations 
were not statistically different among stratified subgroups.  In a further adjusted 
model, we added characteristics that were statistically different between the 
LLT group (W-H ratio and previous BP lowering treatment, systolic BP and 
diastolic BP at randomization) in the adjusted model. The results were similar 
to the adjusted model, and no substantial difference was recorded. 
Discussion 
In this post-hoc analysis of ANBP2, we found a positive association 
between LLT with long-term all-cause, non-CVD and cancer mortality, but the 
protective association with CVD mortality did not reach statistical significance. 
For short-term outcomes, no significant association was recorded, although the 
magnitudes of the associations (HRs) were similar to the long-term effects.  
Our long-term findings are consistent with the long-term ASCOT-LLA 
trial266  and a 7.3-year observational study261. All three studies found a 
significant reduction in all-cause mortality and a non-significant reduction in 
CVD mortality. Surprisingly, similar to our study, ASCOT-LLA also observed a 
significant benefit on long-term non-CVD deaths (HR 0.85, 95%CI 0.73-0.99). 
Our study recorded a substantial benefit of LLT on cancer deaths, whereas 
ASCOT-LLA reported a non-significant effect on cancer deaths (HR 0.92, 
95%CI 0.76-1.12), but a significant effect on deaths related to infectious or 
respiratory diseases (HR 0.64, 95% CI 0.42-0.97). The ANBP2 study did not 
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record these outcomes, so we were unable to include these in this analysis. A 
limitation of our findings is that cancer deaths in both the short- and long-term 
may be confounded by the status of diagnosed cancer at entry. If the 
prevalence of diagnosed cancer at study entry were equally distributed between 
LLT and no LLT group, our results would support findings from previous studies 
showing a substantial reduction of cancer-related deaths by statin treatment in 
participants either with pre-existing cancer or no cancer267, 268. In contrast, two 
meta-analyses247, 269 of large randomised controlled trials showed no beneficial 
effect of statins on cancer-related deaths. Yet, most of these RCTs had a high 
proportion of participants with previous CVD.  
In terms of the short-term outcomes, our findings on all-cause and CVD 
mortality are consistent with a previous meta-analysis by Savarese154  who 
reported a non-significant effect of LLT on all-cause mortality with an RR 0.94 
(95% CI 0.86-1.04; p=0.21) and on CVD mortality with an RR 0.91 (95% CI 
0.69-1.20; p=0.49) with a mean follow-up of 3.5 years  (range: 1 to 5.2 years). 
However, in our study, the protective association for all-cause mortality reached 
statistical significance in the long-term analysis with the median follow-up time 
of 10.8 years, suggesting that differences in mortality may take longer to 
accrue. 
In the subgroup analysis by CVD risk,  LLT showed a greater effect on 
short-term all-cause mortality in the highest risk tertile, compared to other lower 
risk groups. We did not find any significant difference in the low or moderate 
risk groups regarding other trial endpoints. In contrast to our results, the 
Cholesterol Treatment Trialists (CTT)’  Collaborators247  observed a substantial 
reduction of all-cause mortality on the total cohort 0.91 (95%CI 0.85-0.97) but 
a non-statistically significant heterogeneity (p for trend=0.2) among risk 
subgroups (5-year risk at baseline <5%, ≥5% and <10%, ≥10% and <20%, 
≥20% and <30%, ≥30%). The CTT meta-analysis included participants at both 
middle and old age. 
Limitations 
Due to the nature of the post-hoc observational design, our findings are 
open to residual confounding, and thus should be interpreted with caution. The 
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results are also only based on one study, so are limited by low power. Another 
limitation of our study is missing details of LLT at baseline and in the post-trial 
period including reason for prescription, dose, duration and adherence to 
treatment. Compared to the ‘no LLT’ group, LLT participants had a substantially 
higher total cholesterol and were more likely to have previous BP lowering and 
antiplatelet use, to be diabetic and to have a family history of CVD suggesting 
that they were at higher underlying baseline risk. Covariate adjustment has 
limited ability to control for ‘confounding by indication’. In the subgroup analysis 
by estimated CVD risk, age, sex and diabetes at baseline ( 
Table appendix 5.1), the magnitudes of the association between LLT and 
mortality were similar in stratified groups, except that the association between 
LLT and short-term all-cause mortality varied according to estimated CVD risk. 
The association between LLT and other short-term or long-term mortality was 
found to be independent of age, sex, diabetes and estimated CVD risk. 
Furthermore, confounding by indication would be expected to bias in favor of 
higher mortality in the LLT group. A final point is that the risk algorithm is for 
untreated populations in both groups, but underestimation should affect those 
in the LLT group to a greater extent as they were on lipid-lowering therapy. 
In conclusion, our study supports the early use of LLT in those 65 years 
or over due to the association with long-term benefits on all-cause mortality, 
although the short-term benefits are likely to be evident only in the high-risk 
population. The findings suggest that the mortality benefit of LLT for the elderly 
may take longer to become evident. 
Postscripts 
This chapter showed a ‘delayed benefits’ of lipid lowering drug treatment 
in the elderly of 65 years or over that may take at least ten years to become 
evident, although the treated high-risk people obtained early benefits on 
reduced risk of all-cause mortality. The next chapter would summarize the key 
findings, their implications and present future directions of research. 
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Appendix           
 
  
  
 
 
 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
(B) 
Figure appendix  5.1 Cumulative incidence of cancer mortality according to 
LLT in short- and long-term follow-up (Kaplan Meier curve). 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. (A): Short-term 
period. (B): Long-term period. 
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(A) 
 
 
 
 
 
 
 
 
 
 
 
(B) 
Figure appendix  5.2 Cumulative incidence of non-CVD mortality according to 
LLT in short- and long-term follow-up (Kaplan Meier curve).  
LLT: lipid-lowering treatment, CVD: cardiovascular disease. (A): Short-term 
period. (B): Long-term period. 
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Table appendix 5.1. Association between LLT and long-term mortality stratified 
by age, sex and diabetes status at baseline. 
  
Event  
(rate per 1000 person-
year) Univariate Adjusted * 
  LLT No LLT HR (95%CI) HR (95%CI) 
All-cause mortality       
Age 
    
<75 15.5 22.7 0.68 (0.53-0.85) 0.74 (0.59-0.94) 
≥ 75 38.4 52.3 0.72 (0.55-0.94) 0.73 (0.56-0.97) 
p for interaction - - 0.73 0.88 
Sex   
  
Males 22.9 35.7 0.63 (0.48-0.83) 0.73 (0.56-0.94) 
Females 19.2 27.6 0.69 (0.54-0.87) 0.82 (0.66-1.04) 
p for interaction - - 0.62 0.52 
Diabetes   
  
No 19.3 30.8 0.62 (0.51-0.75) 0.77 (0.64-0.93) 
Yes 32.9 44.5 0.70 (0.43-1.14) 0.79 (0.51-1.22) 
p for interaction - - 0.62 0.87 
CVD mortality   
  
Age   
  
<75 7.3 9.9 0.74 (0.52-1.04) 0.80 (0.57-1.12) 
≥ 75 24.2 28.2 0.84 (0.60-1.19) 0.84 (0.59-1.19) 
p for interaction - - 0.59 0.69 
Sex   
  
Males 12.3 17.1 0.71 (0.48-1.03) 0.80 (0.55-1.17) 
Females 10.4 13.7 0.76 (0.55-1.04) 0.94 (0.67 -1.30) 
p for interaction - - 0.77 0.63 
Diabetes   
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Event  
(rate per 1000 person-
year) Univariate Adjusted * 
  LLT No LLT HR (95%CI) HR (95%CI) 
No 10.4 14.9 0.69 (0.53-0.90) 0.88 (0.68-1.16) 
Yes 18.1 24.2 0.71 (0.37-1.37) 0.80 (0.43-1.48) 
p for interaction - - 0.93 0.8 
Cancer mortality   
  
Age   
  
<75 5.2 8.2 0.63 (0.42-0.94) 0.69 (0.45-1.04) 
≥ 75 5.4 12.5 0.43 (0.21-0.88) 0.45 (0.22-0.92) 
p for interaction - - 0.34 0.32 
Sex   
  
Males 5.3 11.3 0.46 (0.26-0.81) 0.50 (0.29-0.84) 
Females 5.2 7.7 0.68 (0.43-1.06) 0.73 (0.47-1.14) 
p for interaction - - 0.29 0.26 
Diabetes   
  
No 5.1 9.5 0.53 (0.37-0.77) 0.61 (0.42-0.87) 
Yes 6.6 9.4 0.67 (0.23-1.98) 0.79 (0.29-2.17) 
p for interaction - - 0.68 0.73 
Non-CVD mortality   
  
Age   
  
<75 8.1 12.8 0.63 (0.45-0.87) 0.70 (0.50-0.98) 
≥ 75 14.1 24.1 0.58 (0.37-0.90) 0.60 (0.39-0.94) 
p for interaction - - 0.76 0.66 
Sex   
  
Males 10.6 18.5 0.56 (0.38-0.84) 0.66 (0.45-0.97) 
Females 8.8 14.0 0.62 (0.44-0.88) 0.72 (0.51-1.02) 
p for interaction - - 0.7 0.67 
Diabetes   
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Event  
(rate per 1000 person-
year) Univariate Adjusted * 
  LLT No LLT HR (95%CI) HR (95%CI) 
No 8.9 16.0 0.55 (0.42-0.73) 0.68 (0.52-0.89) 
Yes 14.8 20.3 0.69 (0.34-1.42) 0.69 (0.34-1.42) 
p for interaction - - 0.56 0.65 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. * Sex, family history of CVD, 
non-HDL-C, diabetes, anti-platelet use, clustering effect by general practice, number of 
assigned in-trial BP lowering drugs. Bold p<0.05. 
 
Table appendix 5.2 Association between LLT and short-term mortality stratified 
by age, sex and diabetes status at baseline. 
  
Event 
 (rate per 1000 
person-year) Univariate Adjusted * 
  LLT No LLT HR (95%CI) HR (95%CI) 
All-cause mortality       
Age     
<75 7.1 11.7 0.61 (0.35-1.04) 0.67 (0.39-1.17) 
≥ 75 17.1 24.1 0.71 (0.38-1.32) 0.71 (0.37-1.34) 
p for interaction - - 0.70 0.85 
Sex     
Males 12.6 18.1 0.70 (0.39-1.23) 0.78 (0.43-1.42) 
Females 7.5 13.2 0.57 (0.32-1.02) 0.64 (0.35-1.17) 
p for interaction - - 0.64 0.63 
Diabetes     
No 9.6 15.1 0.64 (0.42-0.97) 0.79 (0.51-1.21) 
Yes 7.8 25.4 0.31 (0.07-1.30) 0.24 (0.04-1.39) 
p for interaction - - 0.29 0.28 
CVD mortality     
Age     
<75 3.3 4.1 0.80 (0.36-1.77) 0.90 (0.39-2.07) 
≥ 75 7.8 10.4 0.75 (0.30-1.87) 0.71 (0.27-1.82) 
p for interaction - - 0.92 0.76 
Sex     
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Event 
 (rate per 1000 
person-year) Univariate Adjusted * 
  LLT No LLT HR (95%CI) HR (95%CI) 
Males 7.8 7.6 1.02 (0.49-2.14) 1.12 (0.50-2.50) 
Females 2.3 4.7 0.49 (0.17-1.37) 0.59 (0.20-1.77) 
p for interaction - - 0.24 0.26 
Diabetes     
No 4.4 5.6 0.78 (0.42-1.46) 1.09 (0.55-2.15) 
Yes 3.9 14.3 0.28 (0.04-2.11) 0.14 (0.01-1.56) 
p for interaction - - 0.27 0.22 
Cancer mortality ¶     
Age     
<75 3.3 5.2 0.63 (0.29-1.39) 0.69 (0.31-1.54) 
≥ 75 4.7 8.6 0.55 (0.17-1.77) 0.48 (0.14-1.62) 
p for interaction - - 0.83 0.77 
Sex     
Males 2.9 6.8 0.43 (0.13-1.37) 0.43 (0.12-1.43) 
Females 4.1 5.8 0.70 (0.31-1.55) 0.73 (0.32-1.66) 
p for interaction - - 0.49 0.48 
Non-CVD mortality     
Age     
<75 3.8 7.5 0.50 (0.24-1.04) 0.55 (0.26-1.15) 
≥ 75 9.3 13.7 0.69 (0.30-1.59) 0.70 (0.29-1.66) 
p for interaction - - 0.58 0.64 
Sex     
Males 4.9 10.5 0.46 (0.17-1.13) 0.52 (0.21-1.30) 
Females 5.2 8.4 0.62 (0.31-1.24) 0.67 (0.33-1.36) 
p for interaction - - 0.60 0.63 
Diabetes     
No 5.2 9.4 0.55 (0.31-0.98) 0.63 (0.36-1.13) 
Yes 3.9 11.0 0.34 (0.04-2.69) 0.28 (0.02-3.33) 
p for interaction - - 0.65 0.69 
LLT: lipid-lowering treatment, CVD: cardiovascular disease. * Sex, family history of CVD, non-
HDL-C, diabetes, anti-platelet use, clustering effect by general practice, number of assigned 
in-trial BP lowering drugs. ¶ Subgroup by diabetes status was not reported due to lack of event 
in diabetes group. Bold p<0.05 
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Chapter 6 Summary, implications, future directions and 
conclusions 
Summary of background 
Cardiovascular disease (CVD) remains the major burden of disease 
worldwide and is no longer limited to developed countries: the so-called 
“epidemiologic transition” 10. It is anticipated that deaths due to CVD would 
continuously increase in the next few years in both developed and developing 
countries due to ageing30-33. Blood pressure and lipid lowering drug treatment  
have been the two most effective drug therapies in the primary prevention of 
CVD. Their benefits are mostly observed in the secondary prevention 
population or in individuals at high CVD risk, Thus, preventive drug therapies 
are now recommended based on absolute CVD risk, not on traditional individual 
BP or blood lipid thresholds. There is a persistent belief 85, 109-111 of ‘irreversible 
damage’ if not treating high BP at a traditional threshold of 140 mmHg, although 
strong evidence70, 74, 84, 88-93  for the beneficial effects of BP lowering drug 
treatment were limited to high risk individuals as mentioned above. Similarly, 
there is a lack of evidence for the benefit of lipid lowering drug treatment on 
mortality in the elderly because the evidence was established when most of the 
elderly are eligible for a drug therapy according to the current absolute risk 
guidelines (age is the main driver of the risk estimation). The current research 
investigated short- and long-term adverse effects of not treating high blood 
pressure in ‘healthy’ adults and short and long-term effects of lipid lowering drug 
treatment in the ‘healthy’ elderly 
Summary of results 
Blood pressure lowering drug treatment was associated with a clinically 
significant absolute risk reduction of major CVD events and all-cause mortality 
in the highest CVD risk tertile. The magnitudes of absolute risk reductions 
linearly increased from low to high tertile at any study endpoints, although the 
heterogeneity was only statistically significant for all-cause mortality. In 
contrast, stratification by tertile of baseline BP did not result in such a trend and 
no heterogeneity of treatment effect was found. These findings reaffirm 
contribute further evidence to the rationale of treating high BP based on 
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absolute CVD risk estimation incorporating major risk factors rather than BP 
level alone.  
In hypertensive individuals with at least one more CVD risk factor, 
previously untreated high BP  tended to be associated with a lower risk of all-
cause and CVD mortality at 10-year and 14-year follow-up compared to 
previously treated BP. Of note, the blood pressure of previously untreated 
participants was  more easily controlled with fewer medications needed to reach 
a treatment target (BP <140/90 mmHg) compared to the previously treated 
group. When these factors were adjusted for, the association between 
previously untreated group and lower risk of mortality became non-significant. 
No substantial ‘harm’ in ‘previously untreated’ individuals was found in the high 
CVD risk subgroup (10-year Framingham risk score>30%).  
In middle-aged adults with mildly elevated BP, no evidence of adverse 
‘legacy effect’ on all-cause and CVD mortality or major CVD event of not 
treating high BP at a threshold of 140 mmHg was recorded in either short-term 
follow-up (median follow-up 4-6 years) or long-term period of more than 10 
years (median follow-up 10-40 years). The non-significant effects on long-term 
all-cause and CVD mortality of ‘untreated’ status were consistent across the 
absolute CVD risk subgroups (low:<20% 10-year Framingham risk score, 
moderate:20-30%, high: >30%).  
In the hypertensive elderly, lipid lowering drug treatment was associated 
with a ‘delayed benefit’ on all-cause mortality that took longer than five years to 
become evident, however high CVD risk individuals may have had an earlier 
beneficial effect than those with low or moderate CVD risk profiles.  
Strengths and limitations of this research 
The research incorporated data from large multi centres randomised 
controlled trials (ANBP, ALLHAT and ANBP2) in which blood pressure lowering 
drug treatments, major risk factors and hard CVD outcomes were 
systematically measured and assessed in a median follow-up of at least four 
years. 
However, there are some major limitations as outlined following: 
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1). Post-hoc analysis carries risk of selection bias.  
The post-hoc analyses conducted in ALLHAT (chapter 4) and ANBP2 
(chapter 5) was limited to participants with no history of CVD. Excluded 
participants with previous CVD events had substantially higher CVD risk than 
the general population. Also, we do not know whether these baseline CVD 
events occurred before or after the use of previous drug treatment.  After 
excluding these participants, some characteristics between those with and 
without previous drug treatment remained imbalanced. The bias was in favour 
of higher mortality in the treatment group. However, the magnitude of the effect 
on long-term all-cause mortality after adjustment for these imbalance 
characteristics decreased and became non-significant regarding BP lowering 
drug treatment and remained significant regarding lipid lowering drug 
treatment.   
2). Observational studies of ALLHAT (chapter 4) and ANBP2 (chapter 5)  are 
subject to confounding by indication. 
 The main exposure in the ALLHAT and ANBP2 are the previous use of 
BP or lipid lowering drug treatment correspondingly. Compared with the 
untreated population, participants with the early use of such preventive drug 
treatment were more likely to have higher underlying CVD risk at baseline.  
These participants could have been exposed to longer periods of high BP or 
lipid, or failed to implement lifestyle modifications. Thus, confounding by 
indication would bias in favour of higher mortality in treatment group. 
3). The lack of information on previous BP and lipid lowering drug treatment 
such as duration of treatment, pre-treatment BP and blood lipid level, 
adherence to treatment, etc limits interpretation of the data. 
4). The systematic review and meta-analysis included a small number of 
studies.  
5). Only mortality outcomes were reported in short- and long-term follow-up, 
while non-fatal events were not assessed in long-term follow-up.   
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Future directions 
Assuming the above limitations of the research, a gold standard 
randomised controlled trial would ideally examine effects of not initiating BP 
lowering drug treatment in ‘healthy’ adults. However, due to the long-term 
established association between high BP and CVD risk, a ‘no drug treatment or 
placebo’ arm is not likely to be ethically possible even when lifestyle 
modifications are done because lifestyle changes alone are not considered 
sufficient to control BP and individuals do not adhere to lifestyle advices as well 
as drug treatment173. Also, a study on low or moderate risk people or those with 
mildly elevated BP requires an enormous sample size or long-term follow-up to 
reach the sufficient power to identify a significant difference between ‘treatment’ 
and ‘no treatment’. In spite of the above challenges, a post-hoc study of a 
randomised controlled trial that records details of pre-trial BP lowering drug 
treatment, non-fatal outcomes (e.g. stroke or coronary heart disease) or safety 
outcomes (hypotension, syncope, electrolyte abnormalities, acute kidney injury, 
or acute renal failure) would contribute to addressing the physicians’ concern 
about adverse effects of delaying BP lowering drug treatment in individuals 
without established CVD.  
Some previous studies270-272 showed that individuals with lower treated 
BP, a smaller number of medications and no history of CVD are likely to 
maintain ‘normal’ BP after drug withdrawal for one year or longer. A pragmatic 
trial273 showed that deprescribing BP and blood lipid lowering drug treatment in 
low CVD risk population was safe, as indicated by the slightly increased CVD 
risk estimation after two years.  The Trial of Nonpharmacologic Interventions in 
the Elderly (TONE)274 focussed on participants with the above characteristics 
(BP<145/85 mmHg on one medication and no history of CVD within six 
months). Kostis et al274 reported that after successfully withdrawing BP lowering 
drug treatment, no substantial difference of major CVD event risk was observed 
over 3-year follow-up between participants randomised to usual care and those 
randomised either to dietary sodium reduction alone, weight loss alone, or 
combined sodium reduction and weight loss. However, there was a trend of 
increasing major CVD events according to increasing age, particularly on those 
over 70 years old. A similar trial on younger population should be performed to 
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investigate the effects on ‘hard’ outcomes such as major CVD events and 
mortality. A subgroup analysis by absolute CVD risk may be helpful to identify 
those who could have potential ‘harms’.  
The association between BP and incidence of dementia is also among 
the other important concerns. Midlife high BP (systolic BP >140 mmHg) was 
associated with an increased risk of dementia, however a steep decline of 
systolic BP during mid-to-late life was also associated with at least two-fold 
increased risk of dementia275. Future studies of BP pharmacological treatment 
in the middle-aged population could examine further ‘benefits’ or ‘harms’ of BP 
lowering effects on cognitive functions and incidence of dementia. 
The research  in chapter 5 found a delayed mortality benefit of lipid 
lowering drug treatment in an observational study, that should be confirmed by 
an intervention trial. STAREE276 is an ongoing randomised controlled trial in the 
‘healthy’ elderly of 70 years or over that will merit the ‘benefits’ or ‘risk’  of statins 
(the most commonly-used lipid lowering drug treatment) regarding fatal and 
non-fatal event over a five year follow-up. STAREE is expected to be completed 
in the next few years and should timely address the uncertainty of statin 
treatment in the ‘healthy’ elderly before widespread use of statins becomes an 
irreversible trend in clinical practice.  
Public health implications 
Our research findings encourage the adoption of the absolute risk 
approach in identifying high CVD risk individuals who are most likely to benefit 
from the lifetime use of BP and lipid lowering drug treatment as recommended 
in most current guidelines in Australia, New Zealand, Europe and the US1, 3, 49,
58. The adoption of these guidelines should be enhanced in current practice.
Indeed, such an approach following the above guidelines has reduced the 
number of undertreatment cases (normal BP but at high risk), however 
overtreatment (elevated BP but at low-moderate) exists due to widespread 
concern about the negative consequences of no treatment. If this is the case, 
the decision making should be shared with patients in terms of the ambiguous 
benefits and harms, quality of life, cost of drug treatment and management. 
Particularly, in the ‘healthy’ elderly (>65 years), the findings from chapter 5 
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indicates that mortality benefits of lipid lowering drug treatment may take longer 
than five years to become evident, life expectancy and polypharmacy burdens 
should be taken into account.   
Conclusions 
The findings of this research provide further justifications for the 
superiority of absolute cardiovascular risk in identifying those who are most 
likely to benefit from blood pressure and blood lipid lowering drug treatments. 
No evidence of adverse ‘legacy effects’ of delayed BP lowering drug treatment 
emerged in both short- and long-term studies in individuals without established 
CVD, even in those with high 10-year CVD risk estimation. In contrast, the 
‘healthy’ elderly may have a delayed mortality benefit from lipid lowering drug 
treatment and the high risk elderly appeared to obtain the benefits earlier.   
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